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Preface  
The main task of the Nordic Expert Group for Criteria Documentation of Health 
Risks from Chemicals (NEG) is to produce criteria documents to be used by the 
regulatory authorities as the scientific basis for setting occupational exposure 
limits for chemical substances. 
For each document, NEG appoints one or several authors. An evaluation is 
made of all relevant published, peer-reviewed original literature found. The 
document aims at establishing dose-response/dose-effect relationships and 
defining a critical effect. No numerical values for occupational exposure limits  
are proposed. 
Whereas NEG adopts the document by consensus procedures, thereby granting 
the quality and conclusions, the author is responsible for the factual content of  
the document.  
The evaluation of the literature and the drafting of this document on Isoflurane, 
sevoflurane and desflurane were made by Dr Anne Thoustrup Saber and Dr Karin 
Sørig Hougaard, National Research Centre for the Working Environment, 
Denmark. The draft document was discussed within the group and the final 
version was accepted by NEG on January 9, 2009 as its document. The following 
experts participated in the elaboration of the document:  
 
Gunnar Johanson  Institute of Environmental Medicine, Karolinska Institutet, Sweden 
(chairman) 
Maria Albin  Department of Occupational and Environmental Medicine, 
University Hospital, Lund, Sweden (former NEG expert) 
Kristina Kjærheim  Cancer Registry of Norway (NEG expert) 
Tiina Santonen  Finnish Institute of Occupational Health, Finland (NEG expert) 
Vidar Skaug  National Institute of Occupational Health, Norway (NEG expert) 
Mattias Öberg Institute of Environmental Medicine, Karolinska Institutet, Sweden 
(NEG expert) 
Jill Järnberg and  
Anna-Karin Alexandrie  
Swedish Work Environment Authority, Sweden (NEG secretariat) 
 
Editorial work and technical editing were performed by the NEG secretariat. 
This work was financially supported by the Swedish Work Environment Authority 
and the Norwegian Ministry of Labour and Social Inclusion. 
All criteria documents produced by the Nordic Expert Group may be down-
loaded from www.nordicexpertgroup.org. 
 
 
Gunnar Johanson, Chairman of NEG 
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Abbreviations and acronyms 
CI confidence interval 
EC electron capture detection 
EEG electroencephalography 
EPSC excitatory postsynaptic current 
FA alveolar blood concentration of flurane 
FDVE fluoromethyl 2,2-difluoro-1-(trifluoromethyl)vinyl ether (also called 
compound A) 
fEPSP field excitatory postsynaptic potential 
FEV1 forced expiratory volume in one second 
FI concentration of inspired flurane 
GC gas chromatography 
HFIP hexafluoroisopropanol 
IL interleukin 
LC50 lethal concentration for 50% of the exposed animals at single 
inhalation exposure 
LOAEL lowest observed adverse effect level 
MAC minimum alveolar concentration of anaesthetic that produces 
immobility in 50% of subjects exposed to a supramaximal 
painful/noxious stimulus 
MS mass spectrometry 
NOAEL no observed adverse effect level 
OR odds ratio 
PET positron emission tomography 
PS population spike 
SCE sister chromatid exchange 
SD standard deviation 
TFA trifluoroacetic acid 
TNFα tumour necrosis factor alpha 
TWA time-weighted average 
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1. Introduction 
Isoflurane, sevoflurane and desflurane are halogenated ethers and are used as 
inhalation anaesthetic agents. These agents are either used separately or in 
combination with nitrous oxide, intravenous anaesthetics, and muscle relaxants. 
Enflurane is also a member of this family but is no longer sold in the Nordic 
countries. For that reason enflurane is not included in this criteria document.  
This document was made on initial request from the Danish Working 
Environment Authority due to a report indicating exposure of personnel at Danish 
hospitals to these agents and the lack of occupational exposure limits (16).  
Until the 1990s, halothane and enflurane together with nitrous oxide were the 
primary anaesthetic gases. During the last decade, halothane and enflurane have 
been phased out and gradually replaced by isoflurane, desflurane and sevoflurane 
which, compared to halothane and enflurane, are less prone to metabolism causing 
immune hepatitis and other side-effects. As an example from the Nordic countries, 
isoflurane has been used in Denmark since 1984, while desflurane and sevoflurane 
are relatively new anaesthetics, introduced in 1994 and 1996, respectively (150-
152). 
In this document, the term fluranes is used as a common term for isoflurane, 
sevoflurane and desflurane. Some selection of literature has been performed.  
As opposed to most chemicals that occur in the work environment, the fluranes 
are meant to exert effects in humans at high dose levels. Thus, a large body of 
literature exists on pharmacological and toxicological effects in humans, mostly 
after a single exposure at anaesthetic dose levels, i.e. at exposure levels far ex-
ceeding the levels met in the working environment. Where relevant, effects of 
such high acute exposures in humans are described as summarised in reviews. 
Animal studies are generally described in detail for effects where human data are 
lacking or scarce, or if the studies were conducted at subanaesthetic concentrations 
or included repeated exposures. 
2. Substance identification  
The three fluranes are all ethers. Isoflurane and desflurane are halogenated 
methylethyl ethers with a difluoromethyl group and a fluorinated ethyl group.  
In isoflurane, one of the fluorine atoms in the ethyl group is substituted with 
chlorine. Sevoflurane is a polyfluorinated methyl isopropyl ether (55). Substance 
identification data for the fluranes are given in Table 1. 
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Table 1. Substance identification for the fluranes (46). 
Generic name Isoflurane Desflurane  Sevoflurane 
CAS No. 26675-46-7 57041-67-5 28523-86-6 
EINECS No. 247-897-7 Not available Not available 
IUPAC names 2-chloro-2-(difluoromethoxy)-1,1,1-trifluoro-
ethane 
2-(difluoromethoxy)-1,1,1,2-tetrafluoro-
ethane  
1,1,1,3,3,3-hexafluoro-2-(fluoromethoxy)pro-
pane  
Synonyms 1-chloro-2,2,2-trifluoroethyl difluoromethyl 
ether, forane, isofluorane 
1,2,2,2-tetrafluoroethyl difluoromethyl ether, 
difluoromethyl 1,2,2,2-tetrafluoroethyl ether, 
suprane 
fluoromethyl 1,1,1,3,3,3-hexafluoroisopropyl 
ether, sevorane 
Molecular formula C3H2F5ClO C3H2F6O C4H3F7O 
Molecular weight 184.5 168.0 200.1 
Structural formula  
H C O C C F
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FF
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3. Physical and chemical properties 
Isoflurane, sevoflurane and desflurane are stable, clear, colourless volatile liquids 
at room temperature (desflurane boils at 23 °C). They neither burn nor explode. 
Sevoflurane seems the least pungent of the three fluranes and the odour has 
been described as pleasant, much like chloroform. The odour of desflurane has 
been described as ether-like and unpleasant. Isoflurane has a mildly pungent, 
musty ethereal odour (55, 160). During exposure to 1 200 ppm of isoflurane, three 
of six volunteers rated the isoflurane smell as absent, whereas the other three rated 
it to be present (79). Some physical and chemical properties of the three fluranes 
are given in Table 2.  
To minimise waste and decrease costs, flurane anaesthetics are delivered through 
a system which recirculates the anaesthetic after removal of carbon dioxide by an 
absorbent. The absorbent is a strong base such as calcium hydroxide.  
Fluranes containing –CHF2, such as isoflurane and desflurane, react with strong 
bases in carbon dioxide absorbents resulting in the formation of carbon monoxide 
(as reviewed by Anders (10). Carbon monoxide is a highly toxic gas. The simpli-
fied mechanism for the degradation of desflurane into carbon monoxide and 
hydrogen fluoride is shown in Figure 1. The chemical degradation occurs only  
in the recirculation system and not in biological tissues.  
 
Table 2. Physical and chemical properties of the fluranes (69, 91, 160, 193).  
Anaesthetic Isoflurane Sevoflurane Desflurane 
Tissue:gas partition coefficients a at 37 °C 
Blood  1.4 0.65 0.45 
Brain  2.2 1.1 0.55 
Heart  2.2 1.1 0.55 
Liver  2.6 1.3 0.67 
Kidney  1.4 0.78 0.4 
Muscle  3.6 1.7 0.78 
Fat b 70 37 13 
Olive oil 98 47 19 
Other properties  
Boiling point (°C) at 101.3 kPa 48.5 58.5 22.8 
Saturated vapour pressure (kPa) 
at 20 °C  
32.0 21.3 89.2 
Gas density (kg/m3) of 1 MAC  
of flurane in 25% oxygen and 
75% nitrogen at 0 °C, 101.3 kPa 
1.35 1.45 1.70 
Conversion factors at 25 °C, 
101.3 kPa 
1 ppm = 7.55 mg/m3 
1 mg/m3 = 0.13 ppm 
1 ppm = 8.2 mg/m3 
1 mg/m3 = 0.12 ppm 
1 ppm = 6.9 mg/m3 
1 mg/m3 = 0.15 ppm 
a
 Human data. 
b Estimated from the assumption that 70% of fat has the solubility of oil and 30% that of blood. 
MAC: minimum alveolar concentration that produces immobility in 50% of the subjects exposed to 
supramaximal painful/noxious stimulus. 
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Figure 1. Simplified mechanism of carbon monoxide (CO) and hydrogen fluoride (HF) 
formation from desflurane (52).  
Sevoflurane is partly degraded by strong bases in the carbon dioxide absorbent 
in clinical anaesthesia machines to fluoromethyl 2,2-difluoro-1-(trifluoromethyl)-
vinyl ether (FDVE, also called compound A) (134). FDVE may thus contaminate 
the anaesthetic gas phase in the anaesthetic circulatory system (Figure 2). The 
chemical degradation occurs only in the recirculation system and not in biological 
tissues. 
The formation of carbon monoxide increases as the water content in the ab-
sorbent decreases (10). It has been shown that the use of new carbon dioxide 
absorbents (without strong bases) decreases the formation of carbon monoxide 
and the formation of FDVE (136).  
4. Occurrence, production and use 
High doses of isoflurane, sevoflurane and desflurane induce anaesthesia and  
all three compounds are used as anaesthetic gases. The fluranes do not appear 
naturally, but are synthesised in closed systems. Fluranes are often used in com-
bination with oxygen/nitrous oxide (O2/N2O) and other anaesthetics to induce and 
maintain general anaesthesia.  
Fluranes are volatile liquids and are delivered using an anaesthesia machine. An 
anaesthesia machine allows for composition of a mixture of oxygen, anaesthetics 
and ambient air, delivers the mixture to the patient, and monitors the patient. The 
vapourisation of liquid anaesthetics takes place in the anaesthesia machine. The 
regular doses for the induction of anaesthesia are 5 000-25 000 ppm isoflurane  
in oxygen/nitrous oxide and 60 000-80 000 ppm sevoflurane in oxygen/nitrous 
oxide. Because of its airway irritating effect, desflurane is not normally used  
for induction of anaesthesia. The corresponding doses for the maintenance of 
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Figure 2. Chemical degradation of sevoflurane to fluoromethyl 2,2-difluoro-1-(trifluoro-
methyl)vinyl ether (FDVE) (223).  
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anaesthesia are 10 000-25 000 ppm isoflurane, 5 000-30 000 ppm sevoflurane and 
20 000-60 000 ppm desflurane (147-149). 
Occupational exposure to anaesthetic gases occurs in operating rooms at 
hospitals and in practises of specialists, recovery rooms, dental operatories, and 
veterinary facilities. Some decades ago, excess anaesthetic gases were usually 
exhausted into the surrounding air. Although excess gases are nowadays usually 
collected by a local exhaust system, some pollution of ambient air by anaesthetic 
gases is difficult to avoid completely. Thus, leaks around a patient’s face mask, in 
the breathing system, or the ventilator may cause release of anaesthetics. Other 
sources of pollution include liberation of anaesthetics through leaks in connection 
tubes and accidental spillage of liquid anaesthetics when filling vapourisers. This 
makes dermal exposure to liquid anaesthetics possible. In addition, the patient will 
continue to exhale anaesthetics for some time after termination of the anaesthesia. 
This may contaminate the air in the recovery room (40). As described in Chapter 
3, toxic degradation products are formed due to reaction of fluranes with carbon 
dioxide absorbents in the anaesthetic recirculation system. Exposure of personnel 
to these compounds may thus only occur due to leakage from the anaesthetic 
recirculation system. It is unknown whether personnel are exposed to FDVE. 
Since the fluranes are synthesised in closed systems, exposure during production 
occurs only through leaks in the synthesis equipment. 
The degree of pollution in operating theatres depends mainly on the efficiency 
of the gas scavenging system, but also on other factors such as the number of air 
exchanges per hour, anaesthetic techniques, and the inspiratory and expiratory 
concentrations of the inhalation anaesthetics. An anaesthetic gas scavenging 
system collects and removes waste gases at the site of overflow from the breathing 
circuit and disposes of these gases to the outside atmosphere (40). 
Local exhaust equipment is mandatory by law in e.g. Denmark and Sweden (15, 
18, 19). No specific rules regarding occupational exposure to anaesthetics for 
pregnant women exist in Denmark but it is recommended that the exposure of 
pregnant women to anaesthetics is kept below 1/10 of the occupational exposure 
limit (17). 
The annual use of isoflurane, sevoflurane and desflurane in the Nordic countries 
for the period 2000-2005 is listed in Table 3. During this period, the annual use of 
isoflurane in humans has been halved in Denmark, Norway, and Sweden, and in 
Finland, the use of isoflurane has diminished by 75%. Sevoflurane is the most 
widely used of the anaesthetics in humans and has primarily been used for the 
induction of anaesthesia in children because of its lack of irritative effect. The use 
of sevoflurane during 2000-2005 has been stable in Denmark and Norway, while a 
slight increase is observed in Sweden and Finland. In Denmark and Sweden, the 
amount of desflurane was largely unchanged from 2002 to 2005. In contrast, the 
use of desflurane in Norway doubled during this time period. The use of des-
flurane in Finland has been fluctuating with its maximum use in 2002-2003 and 
the lowest use in the end of the time period. Isoflurane is the only flurane used for 
veterinary purposes, and data have only been obtained for Denmark and Sweden.  
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Table 3. Annual uses of the fluranes in the Nordic countries (litres). 
Year Reference Anaesthetic/ 
country 2000 2001 2002 2003 2004 2005  
Human use 
       
Isoflurane        
Denmark 720 550 395 360 400 275 (146) 
Sweden 1 950 1 680 1 515 1 624 1 248 1 101 (11) 
Norway 1 142 899 805 730 665 571 (176) 
Finland 1 221 883 600 570 363 266 (177) 
Sevoflurane        
Denmark 2 700 2 825 2 825 2 900 2 925 2 875 (146) 
Sweden 6 934 7 416 7 826 7 732 7 816 8 110 (11) 
Norway 2 331 2 668 2 602 2 729 2 771 2 696 (176) 
Finland 3 830 4 277 4 251 4 140 4 593 4 822 (177) 
Desflurane        
Denmark 125 225 500 550 500 552 (146) 
Sweden 657 637 620 663 671 620 (11) 
Norway 281 276 421 576 613 641 (176) 
Finland 298 496 878 728 183 166 (177) 
Veterinary use 
Isoflurane        
Denmark No data 164 246 167 307 315 (54) 
Sweden 158 479 555 475 1 144 1 357 (11) 
Norway   ----------------------------------- No data ----------------------------------------------- 
Finland   ----------------------------------- No data ----------------------------------------------- 
Sevoflurane   ----------------------------------- Not used ---------------------------------------------- 
Desflurane   ----------------------------------- Not used ---------------------------------------------- 
In numbers for the Norwegian use of fluranes it is assumed that the number of inhabitants is 
4 681 134 (185).  
 
In the described time period, the veterinary use of isoflurane has increased 2- and 
8-fold in Denmark and Sweden, respectively. 
It should be noted that the anaesthetic potency of sevoflurane is only about  
half that of isoflurane, whereas desflurane is the least potent of the three. This is 
reflected by the minimum alveolar concentration (MAC) that denotes the con-
centration of an anaesthetic that produces immobility in 50% of the subjects 
exposed to a supramaximal painful/noxious stimulus. MAC-values for the three 
fluranes are given in Table 4. 
 
Table 4. MAC-values for the fluranes.  
MAC Anaesthetic Reference 
(ppm) Isoflurane Sevoflurane Desflurane  
Humans a  11 500-12 200 21 000 60 000 (69) 
Rats  14 000, 14 200 25 000 72 100 (31, 66) 
Mice  13 100 - 17 700 b 25 000 65 500 - 91 200 b (194, 222) 
a
 The tabulated values are stated for humans 36-49 years of age, as the MAC-values are age 
dependent and decrease with age. 
b
 The tabulated ranges are stated for 15 inbred mouse strains. 
MAC: minimum alveolar concentration that produces immobility in 50% of the subjects exposed to 
supramaximal painful/noxious stimulus. 
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5. Measurements and analysis of workplace exposure 
5.1 Environmental exposure monitoring 
Monitoring of the anaesthetics in ambient air was performed by discontinuous gas 
chromatography (GC) until about 1980. Since then, infrared spectrophotometry 
has been the almost exclusively used method for monitoring of air concentrations 
of the fluranes. Infrared spectrophotometry holds many advantages compared to 
GC, e.g. continuous measurement and measurement of peak exposure levels (40).  
In most cases, flurane concentrations have been measured in the breathing zone 
using a photoacoustic infrared spectrophotometer connected to sampling tubes 
fitted at the operating theatre personnel’s masks. The majority of measurements 
using this technique have been performed by employing two different analysers: 
1302/1309 Multigas Monitor (Brüel and Kjær, Denmark) and Miran 1B2 
(Foxboro, East Bridgewater, Massachusetts). The detection limits of the method 
for the respective flurane are given in Table 5. 
5.2 Biological exposure monitoring 
Biological monitoring of unmodified urinary volatile anaesthetics (84) as well as 
breakdown products of anaesthetics excreted in urine (106) has been described. 
Several studies have indicated that the urinary isoflurane concentration might  
be used as an appropriate biological exposure index (119). Accorsi et al used gas 
chromatography-mass spectrometry (GC-MS) to detect both isoflurane and 
sevoflurane in urine supernatants. The limits of detection for isoflurane and 
sevoflurane were 0.02 and 0.03 µg/l, respectively (1). Isoflurane in urine has also 
been determined using head-space GC with electron capture detection (GC-EC). 
The sensitivity for this method has been reported to be 1 µmol/m3 (120). 
Urinary sevoflurane (1, 2) as well as its urinary metabolite hexafluoroiso-
propanol (HFIP) (97) have been proposed for the evaluation of occupational 
sevoflurane exposure. Recently, Accorsi et al analysed connected data for 
concentrations of airborne sevoflurane, urinary sevoflurane and HFIP (3). The 
authors of the study concluded it advantageous to measure urinary sevoflurane 
compared to HFIP. The urine samples were analysed by headspace GC-MS. The 
limit of detection for urinary sevoflurane was 0.03 µg/l (1-3). 
 
Table 5. Detection limits for the fluranes in photoacoustic infrared spectrophotometry. 
Anaesthetic 1302 Multigas 
Monitor 
Reference Miran 1B2 Reference 
Isoflurane 0.008-0.1 ppm (33, 104, 108, 217) 0.1 ppm (217) 
Sevoflurane 0.01 ppm (33) 0.1 ppm (217) 
Desflurane 0.05-0.1 ppm (33, 104, 217) 0.1 ppm (217) 
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6. Occupational exposure data 
Occupational exposure to the fluranes occurs primarily via inhalation. Isoflurane, 
sevoflurane, and desflurane concentrations have been measured at different work-
sites in hospitals and veterinary clinics (Table 6-8). The measurements have been 
performed either as room measurements or measurements in the breathing zone  
of personnel. No exposure data from the production of flurane anaesthetics have 
been located.  
A number of studies show that the level of exposure depends on the type of 
mask used during anaesthesia (93) and that the highest exposure of health care 
personnel occurs during mask induction of anaesthesia (103).  
The occupational inhalation exposure to anaesthetics in operating rooms at 
selected Danish hospitals from 1986 to 2000 was evaluated in a report elaborated 
on the initiative of the Danish Working Environment Authority (16). Measure-
ments of isoflurane were initiated in 1990, while sevoflurane and desflurane 
measurements began in 1996. The use of isoflurane increased steadily from 1990, 
and was used in approximately 50% of the surgical operations in the year 2000.  
At the same time, sevoflurane was used in approximately 30% of the procedures. 
Desflurane concentrations were very low throughout the period. During the years 
of measurement, the average exposure to isoflurane and sevoflurane ranged from 
approximately 0.2 to 1 ppm (average of 2-31 measurements per compound/year) 
(16).  
Exposure to the fluranes was measured in operating and recovery rooms in nine 
Swedish hospitals. A total of 7 desflurane, 21 isoflurane and 100 sevoflurane 
measurements were performed in 1999, 2002 and 2003 on personnel participating 
in different kinds of operations and examinations. Air concentrations were 0.04-
0.22 ppm for isoflurane, 0.02-14.4 ppm for sevoflurane and 0.04-0.21 ppm for 
desflurane (117).  
Isoflurane 
Most measurements relate to exposure to isoflurane in hospitals (Table 6). In 
general, the levels of exposure to isoflurane have decreased over time and in the 
most recent studies performed at hospitals, the exposure levels stayed below 2 
ppm. Not surprisingly were air values lower when scavenging was applied. 
In two studies evaluating exposure to isoflurane at veterinary clinics (Table 6), 
where some of the highest exposures to isoflurane have been registered (105, 141), 
exposure levels reached several ppm. 
Sevoflurane 
As for isoflurane, the levels of exposure seem to be decreasing over time. Thus, 
the exposure levels stayed below 1 ppm in the most recent investigations (Table 
7). 
In one interesting study, the breath was screened of 40 operating room staff 
members (mixed gender) before operating room duty, 0, 1, 2, and 3 hours after 
9 
duty, and before commencing duty on the following day, and of 370 control 
persons. Staff members exhibited significantly increased sevoflurane levels in 
exhaled air at all times. The average after duty value was 0.80 ppb (0 hours), 
decreasing to 0.24, 0.27, 0.28, and 0.11 ppb, respectively, at the other measured 
time points. Significant concentrations of sevoflurane may be continuously present 
in persons exposed to sevoflurane on a daily basis (226).  
Desflurane 
Most of the occupational exposure levels of desflurane listed in Table 8 are  
below 1 ppm. However, higher levels of desflurane have been measured in 
postanaesthesia care units, intensive care rooms and recovery rooms (36, 217). 
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Table 6. Occupational exposure levels of isoflurane at different worksites. 
Worksite Sampling No. of samples/ 
patients 
Measurement Personnel Exposure level, ppm 
median (range), mean ± SD 
Publication year  
(Reference) 
Intensive care unit Stationary (0.5 m 
above patient’s head).  
Personal (8-h shift)  
15 patients 
 
10 nurses 
IR 
 
GC on passive 
lapel dosimeters 
Area 
 
Nurses 
0.0-0.5 (range of means) 
 
0-0.16 (range of means)  
(8-h TWA)  
2005 (210) 
Operating and 
recovery rooms at  
9 Swedish hospitals 
Personal (8-h shift) 21 samples GC Hospital staff 0.04-0.22 (range of means) 2004 (117) 
Operating rooms at 
14 Danish hospitals 
Not described 154 samples GC Nurses 0.1-0.3 (range of medians) 2001 (16) 
Postanaesthesia care 
unit (PACU) 
Stationary 16 patients Proton transfer 
reaction-MS 
PACU personnel 0.0095 (mean) 2001 (204) 
Operating room Personal Not described Photoacoustic IR Without active scavenging, 1996: 
Anaesthetists:  Workplace A 
                        Workplace B 
                        Workplace C 
With active scavenging, 1997: 
Anaesthetists:  Workplace A 
                        Workplace B 
                        Workplace C 
Median: 
1.7  
3.8  
25.9 
Median: 
1.4 
1.7 
0.3  
2000 (242) 
Anaesthetic room 
Operating room 
Recovery room 
Stationary and 
personal 
12 locations a 
  3 locations a 
  6 locations a 
IR Area 
Anaesthetists 
Recovery room personnel  
1 (0-2) 
3 (2-3) 
1 (0-2) 
1999 (101) 
Veterinary clinics Personal and 
stationary 
178 samples 
132 samples 
229 samples 
Single-beam IR Veterinarians 
Assistants 
Area 
5.3 ± 2.7 
4.7 ± 2.5 
4.6 ± 2.2 
1999 (141) 
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Table 6. Occupational exposure levels of isoflurane at different worksites. 
Worksite Sampling No. of samples/ 
patients 
Measurement Personnel Exposure level, ppm 
median (range), mean ± SD 
Publication year  
(Reference) 
Postanaesthesia care 
unit (PACU) 
Personal 19 patients IR Nurses 1.1 ± 0.7  1998 (217) 
Recovery room Stationary 207 patients Real-time IR Recovery room personnel 1.4 ± 0.31 1998 (239) 
Veterinary clinic Personal (breathing 
zone) 
Not described Photoacoustic IR Veterinary personnel 1.9 ± 2.5 (8-h TWA) 
5.3 ± 8.1 (8-h TWA,  
open mask) 
Peak values > 300 
1998 (105) 
Operating room Personal  15 patients Photoacoustic IR Anaesthetists 
Surgeons 
Nurses 
Patients’ mouth 
0.19 (0.01-0.78) 
0.15 (0.01-0.69) 
0.27 (0.02-1.57) 
0.41 (0.01-3.15) 
1998 (102) 
Operating room Personal  10 patients 
 
 
10 patients 
Photoacoustic IR Without scavenging: 
Anaesthetists 
Perfusionists 
With scavenging: 
Anaesthetists 
Perfusionists 
 
0.31 (0.15-2.08)  
0.33 (0.15-2.10)  
 
0.14 (0.13-0.19)  
0.16 (0.13-0.20) 
1997 (104) 
Operating theatre  Stationary 100 + 165 
measurements 
Photoacoustic IR Area 0.35 (0.1-6.2) 1997 (159) 
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Table 6. Occupational exposure levels of isoflurane at different worksites. 
Worksite Sampling No. of samples/ 
patients 
Measurement Personnel Exposure level, ppm 
median (range), mean ± SD 
Publication year  
(Reference) 
Operating room Personal (breathing 10 patients Photoacoustic IR Laryngeal mask airway anaesthesia: 1996 (108) 
 zone) and 
stationary (3 leakage 
related locations) 
 
 
 
 
 
 
10 patients 
 Anaesthetist 
Surgeon 
Nurse 
Operating area 
Patients’ mouth 
Anaesthesia machine 
Tracheal tube anaesthesia:  
Anaesthetist 
Surgeon 
Nurse 
Operating area 
Patients’ mouth 
Anaesthesia machine 
0.50 (0.28-2.28) 
0.36 (0.20-3.93) 
0.64 (0.22-26.98) 
2.54 (0.22-31.02) 
32.81 (0.46-2150) 
0.37 (0.26-3.36) 
 
0.35 (0.02-0.73) 
0.29 (0.01-0.50) 
0.31 (0.02-1.07) 
0.32 (0.06-0.76) 
0.89 (0.32-11.42) 
0.30 (0.05-0.92) 
  
Operating room Personal and 
stationary: Diffusive 
sampler Orsa 5 
(Dräger) for TWA 
Measurements 
16 
  5 
 
29 
13 
GC-MS Open circuit without scavenging: 
Anaesthetists and nurses  
Ventilator zone 
Open circuit with scavenging:  
Anaesthetists and nurses  
Ventilator zone 
 
5.0 ± 0.4  
6.3 ± 0.3 
 
1.7 ± 0.2 
1.5 ± 0.1 
1995 (119) 
    Low flow anaesthesia without scavenging:   
  29 
12 
 Anaesthetists and nurses  
Ventilator zone 
2.0 ± 0.3 
1.4 ± 0.3 
  
    Low flow anaesthesia with scavenging:   
  19 
12 
 Anaesthetists and nurses  
Ventilator zone 
0.6 ± 0.04 
0.9 ± 0.1 
  
a
 Measurements took place at 8 different hospitals in anaesthetic rooms, operating theatres and recovery rooms at 12, 3 and 6 different locations, respectively. 
GC: gas chromatography, IR: infrared spectrophotometry, MS: mass spectrometry, PACU: postanaesthesia care unit, SD: standard deviation, TWA: time-weighted 
average. 
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Table 7. Occupational exposure levels of sevoflurane at different worksites. 
Worksite Sampling  No. of samples/ 
patients 
Measurement   Personnel Exposure level, ppm 
median (range), mean ± SD 
Publication year 
(Reference) 
Operating room Personal 78 measurements GC-MS-SIM Anaesthetists 
Surgeons 
Nurses 
Auxiliary personnel 
0.69 ± 2.23 2005 (3) 
Operating room Stationary 
Personal 
6 hospitals 
14 samples 
Photoacoustic IR Area: 
Central operating 
theatres 
Intervention rooms 
Anaesthetists  
 
0.09-0.21 (range of medians)  
 
0-24.8 (range of medians) 
0.19 (median) 
2005 (215) 
Operating room Personal 22 samples 
15 samples 
30 samples 
11 samples 
GC Anaesthetists (n=10) 
Surgeons (n=10) 
Nurses (n=12) 
Auxiliary (n=4) 
0.65 (median) 
0.07 (median) 
0.17 (median) 
0.04 (median) 
2004 (81) 
Operating and recovery 
rooms at 9 Swedish 
hospitals 
Personal  
(8-h shift)  
100 measurements GC Hospital staff 0.02-14.4 (range of means) 2004 (117) 
Operating room Personal 5 patients Photoacoustic IR  
Anaesthetists 
Surgeons 
Perfusionists 
Before surgery (during surgery) 
0.03 ± 0.02 (0.04 ± 0.01) 
0.16 ± 0.05 (0.14 ± 0.05)  
Not determ. (0.18 ± 0.03) 
2003 (173) 
12 operating areas Personal 61 personnel GC-MS Operating room staff 
members 
0.28 (0-1.88, all) 
0.41 (0.02-1.88, open circuit) 
0.18 (0-1.4, semi closed circuit) 
2003 (232) 
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Table 7. Occupational exposure levels of sevoflurane at different worksites. 
Worksite Sampling  No. of samples/ 
patients 
Measurement   Personnel Exposure level, ppm 
median (range), mean ± SD 
Publication year 
(Reference) 
Operating room Personal  33 patients Photoacoustic IR Patients’ mouths 
 
 
 
 
 
Anaesthetists’ 
breathing zone 
Cuffed oropharyngeal airway:  
8.1 ± 12.2 
Conventional face mask: 
46.5 ± 19.6 
Laryngeal mask airway: 
18.5 ± 25.8 
Cuffed oropharyngeal airway:  
0.5 ± 0.2 
Conventional face mask: 
2.2 ± 0.9 
Laryngeal mask airway: 
1.0 ± 0.9 
2002 (93) 
Operating rooms at 14 
Danish hospitals 
Not described  102 measurements GC Nurses 0.1-2 (range of medians) 2001 (16) 
Postanaesthesia care 
unit  
Stationary 16 patients Proton transfer 
reaction-MS 
Area  0.0159 ± SD (not given) 2001 (204) 
Operating room Personal 20 patients, children 
<10 yrs 
5 patients, teenagers 
≥10 yrs 
Real-time 
photoacoustic IR 
Surgeons 
Anaesthetists 
Surgeons 
Anaesthetists 
0.95 ± 1.25 
0.87 ± 1.05 
0.39 ± 1.20 
0.35 ± 1.03 
2001 (39) 
Operating room 
-heart-thorax operation 
 
-child operation room  
 
Child clinic 
 
Recovery room 
Personal  
10 patients 
 
20 patients 
 
20 patients 
 
33 patients 
Photoacoustic IR  
Anaesthetists 
Surgeon/nurses 
Anaesthetists 
Surgeon/nurses 
Anaesthetists 
Surgeon/nurses 
Nurses 
 
0.01 ± 0.002 
0.04 ± 0.01 
0.99 ± 32 
1.10 ± 0.34 
3.07 ± 0.97 
1.93 ± 0.59 
2.50 ± 0.31 
1999 (36) 
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Table 7. Occupational exposure levels of sevoflurane at different worksites. 
Worksite Sampling  No. of samples/ 
patients 
Measurement   Personnel Exposure level, ppm 
median (range), mean ± SD 
Publication year 
(Reference) 
Operating room Personal 25 patients Photoacoustic IR Anaesthetist 
Surgeon 
Auxiliary nurse 
0.75 (0.13-1.95)  
0.59 (0.13-1.80)  
0.61 (0.13-3.81) 
1997 (109) 
Operating room Personal  20 patients Photoacoustic IR  
Anaesthetists  
Nurse 
 
Anaesthetists 
Nurse 
 
Anaesthetists 
Nurse 
Mask induction:  
5.4 (3.7-11.9)  
2.9 (2.3-3.6)  
During maintenance: 
0.6 (0.2-1.6) 
0.5 (0.1-1.2) 
Total anaesthesia time: 
0.9 (0.4-4.6) 
0.5 (0.3-2.2) 
1997 (103) 
Operating room Personal 25 patients Photoacoustic IR Anaesthetist 
Surgeon 
Nurse 
0.75 (0.13-1.95) 
0.59 (0.13-1.80) 
0.61 (0.13-3.81) 
1997 (109)  
Anaesthetic room Stationary  
Personal 
23 patients 
  6 samples 
Single beam IR Area 
Anaesthetist 
1.1 (0.6-1.7) (8 h-TWA) 
1.2 (0.8-2.1) 
1997 (94) 
GC: gas chromatography, IR: infrared spectrophotometry, MS: mass spectrometry, SIM: selected-ion monitoring, SD: standard deviation, TWA: time-weighted average. 
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Table 8. Occupational exposure levels of desflurane at different worksites.    
Worksite Sampling  No. of samples/ 
patients 
Measurement Personnel Exposure level, ppm 
median (range), mean ± SD 
Publication year 
(Reference) 
Operating and recovery rooms 
at 9 Swedish hospitals 
Personal  
(8-h shift)  
7 measurements GC Hospital staff 0.04-0.21 (range of means) 2004 (117) 
Operating room Personal 5 patients Photoacoustic IR  
Anaesthetists 
Surgeons 
Perfusionists 
Before surgery (during surgery) 
0.02 ± 0.01 (0.02 ± 0.003) 
0.21 ± 0.10 (0.62 ± 0.28) 
Not determ. (0.82 ± 0.26) 
2003 (173) 
Operating rooms at 14  
Danish hospitals 
Not described  20 measurements GC Nurses 0.1-1 (range of medians) 2001 (16) 
Operating room Personal 10 adult patients 
 
10 child patients 
Photoacoustic IR  Anaesthetists 
Surgeons 
Anaesthetists 
Surgeons 
0.02 ± 0.03 
0.21 ± 0.24 
0.02 ± 0.03 
0.30 ± 0.14 
2000 (38) 
Operating room 
-heart-thorax operation 
 
-eye operation 
 
-ear, nose, throat operation 
 
Intensive care room 
Recovery room 
Personal  
5 patients 
 
10 patients 
 
10 patients 
 
5 patients 
34 patients 
Photoacoustic IR  
Anaesthetists 
Surgeon/nurses 
Anaesthetists 
Surgeon/nurses 
Anaesthetists 
Surgeon/nurses 
Nurses 
Nurses 
 
0.004 ± 0.001 
0.18 ± 0.06 
0.07 ± 0.04 
0.48 ± 0.24 
0.001 ± 0.002 
0.02 ± 0.01 
6.04 ± 2.80 
2.20 ± 0.34 
1999 (36) 
Operating room Personal 20 child patients IR Surgeons 
Anaesthetists 
2.8 ± 1.42 
0.43 ± 0.23 
1999 (37) 
Operating room Personal 15 patients Photoacoustic IR Anaesthetists 
Surgeons 
Nurses 
Patients’ mouth 
0.47 (0.05-4.89) 
0.43 (0.02-2.51) 
0.48 (0.01-7.53) 
0.76 (0.01-7.82) 
1998 (102) 
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Table 8. Occupational exposure levels of desflurane at different worksites.    
Worksite Sampling  No. of samples/ 
patients 
Measurement Personnel Exposure level, ppm 
median (range), mean ± SD 
Publication year 
(Reference) 
Postanaesthesia care unit Personal 31 patients IR Nurses 2.1 ± 1.2 1998 (217) 
Operating room 
-ear, nose, throat operation 
 
-cleft palate operation 
Personal Patients: 
10 children  
10 adults  
10 children  
10 adults  
Photoacoustic IR Surgeons  
0.3 ± 0.14 
0.4 ± 0.22 
0.6 ± 0.23 
0.2 ± 0.24 
1998 (240) 
Operating room Personal 10 patients 
 
 
10 patients 
Photoacoustic IR Without scavenging: 
Anaesthetists 
Perfusionists 
With scavenging: 
Anaesthetists 
Perfusionists 
 
0.90 (0.56-6.08) 
0.93 (0.54-6.10) 
 
0.24 (0.09-0.81) 
0.26 (0.10-0.79) 
1997  (104) 
GC: gas chromatography, IR: infrared spectrophotometry, SD: standard deviation.  
 
18 
7. Toxicokinetics  
Uptake, distribution, biotransformation, and elimination of the fluranes are 
primarily studied in patients exposed to high doses of anaesthetics rather than 
health care personnel exposed to low concentrations during work.  
The toxicokinetics of the fluranes has been reviewed by Delgado-Herrera  
and co-workers (55) and this paper forms the basis for the following sections, 
supplemented with original studies when relevant.  
7.1 Uptake  
Fluranes are volatile liquids that are administered to patients in a vapourised state. 
Therefore, exposure to health care personnel occurs most likely via inhalation of 
waste gas. Isoflurane, sevoflurane and desflurane are all characterised by having 
low blood:gas partition coefficients (Table 2). This is associated with a rapid 
induction of and rapid recovery from anaesthesia, as the fluranes equilibrate 
rapidly between air and blood in the airways. The uptake of fluranes was evaluated 
in healthy volunteers 30 minutes after initiation of anaesthesia by measuring the 
ratio between the alveolar blood concentration of flurane (FA) and the concentration 
of inspired flurane (FI), i.e. FA/FI. After 30 minutes, the FA/FI ratio was 0.9 (des-
flurane), 0.85 (sevoflurane) and 0.73 (isoflurane), showing that the uptake of 
desflurane and sevoflurane is faster than that of isoflurane.  
Uptake of isoflurane was estimated in pieces of male rat skin. After exposure to 
41 ppm (302 mg/m3) or 202 ppm (1 496 mg/m3) isoflurane for 6 hours at 32 ˚C, 
the partition coefficient for skin:air was 4.5 ± 0.3 (mean ± standard deviation (SD)) 
irrespective of concentration tested (165).  
Dermal uptake of the fluranes may occur to a small extent. The dermal 
absorption of isoflurane vapour in vivo was evaluated in rats (171). Male Fisher 
344 rats with a closely clipped fur were exposed whole body to 50 000 ppm 
isoflurane for 4 hours while breathing fresh air through a latex mask. The flux was 
calculated to be 0.0096 mg/cm2/hour, and the permeability constant for isoflurane 
was estimated to 0.025 ± 0.004 cm/hour. Mean blood concentrations reached 1.8 
µg/ml. According to these experiments and calculations, the dermal uptake in rats 
is only about 0.1% of the inhaled amount upon whole-body exposure to vapours. 
The dermal uptake is likely to be lower in humans than in rats. In addition, the 
fluranes have low boiling points (23-59 ˚C) and high volatility, therefore any spill 
on the skin will quickly evaporate into the air. Thus, although human data are 
lacking, the potential for significant systemic uptake of fluranes via the skin seems 
low. 
7.2 Distribution  
Following uptake, the fluranes are rapidly distributed in the body. The partitioning 
in human fat from air is much higher (20-50 times, Table 2) than in any other 
human tissue or blood from air. When the distribution of sevoflurane to different 
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body compartments (lungs, vessel-rich organs, muscles, fat adjacent to the vessel-
rich organs and peripheral fat) was estimated in a physiologically based pharmaco-
kinetic model for human distribution of anaesthetics, muscle tissue received the 
highest volume of fluranes followed by vessel-rich organs (reviewed in Delgado-
Herrera et al (55)). 
Both isoflurane and sevoflurane pass the placenta and transfer from maternal to 
foetal blood, as assessed during late pregnancy (described below). 
Isoflurane  
Partial pressures of isoflurane in maternal and umbilical blood were measured in 
12 healthy pregnant women undergoing caesarean section. The pregnant women 
were exposed to 8 000 ppm isoflurane to supplement nitrous oxide/oxygen 
anaesthesia. Maternal and umbilical blood was sampled for isoflurane measure-
ments at delivery. The maternal mean arterial pressure of isoflurane as a fraction 
of the inspired partial pressure was 0.44. Umbilical venous partial pressures of 
isoflurane as a fraction of maternal arterial partial pressures averaged 0.71, 
indicating that foetal arterial blood contained more than two thirds of the 
concentration measured in maternal blood. The mean time from induction of 
anaesthesia until delivery was 11.7 minutes (61). In another study, in which 10 
pregnant women were exposed to 6 000 ppm isoflurane, an average maternal 
blood concentration of 2.4 mg/dl and a foetal umbilical blood concentration of  
0.7 mg/dl were reported. Thus the ratio of the anaesthetic concentration between 
the umbilical vein and maternal arterial blood was 0.27 for an average inhalation 
time of 8 minutes. This ratio correlated positively with inhalation time, and was 
calculated to be higher (approximately 0.4) for a delivery time of 13 minutes 
(213). When the solubility of isoflurane was determined in vitro in paired samples 
of maternal and mixed placental (foetal) blood, the blood:gas partition coefficients 
were significantly higher in maternal blood than in blood from the foetal com-
partment (1.51 ± 0.10 SD versus 1.35 ± 0.09 SD), resulting in a foetal:maternal 
ratio of 0.89. Similar ratios were obtained for plasma and erythrocytes (82). 
Fisher et al experimentally determined human milk:blood partition constants 
using a vial equilibrium method, by introducing anaesthetic into the head space of 
vials with 500 µl fresh blood (n=6) or 200 µl thawed milk (n=25). The partition 
coefficient for blood:air was 3.40±3.76 SD, and that for milk:air 6.03 ± 4.56 SD. 
From these values, the milk:blood partition coefficient was calculated to be 1.77. 
These values were entered into a physiologically based pharmacokinetic lactation 
model. This model predicted that an infant would ingest 0.37 mg isoflurane through 
breast milk during a 24-hour period if the woman worked 9 hours at an air con-
centration of 50 ppm (75).  
Sevoflurane 
Ten pregnant women were exposed to 8 000 ppm sevoflurane from the time  
of initiation of caesarean section until delivery. Maternal blood concentration 
reached 5.2 mg/dl after 13 minutes, compared to an average concentration in 
foetal umbilical vein blood of 2.0 mg/dl, resulting in a ratio between the  
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Table 9. Human biotransformation of inhaled anaesthetic doses of the isoflurane, 
sevoflurane and desflurane (30, 130, 134).  
Anaesthetic Biotransformation % Major metabolites 
Isoflurane 0.2 F-, trifluoroacetic acid 
Sevoflurane 2-5 F-, hexafluoroisopropanol 
Desflurane 0.02 F-, trifluoroacetic acid  
 
sevoflurane concentration in blood from the umbilical vein and maternal arteries 
of 0.38 (213). 
Desflurane 
No publications regarding distribution of desflurane have been identified. 
7.3 Biotransformation 
All the fluorinated anaesthetics undergo biotransformation to some small extent  
to inorganic fluoride and fluoroorganic metabolites. Human metabolism of iso-
flurane, desflurane, and sevoflurane has been characterised both in vitro and in 
vivo (135). The metabolism of the fluranes takes place mainly in the liver, and,  
to a lesser extent in the kidneys and the lungs. The fluranes are metabolised in  
the liver by cytochrome P450, especially by the isoenzyme CYP2E1, and the 
oxidative route is dominant. The induction of liver microsomal enzymes, by e.g. 
phenytoin, isoniazid, phenobarbital, alcohol and halothane, may increase the 
metabolism of the fluranes (190). Smoking does not seem to influence fluoride 
formation from the metabolism of sevoflurane (153). Table 9 lists the degree of 
biotransformation and major metabolites. It is apparent that the rate of metabolism 
is 10-100-fold greater for sevoflurane than for isoflurane and desflurane. 
The metabolism of isoflurane and desflurane is similar; they are both meta-
bolised to inorganic halide ion (chloride or fluoride) and trifluoroacetic acid 
(TFA). The simplified metabolic pathway for isoflurane and desflurane is shown 
in Figure 3. 
The main pathway of metabolism of sevoflurane is depicted in Figure 4. 
Sevoflurane is metabolised in the liver by CYP2E1 to a transient intermediate that 
decomposes to equimolar concentrations of HFIP and inorganic fluoride ions. 
 
F3C OCHX CHF2 F3C C
OH
F3C C
O
X
F3C C
O
NH
O
FCYP2E1 +
protein
TFAisoflurane/desflurane
 
Figure 3. Metabolism of isoflurane (X=Cl) and desflurane (X=F) (modified from (130, 
135). TFA: trifluoroacetic acid.  
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Figure 4. Metabolism of sevoflurane (135). HFIP: hexafluoroisopropanol. 
HFIP accounts for more than 80% of the organic fluorinated metabolites. HFIP 
conjugates rapidly with glucuronic acid, forming HFIP-glucoronide (134). The 
metabolism of sevoflurane is dose-dependent and related also to the duration of 
anaesthesia. In rats exposed to sevoflurane, serum levels and urinary excretion  
of fluoride and HFIP increased linearly up to 1.25%, but did not increase further 
above this exposure level. In human patients, peak plasma inorganic fluoride ion 
concentrations have been shown to correlate with the duration of sevoflurane 
administration. However, no difference in the post-anaesthetic decrease in plasma 
fluoride was seen in patients anaesthetised for less than 7 hours, compared to 
those anaesthetised for more than 7 hours (55). 
7.4 Excretion  
Exhalation is the major elimination route for the fluranes, due to low metabolism 
and low blood solubility, as shown for isoflurane (43). Percutaneous loss esti-
mated in human volunteers amounted to less than 0.4% for all three fluranes (73, 
158). A minor fraction of the fluranes is excreted unchanged in urine. 
Approximately 90 minutes after cessation of anaesthesia, the ratio between  
the alveolar blood concentration of flurane (FA) and the concentration of inspired 
flurane (FI), i.e. FA/FI had approached 0.01 or less for the three fluranes (55). The 
elimination of isoflurane has been described to occur in three phases, i.e. a short 
phase with a half-time of 2 minutes, where the elimination is determined by the 
speed of elimination over the alveolar membrane. A middle phase with a half- 
time of 19 minutes can be ascribed to the elimination of isoflurane from the inner 
organs. The half-time of the long phase is 233 minutes and relates to elimination 
of isoflurane from muscle and adipose tissue (56). 
The sevoflurane metabolite HFIP-glucoronide is excreted in the urine with a 
half-time of approximately 14 hours (113).  
Isoflurane does not seem to accumulate in the body during the working week 
(159).  
8. Biological monitoring  
Isoflurane 
Several studies indicate that the urinary isoflurane concentration might be used as 
an appropriate biological exposure index. Thus, the concentration of isoflurane 
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was measured in the ambient atmosphere in 11 operating theatres at 5 hospitals in  
Italy and in the urine of 45 of the exposed health care personnel (anaesthetists, 
surgeons, and nurses). A significant correlation was found between the concen-
trations of isoflurane in urine and air (r=0.90) (120). In a follow-up study, the 
measurements were extended to 362 subjects, using personal passive samplers and 
covering 190 operating theatres in 41 hospitals. Again, significant correlations 
were found between urine and air levels (121).  
Imberti et al investigated isoflurane exposure during different exposure scen-
arios as described in Table 6, i.e. during open circuit and low flow anaesthesia. 
The effects of active and passive scavenging were also investigated, ensuing large 
variations in air concentrations. The study involved anaesthetists and nurses 
during routine activity. A highly significant correlation was found between 
breathing zone (time-weighted average, TWA) and urinary concentrations of 
isoflurane when measured after 3 hours of continuous exposure (119). 
Finally, exposure to isoflurane was monitored in 112 operating theatre workers. 
Urine samples were collected for each subject after the end of the shift on the  
first and after the last day of a 4-day working week. Time integrated exposure 
levels during the shift were monitored by means of stationary sampling, with the 
instrument placed so as to collect the air in a standardised position, close to the 
patient’s head and at the height corresponding to the operator’s airway. End of 
shift urinary isoflurane was 0.7 µg/l (95th percentile 2.6, range 0-4.7) on the first 
day and 0.8 µg/l (95th percentile 2.0, range 0-5.6) on the last. Atmospheric con-
centrations in operating theatres ranged from 0.1 to 6.2 ppm isoflurane, with 
average values of approximately 0.35 ppm. The correlation between atmospheric 
and biological indicators was not significant. The authors explained this finding in 
that stationary sampling generally shows higher levels than those that are in fact 
absorbed by the organism of each individual and that can be measured by diffusive 
passive sampling (159).  
The relationship between isoflurane air concentrations in operating rooms and 
the corresponding isoflurane concentrations in the exhaled air of the operating 
personnel at the end of the exposure has also been investigated. Isoflurane was 
retained in an adsorbent cartridge and after thermal desorption the concentration 
was estimated by GC. A close relationship was found between the log of exposure 
dose (expressed as TWA exposure multiplied by exposure time) and the log of 
concentration in exhaled air (r=0.79). The good correlation between ambient air 
and exhaled air isoflurane concentrations allowed the biological exposure limits to 
be calculated. Thus, the biological concentration in mixed exhaled air at end of 
exposure was 0.52 ppm for exposure to 2 ppm and 1.77 ppm for exposure to 10 
ppm (192). No studies on biomonitoring of the isoflurane metabolite TFA were 
identified. 
Sevoflurane 
Thirteen men and 23 women occupationally exposed to volatile anaesthetics in 
paediatric operating rooms were studied during a 2-week period. Sevoflurane 
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inhalation exposure was monitored by personal passive samplers and post-shift 
urine samples were collected after 1.75-6 hours morning exposure and analysed by 
headspace GC-MS. Median sevoflurane air values were 0.13 ppm (range 0.03-18.8 
ppm; n=78), urinary sevoflurane levels 0.6 µg/l (not detectable (ND)-18.5 µg/l; 
n=76) and total urinary HFIP levels 0.49 mg/l (ND-6 830 mg/l; n=75). The low 
detection limit for urinary sevoflurane (0.03 µg/l), allowed quantitation of all but 
one sample, whereas the HFIP content was below the detection limit in more than 
25% the of urine samples. Urinary sevoflurane correlated well with breathing zone 
data (r2=0.697). The correlation was lower for total urinary HFIP that appeared to 
be influenced also by smoking habits. The biological exposure values correspond-
ing to 0.5 and 2 ppm sevoflurane in air were 1.4 and 3.9 µg/l urine, respectively 
(calculated by linear regression). For HFIP, these values were 0.82 and 2.66 mg/l 
urine. In summary, urinary unmodified sevoflurane seemed to be a more sensitive 
and reliable biomarker of short-term exposure to sevoflurane compared to total 
urinary HFIP (which appeared to be influenced by physiological and/or genetic 
individual traits and seemed to provide an estimate of integrated exposure) (3). 
Sevoflurane in urine and breathing area were monitored in 124 subjects in 11 
operating theatres. Passive personal samplers were collected after 2.5-7 hours  
of exposure, at the same time as post-shift urinary samples. A static headspace 
sampler coupled with GC-MS was used for analytical determinations (the limit of 
detection was 0.1 µg/l urine and 50 ppb). Median (range) post-shift urinary and air 
values for sevoflurane were 1.2 µg/l (0.1-5.0) and 0.4 ppm (0.05-3.0). Urinary 
levels closely correlated with air levels (r2=0.754). The biological exposure value 
corresponding to exposure to 2 ppm sevoflurane for 8 hours, calculated as means 
of regression slope and intercept, was 3.6 µg/l urine (2).  
Mean individual workplace air exposures to sevoflurane and urinary sevo-
flurane were monitored in 36 subjects working in two paediatric operating rooms. 
Air and urinary levels were significantly greater in anaesthetists compared to other 
groups of hospital staff, with median values of 0.65 ppm (interquartile range 1.36; 
95th percentile 4.36) for breathing zone sevoflurane and 2.1 µg/l (interquartile 
range 2.6; 95th percentile 7.6) for urinary sevoflurane. Log-transformed urinary 
concentrations appeared closely and significantly related to the breathing zone 
concentrations for the anaesthetists and the nurses, but the relationship was 
weaker and non-significant for the surgeons and the auxiliary personnel (81). 
Desflurane 
No studies on biomonitoring of desflurane or its metabolite TFA were identified.  
Conclusion 
Both urinary and exhaled concentrations of unmodified isoflurane seem 
appropriate for biological monitoring.  
Unmodified sevoflurane in urine may be used for biological monitoring  
of occupational exposure, whereas monitoring of urinary HFIP seems less 
appropriate.  
No studies were found for desflurane.  
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9. Mechanisms of toxicity  
Neurotoxicity  
High doses of isoflurane, sevoflurane and desflurane induce anaesthesia, which 
account for the widespread use of these compounds. At supraclinical doses, the 
fluranes cause respiratory depression and death. The exact mechanisms for the 
anaesthetic effects remain to be identified (87). General anaesthetics were once 
thought to be drugs without receptors, but probably volatile anaesthetics exert very 
specific actions at the molecular level with protein receptors as primary targets. 
The current paradigm of mechanistic investigations focuses heavily on γ-amino-
butyric acid A (GABAA) receptors and anaesthetics as allosteric modulators of 
ligand-gated ion channels. Furthermore, lipids are crucial in neural structure  
and function and are therefore viable subjects for further research into general 
anaesthetic mechanism (reviewed by Hemmings et al and Mashour et al (100, 
163)).  
Nephrotoxicity 
Nephrotoxicity after anaesthesia with sevoflurane has been hypothesised to occur 
due to inorganic fluoride liberated during metabolism of the anaesthetic. Nephro-
toxicity due to liberation of inorganic fluoride is a clinical concern from the time 
when anaesthesia with methoxyflurane was shown to cause deterioration in renal 
function. The resulting plasma peak fluoride concentration due to liberation from 
methoxyflurane was noticed to correlate with the degree of renal injury, with a 
critical threshold around 50 µM inorganic fluoride. The general structure of the 
three fluranes in this document resembles that of methoxyflurane. For sevoflurane, 
serum inorganic fluoride concentrations reach only about 1/3 to 1/4 of that after 
anaesthesia with methoxyflurane (reviewed by Reiche and Conzen) (200)). Serum 
levels of fluoride after sevoflurane anaesthesia may exceed 50 µM in approximate-
ly 8% of the cases. However, exposure to sevoflurane at anaesthetic dose levels  
in a large number of patients has not been associated with impairment of renal 
function. Furthermore, there is no evidence for exacerbation of pre-existing renal 
or hepatic dysfunction in adults or children by sevoflurane (reviewed in (55)). 
Possibly the differences in nephrotoxicity between methoxyflurane and sevo-
flurane are based on differences in local kidney activity of cytochrome P450 
subtypes, which is 3- to 10-fold higher for methoxyflurane than for sevoflurane. 
Sevoflurane is metabolised to a much higher extent than isoflurane and desflurane 
(Table 9). The risk for nephrotoxicity due to high fluoride ions would thus be 
expected to be much higher for sevoflurane than for isoflurane and desflurane, 
reviewed in (200)1. 
                                                 
1
 Absorbents can degrade sevoflurane and produce the metabolite FDVE, especially in a high 
respiratory gas temperature as in low-flow technique. In rodent studies, FDVE has been associated 
with nephrotoxicity, but there is no evidence for nephrotoxicity in surgical patients (200). 
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Cardiovascular effects 
All three fluranes decrease blood pressure as a result of diminished cardiac output 
and vascular resistance. This is due to direct effects of the anaesthetics on the 
heart and vascular smooth muscle and to indirect effects of the anaesthetics on the 
autonomic nervous system. The increase in heart rate may be a compensatory 
response, to maintain perfusion even if blood pressure decreases. It occurs to a 
lesser degree with sevoflurane compared to isoflurane and desflurane (211). For 
sevoflurane it has been shown that with increasing exposure concentrations, 
cardiac sympathetic nerve traffic decreases whereas parasympathetic traffic 
remains unchanged. This might in part explain the absence of tachycardia with 
increasing doses of sevoflurane. In contrast, sympathetic nerve traffic increases 
with administration of desflurane at higher dose levels, reviewed in (63). 
Hepatotoxicity 
The proposed mechanisms for hepatotoxicity caused by inhaled halogenated 
anaesthetics have been reviewed (55, 131, 200). These compounds have been 
associated with two different forms of hepatotoxicity, metabolic and immune-
mediated, both described in detail for halothane. 
The metabolic form is the milder of the two. It is clinically detected as a 
transient elevation of liver enzymes and altered cellular integrity, as observed  
by electron microscopy. For halothane, the lesion results from intracellular 
degradation of the compound via its anaerobic and aerobic pathways in com-
bination with local hypoxia caused by an alteration of the hepatic oxygen demand 
and supply relationship. This form can be observed in about 20% of halothane-
treated patients. Laboratory studies indicate that this effect is most pronounced 
after halothane exposure, and less so after isoflurane and sevoflurane exposure. 
Further, this type of injury is considered concentration- and/or dose-dependent 
(200).  
The immune-mediated form is potentially life-threatening. It is not caused by 
the parent compounds, but rather by metabolites produced by cytochrome P450-
mediated biotransformation. Metabolism of the halogenated anaesthetics generates 
reactive intermediates. These intermediates may in turn bind covalently to hepatic 
proteins, resulting in tissue acetylation by trifluoroacetyl (CF3CO-) as the first step 
in pathogenesis. The second step involves formation of antibodies directed towards 
these acetylated neo-antigens. Thus, the suggested mechanism for this type of 
hepatotoxicity is an autoimmune response directed against hepatic proteins that 
have been altered by the covalent binding of metabolites of the anaesthetics. 
Immune-mediated hepatotoxicity occurs in a small number of patients, i.e. the 
incidence for halothane is 1:35 000. Occupational exposure to halothane has  
also been shown to induce hepatotoxicity. Very few cases of hepatotoxicity have 
been reported in patients after anaesthesia with isoflurane and desflurane. As 
investigated at anaesthetic dose levels in a large number of patients, no evidence 
suggests that sevoflurane impairs liver function. Trifluoroacetyl is formed during 
the metabolism of isoflurane and desflurane, but not sevoflurane. Further, the 
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amount of acetylated hepatic proteins correlates with the well-documented relative 
rates of metabolism of halothane, isoflurane or desflurane (Table 9). The rareness 
of hepatotoxicity after isoflurane and desflurane anaesthesia is presumably ex-
plained by the very limited metabolism of these substances. Sevoflurane is meta-
bolised by a distinctly different pathway compared to the halogenated anaesthetics 
with a methyl-ethyl structure, i.e. halothane, enflurane, isoflurane and desflurane. 
This may explain the lack of immune-mediated hepatoxicity following anaesthesia 
with sevoflurane (30, 55, 131, 200).  
Genotoxicity 
Some studies indicate that the fluranes cause genotoxic effects. The mechanisms  
by which the fluranes might induce DNA damage are not well understood. A 
mechanism for the genotoxic activity could be the direct reaction of the parent 
anaesthetics with DNA (9). If isoflurane reacts with DNA directly, the most 
probable alkaline-labile modification is an alkylation at the N7 position of purines. 
Another mechanism of genotoxicity could be the formation of reactive metabolites. 
The sevoflurane degradation product formed in the anaesthesia machines, FDVE, 
is an alkylating agent, and therefore a potential genotoxin (68). No empirical 
studies were found. 
Developmental toxicity 
An increased neuronal death has been associated with exposure to isoflurane 
during the period of brain growth spurt (the period of synaptogenesis) in juvenile 
rats. This probably stems from induction of widespread neuronal apoptosis. It  
has been proposed that isoflurane promotes the spontaneous apoptotic neuro-
degenerative process that occurs naturally in the normal developing brain (124, 
249). 
10. Effects in animals and in vitro studies  
Animal studies described below that are of relevance for dose-effect and dose-
response relationships are summarised in Tables 13-15 in Chapter 12. For the 
single exposure studies, only exposure levels below 0.8 MAC (human) are 
included in the tables. 
10.1 Irritation and sensitisation 
Isoflurane 
No appropriate investigations of airway irritation were located. 
Tissue irritation was investigated by injecting adult Lewis rats (n=6-24, mixed 
sex) intraperitoneally through the midline into the lower abdomen with isoflurane 
(0.5, 1.0 or 1.5 ml/kg). Necropsies two weeks later revealed fibrosis of surfaces of 
liver, spleen, omentum and diaphragm surfaces with rounding and fusion of liver 
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lobes, and, occasionally, adhesions of these organs (156). The results indicate that 
isoflurane is irritating at high dose levels.  
Sevoflurane 
Lewis rats (n=6-24, mixed sex) were injected intraperitoneally through the mid-
line into the lower abdomen with 0.5-4 ml/kg sevoflurane, in 0.5 ml increments. 
At necropsy two weeks later, no visible lesions were detected (156). 
No signs of airway irritation, such as coughing, were registered in six horses 
during determination of the MAC for sevoflurane. Sevoflurane was given through 
a face mask and the responses of the horses to painful stimuli were examined 
while increasing or decreasing the inspiratory sevoflurane concentration in 2 000 
ppm steps from 26 000 ppm. In reality, the examined inspiratory concentrations 
varied between 21 000 and 28 000 ppm (4). 
The results indicate that sevoflurane is not irritating even at high exposure 
levels. 
Desflurane 
No animal studies on irritation and sensitisation were identified. 
10.2 Effects of single exposure 
10.2.1 Lethality 
Reported lethal concentrations for 50% of the exposed animals at single inhalation 
exposures (LC50) of 3-4 hours duration are given in Table 10. Comparison of 
LC50s for a 3-hour exposure period indicates that sevoflurane possesses approxi-
mately half the acute toxicity of isoflurane, comparable to the difference in MAC-
values for these compounds (Table 4). No LC50s were identified for desflurane.  
 
Table 10. Lethal concentrations for 50% of the exposed animals at single inhalation 
exposure (LC50).  
Anaesthetic/ 
species 
Exposure duration 
(hours)  
 LC50 (ppm) Reference 
Isoflurane    
Rat 0.5 125 200 (138) 
Rat/mouse 1 58 000-83 000 (160) 
Rat 3 15 300 (209) 
Mouse 3 16 800 (209) 
Sevoflurane    
Rat 3 28 800 (209) 
Mouse 3 28 300 (209) 
Desflurane No data available  
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10.2.2 Central nervous system effects 
Comparative studies 
Amnesic potency of isoflurane, sevoflurane and desflurane were investigated in 
adult male Sprague Dawley rats. During exposure to either air or subanaesthetic 
concentrations of isoflurane (530, 1 160, 2 010, or 3 020 ppm), sevoflurane (1 050, 
2 160, 3 080, or 4 110 ppm) or desflurane (4 400, 10 130, or 20 200 ppm), rats 
were trained in the inhibitory avoidance procedure (n=4 - 21). In a device with  
two compartments, the rat was placed into the bright compartment. After three 
minutes, a door was opened into the dark compartment. Rats instinctively prefer 
dark environments, but as the rat stepped into the darkness, a foot shock was 
delivered until the animal escaped back into the bright starting compartment. 
Learning was considered to have occurred when the animal avoided going back to 
the dark-shock compartment for more than 100 consecutive seconds. Memory was 
tested 24 hours later in the same device. Anaesthetic effects on pain thresholds 
were separately determined by assessment of tail shock pain sensitivity threshold. 
For isoflurane, the number of shocks to learning the 100-second criterion was 
increased at the two highest exposure levels, but this was not significant. Memory 
retention latency was significantly decreased, consistent with amnesia at 2 010 
ppm, and even more so at 3 020 ppm isoflurane. The tail flinch threshold was 
significantly increased at 2 010 ppm, indicating an analgesic response. For 
sevoflurane, there was a significant increase in the trials to criteria at 3 080 ppm. 
Memory retention latency was numerically decreased at 2 160 ppm and signifi-
cantly decreased at the two higher exposure levels. The flinch threshold for tail 
withdrawal increased significantly from 1 050 ppm. For desflurane, significant 
inhibition of task acquisition was observed at 10 130 ppm, increasing further at the 
highest exposure level. Retention latency was decreased already at the lowest ex-
posure level, i.e. 4 400 ppm, and further decreases were observed at the two higher 
levels. An analgesic response was only significant at the highest concentration. 
Amnesic potency and oil:gas partition coefficients generally correlated well (6). 
In the same device, it was investigated whether isoflurane, sevoflurane or 
desflurane might enhance aversive memory. Male Sprague Dawley rats (n=22) 
were exposed to air, 1 200 ppm isoflurane, 1 100 ppm sevoflurane, or 7 700 ppm 
desflurane during inhibitory avoidance training as described above, although the 
animals in this study were removed immediately after delivery of one shock in the 
dark compartment. Memory was assessed after 24 hours. It took significantly 
longer time for the animals to cross over into the dark side of the apparatus when 
they had been exposed to sevoflurane during training, whereas no effect of iso-
flurane and desflurane was observed. These data indicate that sevoflurane may 
enhance aversive memory formation in the rat (7).  
Isoflurane 
The analgesic potency of isoflurane was measured in male Sprague Dawley rats 
(n=6-9) by means of the latency to withdraw the hind paw when exposed to heat. 
After baseline measurements, isoflurane was delivered in a stepwise manner, each 
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step held at 30-40 minutes. At 1 145 ppm, isoflurane was hyperalgesic (anti-
analgesic), as latency to remove the paw in response to heat was decreased 
compared to controls. At the higher exposure levels of 2 920 and 5 840 ppm, 
isoflurane was analgesic (255). 
The effects of isoflurane on learning of the rabbit nictitating membrane 
responses were studied. Classical conditioning of the nictitating membrane 
responses was accomplished by presenting a 400-millisecond tone conditioned 
stimulus before the presentation of a 100-millisecond shock unconditioned 
stimulus over 6 daily training sessions. The percentages of conditioned responses 
were calculated for New Zealand albino rabbits treated with 0, 2 000, 4 000, or 
8 000 ppm isoflurane (n=7-13, sex not specified) for 20 minutes. Isoflurane 
suppressed acquisition of the conditioned response dose-dependently. Animals  
in the low-exposure group learned the task slower than the controls, 4 000 ppm 
isoflurane allowed some learning, whereas 8 000 ppm isoflurane completely 
abolished the acquisition of the conditioned response (70). 
Male ddN mice (n=15-20) were trained to escape an aversive electric foot  
shock as an unconditioned stimulus within 3 seconds after being exposed to light 
and a buzzer as a conditioned stimulus. Immediately after training, the animals 
were exposed to isoflurane for 2 hours. After a period of recovery, the animals 
were retested on the avoidance task (second session). Two experiments were 
performed. In the first experiment, isoflurane concentrations were 2 960, 6 020, 
and 12 040 ppm, and the intersession interval was 2 hours and 30 minutes (139). 
In the second experiment, the interval was 24 hours, and the exposure levels of 
isoflurane were 2 960 and 12 950 ppm (140). In both studies, performance was 
increased more during retest if the animals had been exposed to 2 960 ppm iso-
flurane immediately after the training session compared to the control condition 
with no exposure. Performance neither increased nor decreased at the higher 
exposure levels. 
Male Sprague Dawley rats (n=8-16) were trained to fear tone by applying three 
(three-trial) or one (one-trial) tone-shock pairs while breathing 3 700, 5 700 or 
7 500 ppm isoflurane for 30 minutes. Groups of rats were similarly trained to  
fear context while breathing isoflurane by applying shocks (without tones) in a 
distinctive environment. The next day, memory of the conditioned stimuli was 
determined by presenting the tone or context (without shock) and measuring the 
proportion of time each rat froze, i.e. appeared immobile. Isoflurane provided 
dose-dependent amnesia for classic fear conditioning with clear effects at 
exposure levels of 3 700 ppm and above (59). 
Sevoflurane 
Tight-seal whole-cell recordings were made from CA1 pyramidal cells in 
hippocampal slices prepared from adult male ddY mice (n=5-6). The effects of 
0.05-0.07 and 0.5 mM sevoflurane (corresponding to 900-1 200 and 9 000 ppm, 
respectively) on the glutamatergic excitatory postsynaptic currents (EPSCs) were 
investigated. For the lowest dose level, also extracellular recordings of field 
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excitatory postsynaptic potential (fEPSP) and population spike (PS) were made, 
and long-term potentiation effects on the fEPSP slope and PS amplitude were 
analysed. Sevoflurane at 0.5 mM reversibly suppressed the amplitude of EPSCs 
with an increase in the paired-pulse facilitation ratio, whereas 0.05 mM sevo-
flurane reversibly increased the EPSC amplitudes without appreciable changes in 
the ratio. The 0.07 mM sevoflurane dose also showed facilitatory influences on 
long-term potentiation of PS amplitude but not on long-term potentiation of the 
fEPSP slope. The observations suggest that sevoflurane at low subanaesthetic 
concentrations postsynaptically enhances excitatory synaptic transmission, where-
as sevoflurane at higher concentrations presynaptically inhibits excitatory synaptic 
transmission in the hippocampal CA1 region (187).  
Desflurane 
No studies regarding neurotoxicity in animals were found for desflurane besides 
the comparative studies described at the beginning of this section. 
Conclusions 
Several studies have investigated neurofunction after acute exposure to isoflurane 
at subanaesthetic levels. In rats, pain sensitivity during isoflurane exposure was 
unaffected at the lowest level tested, i.e. 530 ppm (no observed adverse effect 
level, NOAEL) (6), but at 1 145 isoflurane exerted antianalgesic effects. At higher 
exposure levels (at and above 2 920 ppm) isoflurane induced analgesia (255). 
Cognitive function has been studied at exposure levels ranging from 530 to 8 000 
ppm. Learning and memory during avoidance training was unaffected by iso-
flurane at exposure levels up to 1 160 ppm in rats, whereas performance was 
impaired at 2 010 ppm (6). At 2 000 ppm, also classical conditioning of the 
nictitating membrane responses was affected in rabbits (70). Even higher exposure 
concentrations, have been associated with increased neurodegeneration in foetal 
guinea pigs and neonatal rats and mice (124, 125, 205), indicating that the 
developing nervous system may be sensitive to isoflurane exposure. The latter 
studies are described in Section 10.6.  
Sevoflurane induced analgesia and increased memory of an aversive event in  
rats at the lowest exposure levels studied, i.e. 1 050 and 1 100 ppm, respectively 
(6, 7). At higher levels, impairment of cognitive function and increased indices  
of anxiety are apparent (Table 14). Thus, for sevoflurane, a NOAEL for neuro-
function effects cannot be identified. 
Neurotoxicity of desflurane has been the topic of interest in two studies with 
single exposure and one short-term study (Section 10.3), all in rats. Exposure 
levels ranging from 4 400 ppm to 20 200 ppm were associated with impaired 
neurofunction in tests of cognitive function and anxiety tests (6, 188). No effect  
on aversive memory was observed at 7 700 ppm, the only level tested for this 
endpoint (7). Thus, also for desflurane, a NOAEL cannot be identified for nervous 
system effects. 
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10.2.3 Nephrotoxicity 
Isoflurane 
The nephrotoxic potential of a 4-hour anaesthesia with 14 000 ppm isoflurane was 
investigated in obese and non-obese male Fischer 344 rats (n=7-9; one year of 
age). Weight-paired rats received either a regular or a high fat diet for 16 weeks 
and gained 20% respectively 45% in weight. Serum fluoride levels increased 
significantly to the same extent in both groups of rats 4 hours after anaesthesia 
compared to pre-anaesthetic levels. Whereas fluoride levels peaked at this time 
point in non-obese rats, levels continued to increase in obese rats until measured 
again 24 hours after termination of exposure. At 72 hours, plasma fluoride levels 
had returned to baseline values, but the urinary excretion rate was still slightly 
elevated. Urinary osmolality decreased slightly, but significantly, following 
anaesthesia in both groups, and creatinine and urea nitrogen clearance were 
decreased in obese rats 1 and 3 days after anaesthesia. Biomarkers of kidney 
function were measured 24 hours post anaesthesia. In non-obese rats, both 
aspartate and alanine aminotransferases were increased, but in obese rats only  
the latter increased (203). 
No studies on subanaesthetic exposure levels were identified. 
Sevoflurane and desflurane 
No studies on nephrotoxicity were identified. 
10.2.4 Cardiovascular effects 
Comparative studies 
Direct myocardial effects of isoflurane, sevoflurane and desflurane were studied 
on isolated human right atrial trabeculae obtained from patients undergoing 
coronary bypass surgery. At clinically relevant concentrations, the agents did not 
modify isometric relaxation (95). 
Isoflurane 
Fourteen anaesthetised mongrel dogs (sex not specified) received, in random 
order, 0, 2 500 or 5 000 ppm end-tidal isoflurane in 40% oxygen. Forty minutes  
of equilibration was allowed for each intervention before measurements of a range 
of cardiovascular and ventilatory parameters were performed. Gas exchange was 
assessed by blood gas analysis and by estimating ventilation and perfusion mis-
match using the multiple inert gas elimination technique. After administration  
at each exposure level, dogs were ventilated without isoflurane for at least 30 
minutes, while values returned to baseline. Cardiac output and systemic vascular 
resistance decreased at 5 000 ppm isoflurane but not at 2 500 ppm (195). 
The effects of isoflurane on the cardiovascular system were investigated in New 
Zealand white male rabbits. Electrocardiogram, mean arterial pressure, and heart 
rate were obtained by telemetry in rabbits in the conscious, unsedated state and at 
the end of 30 minutes of isoflurane anaesthesia, at exposure levels of 0, 9 000, 
18 000, and 27 000 ppm, administered in random order (n=10). Isoflurane in-
creased the heart rate at all exposure levels and decreased systolic, diastolic, and 
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mean arterial blood pressure at the two highest exposures. No significant changes 
were observed for plasma norepinephrine and epinephrine levels. The analysis of 
spectral components of heart rate variability and baroreflex function indicated that 
isoflurane induced a marked reduction in the low- and high-frequency spectral 
power of heart rate variability independent of isoflurane concentrations, and 
reduced baroreflex sensitivity at all exposure levels. In vagotomised anaesthetised 
rabbits, heart rate and blood pressure values were not different from those ob-
tained in intact anaesthetised animals at equal concentrations of isoflurane (161). 
Sevoflurane and desflurane 
No studies were found besides the comparative study described at the beginning of 
this section. 
10.2.5 Hepatotoxicity 
No studies at subanaesthetic exposure levels were identified. 
10.2.6 Lung toxicity 
Isoflurane 
Lung clearance of the radionuclide technetium-99m hexamethyl propylene  
amine oxime (Tc-99m HMPAO) was studied in male New Zealand rabbits (n=6). 
receiving either 0 or 15 000-25 000 ppm isoflurane. Following a 10-minute 
stabilisation period, rabbits were administered the radionuclide intravenously  
and dynamic images were acquired for the following 10 minutes. The imaging 
protocol was repeated 3 days later, apart from the exposure to isoflurane. After 
each imaging session, lung biopsy was performed in two rabbits from each group. 
There was no significant difference between control and isoflurane groups with 
respect to radionuclide lung clearance. Pathological evaluation demonstrated 
minimal changes in isoflurane exposed animals compared to controls (90). 
Sevoflurane 
Sixteen pigs (mixed sex) were randomly selected to receive either thiopentone 
infusion or sevoflurane (n=8) at 4 000 ppm inspiratory concentration in air for 6 
hours. Tissue samples from the lungs were obtained at the end of the experiment 
for histopathological light and electron microscopy. Pulmonary haemodynamics 
were comparable in both groups. Light microscopy showed no difference between 
the groups in the amount of alveolar macrophages, red blood cells, or oedema. 
Electron microscopy showed minor changes such as moderate local swelling of 
alveolar epithelium in both study groups, compared to naive controls. Alveolar 
type II cells were ultrastructurally unaltered in both study groups (228). Arterial 
blood samples were taken 1, 2, 4, and 6 hours after stabilisation of the exposure 
air concentration. At the end of the exposure period, bronchoalveolar lavage 
samples were collected. Compared to baseline controls, significant increases in 
bronchoalveolar lavage leukotriene C4, thromboxane B2, and nitrate levels were 
observed after sevoflurane anaesthesia. Also a significant decrease in total blood 
leukocyte count was observed (229).  
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Desflurane  
No studies on lung toxicity were identified. 
10.2.7 Other studies 
Isoflurane 
Anaesthetised (pentobarbital), ventilated Sprague Dawley rats (n=7) received 
either no treatment, lipopolysaccharide only (5 mg/kg, intravenous), or isoflurane 
(13 000 ppm, inhalation) 15 minutes after administration of lipopolysaccharide. 
After 4 hours of endotoxaemia, inhalation of isoflurane was found to have 
attenuated the release of tumour necrosis factor alpha (TNFα) and interleukin-1 
beta (IL-1β) as compared to the lipopolysaccharide group, while interleukin-6  
(IL-6) and interleukin-10 (IL-10) levels were not significantly altered. Nitrite 
release was significantly increased in the isoflurane group as compared to the 
lipopolysaccharide group. Thus, inhalation of isoflurane at anaesthetic dose levels 
decreased the response to inflammatory stimuli by attenuating the systemic release 
of proinflammatory cytokines (76). 
The effects of air or 22 500 ppm isoflurane on cilia beat frequency were 
investigated in human nasal epithelial brushings from healthy adult and non-
smoking patients (n=6). The epithelial brushings were obtained by passing a 
bronchoscopy brush over the inferior nasal turbinates. Cilia beat frequency was 
observed before and 1, 2, and 3 hours after initiation of exposure. No difference 
was observed at 1 hour, but cilia beat frequency of the samples exposed to 
isoflurane significantly decreased (by approximately 10%) at 2 and 3 hours, 
compared to exposure to air alone. The cilia beat frequency had returned to 
baseline values after 60 minutes of air washout after exposure (198). With the 
same experimental set-up, recovery after air washout was investigated after 
exposure to 22 500 ppm isoflurane for 1 hour. Cilia beat frequency had recovered 
completely after 60, but not 30 minutes (199). 
Female New Zealand white rabbits (n=10) were exposed to 25 000 ppm iso-
flurane in oxygen for 30 minutes. Blood samples were obtained before anaesthetic 
induction, and at 1, 10, 30, 60, 120 minutes and 24, 48 and 72 hours after endo-
tracheal intubation. Serum corticosterone and serotonin levels increased shortly 
after administration was initiated, but adenocorticotropic hormone concentrations 
were largely unaffected. Shortly after isoflurane administration, also serum 
glucose, aspartate aminotransferase, blood urea nitrogen, and creatinine levels 
increased. Values were normalised 24 hour later. Alanine aminotransferase and 
alkaline phosphatase were unaffected throughout the period of monitoring (83). 
Sevoflurane 
Adult male CBi mice were anaesthetised with 30 000 sevoflurane in oxygen for 40 
minutes, and non-treated animals served as controls (n=12). Sevoflurane diminished 
the number of peripheral blood lymphocytes and splenic B-cell counts, enhancing 
CD4+ lymphocytes in the spleen. The in vitro functionality of macrophages and 
the mitogen-induced lymphoproliferative response were preserved, while the in 
vivo immune response to sheep red blood cells was enhanced in treated animals. 
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Microscopic studies revealed conserved architecture of the spleen, thymus,  
lymph node, liver and kidney, and there were no differences in serum parameters 
of hepatic and renal functions between treated and control groups (194).  
Anaesthetised (pentobarbital), ventilated male Sprague Dawley rats (n=6) 
received either no treatment, lipopolysaccharide only (5 mg/kg, intravenous), or 
lipopolysaccharide and sevoflurane inhalation (20 000 ppm) initiated 15 minutes 
after induction of endotoxaemia. After 4 hours of endotoxaemia, the sevoflurane 
group showed significantly attenuated plasma levels of TNFα and IL-1β as 
compared with the lipopolysaccharide only group. Nitrite release from alveolar 
macrophages was significantly suppressed by sevoflurane. Sevoflurane attenuated 
the inflammatory response during endotoxaemia in vivo (112).  
Desflurane 
Platelet-rich plasma was exposed to 10 000 ppm of desflurane or clean air and 
stimulated by platelet agonists adenosine diphosphate and collagen. Response was 
measured by Born aggregometry and percentage of CD62P (P-selectin)-positive 
cells. Aggregation in response to both stimulants was significantly reduced in 
platelets exposed to desflurane. CD62P expression before and after stimulation 
with receptor agonists was not significantly different in platelets exposed to 
desflurane as compared to platelets exposed to air. Thus, desflurane impaired 
platelet aggregation without affecting alpha-degranulation, indicating that the 
anaesthetic may impair platelet thromboxane receptor signalling (27).  
The effects of exposure to 12 000 ppm desflurane for 6 hours on caspase 
activation, amyloid precursor protein processing and amyloid-ss protein 
generation were investigated in H4 human neuroglioma cells (H4 naive cells)  
as well as those overexpressing amyloid precursor protein (H4-APP cells). 
Desflurane alone did not affect either endpoint, but in combination with mild 
hypoxia (18% oxygen) it induced caspase-3 activation, altered amyloid precursor 
protein processing, and increased amyloid-ss protein generation in H4-APP cells 
(254). 
Anaesthetised (pentobarbital), ventilated male Sprague Dawley rats (n=6) 
received either no treatment, lipopolysaccharide only (5 mg/kg, intravenous), or 
continuous inhalation of desflurane (60 000 ppm) just before and during endo-
toxaemia with lipopolysaccharide. After 4 hours of endotoxaemia, the desflurane 
group displayed significantly decreased release of the proinflammatory cytokines 
TNFα and IL-1β in plasma and in bronchoalveolar lavage fluid as compared to the 
lipopolysaccharide only group. Release of IL-6 was unaffected. Within the lung, 
the nitric oxide release was notably increased in supernatants of cultured alveolar 
macrophages from the desflurane group compared to both the other groups. Thus, 
inhalation of desflurane at anaesthetic dose levels decreased the response to 
inflammatory stimuli by attenuating the systemic release of proinflammatory 
cytokines (29). 
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10.3 Effects of short-term exposure (up to 90 days)  
Isoflurane 
ICR mice, Sprague Dawley rats, and Hartley guinea pigs were exposed con-
tinuously for 35 days to 0, 150, 500, 1 500 ppm isoflurane (n=11-31; mixed sex, 
equally divided between males and females). Animals were young and in an active 
phase of growth and were housed under controlled environmental conditions. 
Anaesthetic exposure took place in exposure chambers, and controls and exposed 
groups were treated identically, apart from the exposure. Five days prior to ex-
posure, the animals were placed in the exposure chambers. Animals that failed to 
gain weight in this period were replaced. In the control groups, up to two guinea 
pigs and two mice failed to survive the 35 days of exposure. All rats survived. 
Body weights were recorded 7, 14, and 35 days after initiation of exposure. Small, 
but significant decreases in body weight gain were observed in mice at the two 
highest exposure levels at all time points. After 35 days of exposure, mice in all 
exposed groups had gained significantly less weight than controls. Weight gains 
were decreased to a similar extent in all three groups, i.e. no dependence on dose 
was observed. Body weight gains were also reduced in guinea pigs after 35 days  
of exposure at the highest exposure level. Organ weights generally varied with 
body weights and relative liver weights were unaffected by exposure. Blood was 
obtained from rats exposed from the middle exposure group; haematocrits, 
erythrocyte, leukocyte and differential counts were similar to controls. Livers from 
animals exposed to isoflurane manifested either no or small increases in lesions in 
the high-exposure group compared with controls (224). A lowest observed adverse 
effect level (LOAEL) of 150 ppm can be identified from this study although, as 
also commented by the Deutsche Forschungsgemeinshaft (56), there are some 
miscalculations of body weight gains, and only body weight gains and no absolute 
body weights are given. 
Swiss Webster mice were exposed to compressed air or to 200, 1 000 or 5 000 
ppm of isoflurane for 4 hours/day, 5 days/week for 9 weeks (n=13 each sex). 
Overall, there were no significant differences in body weights among exposure 
groups. Small decreases were present during weeks 1 through 3 for females and 
week 2 for males at the highest exposure level. At all times, differences remained 
within 10% of body weights in control animals. Following 9 weeks of exposure, 
organ weights, haematocrits, and serum aspartate aminotransferase levels were 
similar among exposure groups. Histological evaluation of organs revealed no 
anaesthetic-related organ toxicity. Levels of hepatic cytochromes, b5 and P450 
were similar among exposure groups. Hepatic microsomal metabolism in vitro 
(defluorination) of three volatile halogenated ether anaesthetics (methoxyflurane, 
enflurane, and isoflurane) did not show any difference among the groups (202). 
Groups of 16 male Sprague Dawley rats were subjected to either oxygen or 
13 440 ppm isoflurane in oxygen for 2 hours every second day for 2 weeks, 
yielding a total of six 2-hour exposures. Twenty-four hours after the last exposure, 
the rats were autopsied. Specimens were taken from the brain, pituitary, lung, 
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heart, duodenum, pancreas, kidney, and liver. No tissue damage attributable to 
isoflurane exposure was found nor was weight gain affected (66). 
Sevoflurane 
Rats (sex not specified) received 0 or 3 000 ppm sevoflurane in oxygen, 4 hours/ 
day for 30 days (n=10). The day after termination of exposure, behaviour was 
investigated. In the hole-board test, exploratory activity was significantly decreased 
in sevoflurane exposed animals compared to controls. In the elevated plus maze 
test, exposed animals spent significantly less time on the open arms and more time 
on the closed arms. Also learning and memory, assessed in the multiple T maze 
test, was significantly and adversely affected by sevoflurane, as control rats 
learned faster than exposed rats and made fewer wrong turns (188). 
Cynomolgus monkeys (Macaca fascicularis) were assigned to a control group 
or three treatment groups (4 males and 4 females/group) and anaesthetised with 
sevoflurane at end-tidal concentrations of 0, 21 600, 32 000, or 40 100 ppm, 3 
hours/day, 3 days/week for 8 weeks. Blood was obtained at baseline and 24 hours 
after the 3rd anaesthesia at weeks 1, 2, 4, 6, and 8 (the exposure protocol used 
prevented/minimised production and accumulation of FDVE). No cardiovascular 
or ventilatory support was used, even when indicated. Urine was collected con-
tinuously. The animals were killed 24 hours after the last exposure. Blood was 
assessed by routine haematologic examinations, measurements of serum enzymes, 
clinical chemistry, and serum electrolytes. Urine was evaluated microscopically 
and chemically. All animals went through complete post-mortem examinations, 
including histopathologic examination. Samples from liver and kidney were 
evaluated by electron microscopy. During exposure, marked hypoventilation  
was evident and end-tidal concentrations of carbon dioxide were elevated at the 
highest level. At the highest exposure level, three deaths occurred, and one control 
male died during the study period. Dose-related increases in serum aspartate and 
alanine aminotransferase, lactate dehydrogenase, and creatinine kinase were 
observed in the first week at all exposure levels. Levels stayed elevated for some 
weeks at the higher exposure levels. At the lowest exposure, levels returned to 
baseline by week 2. At termination of the study, all serum enzyme concentrations 
had returned to baseline. Erythrocyte counts were reduced at the two lowest 
exposure levels and white blood cell counts were lowered at the two highest 
exposure levels towards the end of the study period. Apart from reduced relative 
weight of the thymus in exposed monkeys, no gross pathologic, histopathologic, 
or ultrastructural differences were found with relationship to treatment in any 
group of monkeys (221). 
Adult male mice were anaesthetised with 30 000 ppm sevoflurane in oxygen  
for 40 minutes once weekly for 3 weeks and untreated animals served as controls 
(n=6-12). Three days after the latest anaesthetic procedure, the absolute number of 
both leukocyte and lymphocyte counts were reduced in peripheral blood. Splenic 
cell composition, macrophage function, and the mitogen-induced lymphopro-
lipherative response were preserved. The in vivo humoral response to sheep red 
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blood cells was augmented when assessed on day 8 and 9 after the last anaesthetic 
procedure. Sevoflurane-treated animals showed no evidence of histological 
changes or alteration in hepatic or renal function (71).  
Desflurane 
Rats (sex not specified) received 0 or 6 000 ppm desflurane in oxygen, 4 hours/ 
day for 30 days (n=10). The day after termination of exposure, behaviour was 
investigated. In the hole-board test, exploratory activity was significantly de-
creased in exposed compared to controls. In the elevated plus maze test, exposed 
animals spent significantly less time on the open arms and more time on the closed 
arms. Also learning and memory, assessed in the multiple T maze test, was affected 
adversely by desflurane, as control rats learned faster than exposed rats and made 
fewer wrong turns (188).  
Conclusion 
Body weight was unaffected by exposure to even high levels of isoflurane, when 
exposure was limited to shorter periods of time during the week. At continuous 
exposure, body weight gain decreased in mice from the lowest dose level tested, 
i.e. 150 ppm, and in guinea pigs from 1 500 ppm. No significant histopathological 
effects were observed in any study at any dose level tested.  
Rats exposed to sevoflurane (3 000 ppm) or desflurane (6 000 ppm), 4 hours/ 
day for 30 days, displayed decreased activity and anxiogenic behaviour in the 
elevated plus maze test and learning and memory was impaired, the day after 
termination of exposure.  
10.4 Mutagenicity and genotoxicity 
Table 11 gives an overview of in vitro and animal studies investigating the 
mutagenicity and genotoxicity of isoflurane, sevoflurane, and desflurane. 
Isoflurane 
Isoflurane (100-300 000 ppm) was tested for mutagenic activity in Salmonella 
typhimurium strains (TA1535 and TA100) in the presence or absence of liver 
homogenates prepared from rats treated with the enzyme inducer Aroclor 1254. 
The investigators also collected urine samples from patients 24 hours before  
and 24 hours after anaesthesia with isoflurane. The samples were tested in the 
presence and absence of metabolic activation and β-glucuronidase. The latter was 
added to hydrolyse glucuronides, thereby freeing possibly mutagenic, conjugated 
metabolites. Neither isoflurane nor urine from patients anaesthetised with iso-
flurane was mutagenic (20). No information was provided on the duration of 
anaesthesia with isoflurane or the anaesthetic doses administered to the patients.  
Isoflurane (11 600, 50 000, 116 000 ppm) was not mutagenic in the Ames assay 
with Salmonella typhimurium strains (TA98 and TA100) in the presence or 
absence of liver homogenate (236).  
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The mutagenic effect of isoflurane was investigated using the sex-linked 
recessive lethal assay in Drosophila melanogaster. Male wild-type flies were 
exposed to vapour concentrations of 10 000 or 20 000 ppm for 1 hour. Following 
treatment, male flies were mated with untreated virgin females of the Basc strain 
and the rate of sex-linked recessive lethals was determined in the F2 generation. 
Isoflurane was not found to be mutagenic at the tested doses (144). 
The same test was used to study the mutagenic effect of isoflurane in com-
bination with nitrous oxide. Male wild-type flies were exposed to 20 000 ppm 
isoflurane in combination with 75% nitrous oxide for 1 hour and mated with 
untreated Basc females. When the rate of lethal mutations was assessed in the F2 
generation, isoflurane was not mutagenic in the presence of nitrous oxide (22). 
An in vitro sister chromatid exchange (SCE) assay was carried out in Chinese 
hamster ovary cells after exposure to 11 300 and 113 000 ppm isoflurane for 1 
hour. Isoflurane did not increase the number of SCEs, neither in the absence nor  
in the presence of a metabolic activating system (241).  
Chinese hamster lung cells were exposed in vitro to varying doses of isoflurane 
from 5 000 to 40 000 ppm mixed with oxygen, 5% carbon dioxide, and nitrogen 
for 1 hour. Isoflurane did not increase the number of SCEs compared to the 
controls exposed to room air and 5% carbon dioxide (233).  
Human lymphocytes were isolated from 8 male volunteers and exposed to 
different concentrations of isoflurane (0, 0.3, 0.6 and 1.2 mM) for 72 hours. 
Isoflurane exposure increased the number of SCEs compared to the control at  
all concentrations. The effect increased with dose (110). 
Human lymphocytes were exposed in vitro to isoflurane (0.1, 1, 10 mM in 1% 
dimethyl sulphoxide) for 10 or 30 minutes. DNA strand breaks as well as alkali-
labile sites were measured as total comet length (i.e. increase in DNA migration). 
Isoflurane increased DNA migration in a dose-dependent manner (significantly 
different from controls starting at 1 mM isoflurane). Lymphocytes exposed to 
isoflurane at 1 mM repaired completely within 60 minutes (123). 
DNA damage was evaluated by the comet assay in lymphocytes, spleen, bone 
marrow, brain, liver, and lung of male rats (n=50) exposed for 30 or 60 minutes  
to a 10 000 ppm isoflurane atmosphere with or without alcohol administration 
(administrated by gastric intubation at 4 g/kg body weight as a 50% solution). 
DNA damage in lymphocytes, bone marrow, and all the investigated organ tissues 
of rats exposed to isoflurane were found to increase time-dependently. Isoflurane 
administered in combination with alcohol led to additional DNA damage (137).  
Human lymphocytes were isolated and exposed to isoflurane (1 or 10 mM) at 
4 ºC or 37 ºC for 10 or 30 minutes. Isoflurane exposure (10 mM) at 4 ºC increased 
the number of DNA strand breaks significantly compared to the control. Exposure 
to isoflurane at 37 ºC induced DNA damage to a lesser extent than at 4 ºC. Visual 
inspection of the graphs indicated that the effect was not time-dependent (227).  
Isoflurane was tested for its ability to induce micronuclei formation in the rat 
kidney. Twenty-four hours after removal of the left kidney, the male rats were 
treated with folic acid to increase the proliferative activity of kidney cells induced 
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by nephrectomy. Two days after folic acid administration, the rats were exposed  
to a single peroral dose of isoflurane (4 mmol/kg). A significant increase in the 
frequency of micronucleated cells was detected in rats 2 days after the exposure to 
isoflurane (206).  
Sevoflurane 
Sevoflurane was tested for mutagenic activity with Salmonella typhimurium 
(TA1535 and TA100). In one experiment, bacteria were exposed for 8 hours to 
vapour containing 1 000-300 000 ppm sevoflurane. In another experiment, the 
bacteria were exposed to 1, 10 or 30 µl liquid sevoflurane of unknown con-
centration. The tests were run in both in the absence and presence of metabolic 
activation system prepared from the liver of enzyme-induced rats. Sevoflurane 
was not mutagenic in either of the experiments (21). 
Isolated human lymphocytes were exposed to sevoflurane (1 or 10 mM) at 4 ºC 
or 37 ºC for 10 or 30 minutes. Sevoflurane did not increase the number of DNA 
strand breaks under any of the exposure conditions (227).  
Sevoflurane was tested for its ability to induce micronuclei formation in the  
rat kidney. Twenty-four hours after the removal of the left kidney, the rats were 
treated with folic acid to increase the proliferative activity of kidney cells induced 
by nephrectomy. Two days after folic acid administration, the rats were exposed to 
a single peroral dose of sevoflurane (4 mmol/kg). A significant increase in the 
frequency of micronucleated cells was detected 2 days after exposure (206).  
Desflurane 
The only study identified on genotoxic effects of desflurane demonstrated an 
increase in DNA strand breaks in human lymphocytes exposed to desflurane in 
vitro (0.1, 1 and 10 mM) after 5, 10, 30 and 60 minutes compared to controls.  
The greatest damage was seen after the 5-minute exposure, probably due to DNA 
repair occurring after the longer exposures (129). It was not specified whether the 
increase in DNA strand breaks occurred at all doses.  
Summary and conclusion  
No mutagenic effect of isoflurane has been found in the Ames test (20, 236) or 
in Drosophila melanogaster (22, 144). No increases in SCEs were observed in 
Chinese hamster ovary and Chinese hamster lung cell exposed to isoflurane (233, 
241). However, increased frequencies of SCEs (110) and DNA strand breaks (123, 
227) were observed in human lymphocytes exposed to isoflurane in vitro. In rats, 
increases in DNA strand breaks in blood cells and tissues (137) and in micro-
nucleus formation in the kidney (206) were observed.  
No mutagenic effects of sevoflurane were observed neither in the Ames test 
(21), nor with respect to DNA strand breaks in human lymphocytes exposed in 
vitro (227). In contrast, the number of micronucleated cells was increased in rat 
kidneys following exposure in vivo (206). 
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Table 11. Genotoxicity tests with isoflurane, sevoflurane and desflurane.  
Anaesthetic/ 
Test system 
Test concentrations Comment/Effect Reference 
Isoflurane    
Human lymphocytes 
exposed in vitro 72 h 
0.3, 0.6, 1.2 mM  Dose-dependent increase in SCEs at 
all concentrations. 
(110) 
Comet assay, human 
lymphocytes exposed  
in vitro 10 or 30 min 
0.1, 1, 10 mM  
in 1% DMSO 
Dose-dependent increase in DNA 
strand breaks at 1 and 10 mM after 
both 10 and 30 min of exposure. 
(123) 
Comet assay, human 
lymphocytes exposed  
in vitro 10 or 30 min 
1, 10 mM  Increase in DNA strand breaks. The 
effect was not time-dependent. 
(227) 
Comet assay, rats  
exposed by inhalation  
30 or 60 min  
10 000 ppm  Time-dependent increase in DNA 
strand breaks in lymphocytes, bone 
marrow, spleen, brain, liver and lung.  
(137) 
Rats, single-exposed  
orally 
4 mmol/kg Increase in the frequency of micro-
nucleated cells in the kidney. 
(206) 
Chinese hamster ovary 
cells exposed in vitro 1 h 
11 300, 113 000 ppm  No effect on SCEs. (241) 
Chinese hamster lung cells 
exposed in vitro 1 h 
5 000, 10 000, 
20 000, 40 000 ppm 
No effect on SCEs. (233) 
Sex-linked recessive  
lethal assay, Drosophila 
melanogaster 
10 000, 20 000 ppm  No effect on the frequency of lethal 
mutations. 
(144) 
Sex-linked recessive 
lethal assay, Drosophila 
melanogaster 
20 000 ppm  No effect on the frequency of lethal 
mutations. Co-exposure to 75% N2O. 
(22) 
Ames test, Salmonella 
typhimurium strains 
(TA1535 and TA100) 
100-300 000 ppm  No effect on gene mutation in 
presence or absence of metabolic 
activation. 
(20) 
Ames test, Salmonella 
typhimurium strains 
(TA100 and TA98) 
11 600, 50 000,  
116 000 ppm  
No effect on gene mutation in 
presence or absence of metabolic 
activation.  
(236) 
Sevoflurane    
Comet assay, human 
lymphocytes exposed  
in vitro 10 or 30 min 
1, 10 mM No effect on DNA strand breaks. (227) 
Rats, single-exposed  
orally 
4 mmol/kg Increase in the frequency of micro-
nucleated cells in the kidney. 
(206) 
Ames test, Salmonella 
typhimurium strains 
(TA1535 and TA100) 
1 000-300 000 ppm No effect on gene mutation in 
presence or absence of metabolic 
activation. 
(21) 
Desflurane    
Comet assay, human 
lymphocytes exposed in 
vitro 5, 10, 30 or 60 min 
0.1, 1, 10 mM  
in 1% DMSO 
Dose-dependent increase in DNA 
strand breaks. Greatest damage after 
the 5-min exposure. 
(129) 
DMSO: dimethyl sulphoxide, N2O: nitrous oxide, SCE: sister chromatid exchange. 
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Only one study of the genotoxic effects of desflurane has been identified. The 
study showed an increased frequency of DNA strand breaks in human lympho-
cytes exposed in vitro (129). 
In conclusion, recent studies on human lymphocytes exposed in vitro and rats 
exposed in vivo suggest that isoflurane possesses genotoxic potential. Due to the 
limited number of studies, no conclusion on the genotoxicity of sevoflurane and 
desflurane can be made.  
10.5 Effects of long-term exposure and carcinogenicity 
10.5.1 Carcinogenicity 
Isoflurane 
The carcinogenic potential of isoflurane has been investigated in three animal 
studies.  
Mice (mixed sex) were exposed to either air (n=181), 1 000 ppm isoflurane  
(n ≤ 167), or 4 000 ppm isoflurane (n=165), for 4 hours/day, 5 days/week. After  
78 weeks of exposure, the animals were left untreated for 3 weeks and then killed. 
There were no statistical differences among the groups regarding the number of 
mice with a particular tumour at a specific site, the ratio of benign to malignant 
tumours, or the time to tumour appearance. However, body weights were de-
creased in mice exposed to isoflurane at both exposure levels, 1-5% and 5-8%, 
respectively (no statistical analysis of body weights was provided) (23). 
In another study, mice (a total of about 700 animals, mixed sex) were exposed 
for 2-hour periods to 375, 1 500 or 6 000 ppm isoflurane or air during pregnancy 
days 11, 13, 15, and 17. On the 5th day after delivery, exposure of the pups was 
resumed (3 times weekly) for a total of 24 exposures after delivery, altogether 8 
weeks. There was no increase in the number of neoplastic lesions in isoflurane 
exposed offspring compared to control mice at 9 and 15 months after delivery 
(65).  
The number of neoplasms in mice (mixed sex) exposed to isoflurane during 
foetal life and after birth was investigated by Corbett (53). Pregnant mice were 
exposed to either 1 000 ppm isoflurane on gestation days 12, 14, and 16 or to 
5 000 ppm isoflurane on gestation days 12, 14, 16, and 18 (n=20). The offspring 
from both groups were further exposed to 1 000 ppm isoflurane from postnatal day 
5 to 30. Each exposure period lasted 2 hours. A control group of pregnant mice 
and their offspring were exposed to room air. The number of tumours was 
evaluated in the offspring at ages 3, 6, and 9 months. An increased number (not 
significant) of lung adenomas was found in the isoflurane-exposed offspring 
compared to controls. The offspring was examined for hepatic neoplasms at the 
age of 15 months. Male offspring from the low-exposure and high-exposure 
groups of pregnant mice had 17% (5/30) and 27% (10/37) hepatic neoplasms, 
respectively. The number of hepatic neoplasms in the treated mice was 
significantly greater than in controls (53). In a later paper with Corbett as a co-
author (65), it was pointed out that the Corbett study (53) is problematic for 
several reasons: uncertainty of exposure conditions for control mice, risk of 
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contamination of food and lack of blinding of the pathological samples to the 
evaluator. The many uncertainties of the above study make it difficult to conclude 
as to the potential carcinogenicity of isoflurane based on this study. 
In summary, one study showed no carcinogenic effects of isoflurane after about 
1.5 years of exposure to 1 000 and 4 000 ppm of isoflurane (4 hours/day, 5 days/ 
week). Further, there was no evidence of carcinogenicity in 9 and 15 months old 
mice exposed to isoflurane prenatally as well as after delivery. In a third paper, 
increased numbers of mice with adenomas in the liver were observed. However, 
that study was not properly designed and there was a lack of experimental detail.  
Sevoflurane and desflurane 
No reports on carcinogenicity were identified. 
10.5.2 Other effects of long-term exposure 
The hepatic and renal effects of chronic inhalation of isoflurane were studied in 
rats (191). Male Fischer 344 rats were continuously exposed to 20 ppm isoflurane 
or air for 30 weeks (n=12). Urinary fluoride excretion was increased during 
exposure to isoflurane. Chronic isoflurane exposure did neither lead to hepato-
cellular necrosis nor to changes in serum alanine aminotransferase activity, liver 
size, hepatic microsomal cytochrome P450 content, or hepatic fat content. No 
evidence of toxic damage to the renal tubules was observed.  
10.6 Reproductive and developmental studies 
Isoflurane: Fertility and preimplantation development 
The effects of non-toxic doses of isoflurane on fertility and development were 
examined in Drosophila melanogaster. Male and female fruit flies were exposed 
to isoflurane at 0, 5 000, 10 000, 20 000, 40 000, 50 000, or 70 000 ppm. Exposed 
males were mated with untreated females and exposed females were mated with 
untreated males. Isoflurane exposure exerted no effect on fertility, as there were 
no significant differences of brood or total numbers of male and female offspring 
among the different treatment groups (143). 
The epididymal spermatozoa of (C57B1/C3H)F1 mice were examined for 
morphologic abnormalities following exposure to air, 1 000, or 10 000 ppm iso-
flurane for 4 hours/day on 5 consecutive days (n=5). Examination 28 days after 
initiation of exposure revealed no significant increases in the percentages of 
abnormal spermatozoa in isoflurane exposed compared to controls (154). As the 
spermatogenic cycle in mice takes 56 days and male mice began exposure only 33 
days before investigation of epididymal spermatozoa, effects on the earlier stages 
of spermatogenesis would not have been detected in this study. 
The effects on fertility and reproductive wastage were evaluated in Swiss 
Webster mice after exposure to isoflurane. Untreated female mice were mated 
with males exposed to air, 1 000 or 4 000 ppm (n=15-24) isoflurane, 4 hours/day 
for 6 weeks before mating. In a second experiment, male (n=55) and female mice 
(n=110) were distributed to three groups exposed to air, 1 000, or 4 000 ppm iso-
43 
flurane, 4 hours/day for 2 weeks before mating and during mating and pregnancy. 
Body weights and male fertility were unaffected by exposures. When uterine 
examinations were performed on day 18 of gestation, no significant effects on 
pregnancy rate or number of implantations were observed in either experiment. 
The mice exposed to 4 000 ppm isoflurane appeared lightly anaesthetised (166). 
Effects on the earliest stages of spermatogenesis would not have been detected,  
as male mice were exposed to isoflurane for only 42 days before mating. 
Rabbits were exposed to 13 000 ppm isoflurane for 4 hours/day for 5 con-
secutive days (n=7-8). Semen was collected on days 12, 19, 26, 33, and 41 after 
exposure, i.e. analysis was performed throughout a seminiferous tubule cycle. 
Following the last semen collection, testicular biopsies were stained and examined 
by light microscopy. The spermatogenic epithelium was classified as: normal, 
hypospermatogenic, maturation arrest or total or partial atrophy. In exposed 
animals, sperm concentration was significantly reduced by approximately two 
thirds on assessment days 26, 33, and 41 compared to preanaesthetic values. 
Sperm cell motility decreased somewhat during the period, from 36% to 75% 
immotile cells, and was significantly different from the pre-exposure value on day 
41. Histologically, varying degrees of injury to spermatogenic cells were observed 
in exposed animals when assessed at day 41, compared to controls. Sertoli and 
Leydig cells appeared normal (45). The reported observations (described in detail 
below, see sevoflurane heading) should be interpreted in the light of the variations 
observed also in control animals and the lack of proper data presentation. For 
example, not only exposed but also control animals presented with a depressive 
trend with respect to sperm concentration. Thus, the adverse effects cannot be 
entirely attributed to the isoflurane exposure.  
The effects of clinical concentrations of isoflurane on in vitro fertilisation were 
evaluated in a mouse model. Mouse oocytes were exposed to either air, mixtures 
of oxygen + nitrous oxide, or oxygen + nitrous oxide + 5 000 ppm isoflurane  
just prior to insemination. After insemination, development of the zygotes was 
assessed. The fertilisation (2-cell) rate and early embryonic growth rate (i.e. 4-cell 
and morula rates) were similar in the three groups (155).  
Preimplantation mouse embryos were exposed to isoflurane to investigate 
effects on embryo development. Two-cell embryos were exposed for 30 minutes 
in vitro to 15 000, 30 000 or 50 000 ppm isoflurane, 5-6 hours, 3-4 hours, or 0-1 
hour before the onset of their first cleavage (n=31-51). Also the effects of 50 000 
ppm isoflurane on 4-cell embryos exposed about 2 hours after the first cleavage 
and on morula stage embryos were examined. When 2-cell embryos were exposed 
for 3-4 hours or 0-1 hour before the expected onset of cleavage, 30 000 and 50 000 
ppm isoflurane inhibited development to the blastocyst stage. The development of 
embryos exposed to isoflurane at the 4-cell or morula stage was unaffected (235). 
In another study, 2-cell mouse embryos were exposed to 15 000 ppm isoflurane in 
vitro. Isoflurane exposure reduced the number of mouse embryos developing into 
the blastocyst stage (47).  
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The effects of sera from patients given various anaesthetics were investigated 
on in vitro mouse preimplantation embryo development. Patients electing different 
operative procedures were anaesthetised with nitrous oxide combined with either 
isoflurane, fentanyl or morphine (n=8). When sera collected one hour after 
anaesthetic induction was added to 2-cell mouse embryos, the number of 2-cell 
embryos that developed into the blastocyst stage was significantly reduced in the 
isoflurane group as compared to that of preanaesthesia sera. No detrimental effects 
were revealed from sera of patients given nitrous oxide in combination with 
fentanyl or morphine. At least 15 embryos were cultured for each serum sample 
(n=8) (164).  
Isoflurane: Developmental toxicity 
The carcinogenic effect of exposure to isoflurane prenatally was investigated by 
Eger et al (65). No evidence for transplacental carcinogenesis was found in 9-  
and 15-month old mice exposed to isoflurane prenatally as well as after delivery 
(described in Section 10.5).  
Eggs from Drosophila melanogaster were exposed continuously to 1 000 or 
2 000 ppm of isoflurane during development. A dose-dependent increase in the 
duration of metamorphosis and a decrease in the number of flies were seen. No 
morphological abnormalities were observed (145). 
Developmental toxicity was examined in Swiss Webster mice exposed to 60, 
600, or 6 000 ppm isoflurane, 4 hours/day on gestation days 6-15 (n=23-27). 
Uterine contents were examined for external, internal and skeletal abnormalities 
on day 18 of pregnancy. No adverse effects on litter size and sex ratio were 
demonstrated following exposure of dams to isoflurane at any exposure level. 
However, exposure to 6 000 ppm isoflurane resulted in significantly decreased 
foetal weight, decreased skeletal ossification, and increased incidences of minor 
hydronephrosis, increased renal pelvic cavitation, and cleft palate. At this ex-
posure level, dams were lightly anaesthetised and maternal weight gain was 
decreased by approximately 10% (167). Approximately half of the decrease in 
maternal weight gain was due to significantly lower foetal weight combined  
with fewer offspring per dam. Reduced ossification, minor hydronephrosis, and 
increased renal pelvic cavitation may be indicative of retarded foetal maturation, 
and the incidence of cleft palate generally increases when pregnant mice are 
stressed during gestation.  
Both male (n=54) and female Swiss Webster mice (n=110) were exposed to air, 
1 000, or 4 000 ppm isoflurane 4 hours/day for 2 weeks before mating and during 
mating and pregnancy. When uterine examinations were performed on day 18 of 
gestation, the number of implantations, resorptions, live foetuses, viability, foetal 
weight, and sex ratio showed no differences between exposed and control groups. 
One third of the pregnant dams were allowed to deliver and rear their offspring 
until postnatal day 28. Birth weights and survival of exposed offspring did not 
depart significantly from controls. No maternal toxicity was observed but at the 
highest concentration light anaesthesia was observed (166). 
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The reproductive and teratogenic effects of isoflurane were studied in pregnant 
Sprague Dawley rats. Rats were exposed to either air or 3 500 ppm isoflurane for 
24 hours on day 8 of pregnancy (n=30-40). Exposure did not affect the number of 
implantations, resorptions, live foetuses, sex ratio, or mean foetal body weight. No 
increases in visceral or skeletal abnormalities were found. Exposed dams were 
slightly sedated during exposure and their body weights were significantly lower 
on days 12, 14, and 16 of pregnancy compared to controls (78). 
The neurotoxic effects of anaesthesia were studied in Hartley guinea pigs  
in which gestation lasts 59-72 days and brain development is mostly a prenatal 
phenomenon. Pregnant guinea pigs were exposed for 4 hours to 0 or 5 500 ppm 
isoflurane during three different gestational periods: gestation days 20-25, 35-40,  
or more than 50 days. Both control and isoflurane exposed guinea pigs were 
intubated under fentanyl anaesthesia, and in controls, anaesthesia was maintained 
with fentanyl. Therefore a ”true” control group was added, which did not undergo 
treatment at all. During exposure, maternal homeostasis was maintained within 
control values. Two hours after cessation of exposure, several relevant regions in 
foetal brains were immunochemically stained for caspase-3 as a proxy for late 
apoptosis. There were no significant differences in staining between the fentanyl-
treated controls and the true controls, although the level of caspase-3 positive 
neurons was somewhat lower in true controls. In foetuses from animals treated 
with isoflurane on gestation days 35-40, the number of caspase-3 positive neurons 
was increased 3-6 fold compared to true controls in several brain regions (205). 
The outcome of statistical comparisons with fentanyl-treated controls was not 
provided. Only total numbers of pregnant animals in each stage were stated, not 
numbers of pregnant animals in each exposure group. Furthermore, all offspring 
from all mothers were assessed, which increases the risk for litter effects.  
Pregnant Sprague Dawley rats were exposed 6 hours/day on gestation days  
8-10, 11-13, or 14-16 to 10 500 ppm isoflurane or air (n=21-50). The dams were 
lightly anaesthetised and their weight gains were significantly reduced compared 
to controls. At laparotomy on gestation day 21, foetal weights were reduced in 
offspring of rats exposed to isoflurane on gestation days 8-10 and 14-16. Other-
wise no reproductive indices, including malformation rate, were altered in any of 
the exposed groups (168). 
Pregnant Sprague Dawley rats were anaesthetised with 13 000 ppm isoflurane 
or carrier gas (30% oxygen, balanced with nitrogen) for 6 hours at gestational  
day 21. A pilot study (n=4) showed that at this exposure level the dams breathed 
spontaneously and no significant changes were observed for arterial blood gas and 
mean arterial blood pressure as compared to the controls. Some dams underwent 
laparotomy 2 or 18 hours after termination of exposure (n=5-6), other dams 
delivered their offspring naturally (n=7-8). In the latter offspring, lactational 
weight gain was similar in control and exposed offspring. In all groups of off-
spring, apoptosis was quantified in the hippocampus and cortex. Spontaneous 
apoptosis was significantly decreased 2 hours after isoflurane exposure in the 
hippocampal CA1 region and in the retrosplenial cortex, observed as an 80-87% 
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decrease in the density of caspase-3 and TUNEL (terminal deoxynucleotidyl 
transferase biotin-dUTP nick end labelling) positive cells. No differences were 
evident 18 hours after treatment or at postnatal day 5. When the naturally 
delivered pups were examined in the Morris water maze at ages 5 and 17 weeks, 
the only observed difference was a significant increase in the percentage of time 
spent in the probe quadrant for isoflurane exposed compared to control juvenile 
offspring (157). The latter finding is usually interpreted as a sign of increased 
cognitive performance. 
Ten-week-old pregnant Jcl:ICR mice were exposed to 0 or 15 000-20 000 ppm 
isoflurane for 8 hours on day 7 of gestation (data were analysed with the pups 
(n=66-72) rather than the litter (n=4-5) as the statistical unit, thereby introducing 
the risk for litter effects). On gestation day 18, foetal weight and the number of 
ossified sacrococcygeal vertebrae were significantly reduced in exposed offspring 
compared to controls (96).  
Pregnant albino rats were exposed to 17 000 ppm isoflurane on gestation days  
1-5, 6-10, 11-15, or 15-20 for 1 hour/day (n=11-19; n was not stated for the late 
exposure group) to determine effects on development. Eleven control dams and 10 
dams exposed on gestation days 1-5 were sacrificed on day 14 of gestation. The 
remaining dams were sacrificed on day 20 of gestation, apart from the dams 
exposed during late pregnancy that were allowed to deliver and carry their litters 
through weaning. Maternal weight gain was reduced in the late exposure group. 
Otherwise dams were unaffected by exposure, but for signs of sedation. Offspring 
from the earliest treatment group exhibited somewhat depressed body weights, 
and dams in the late exposure group delivered and weaned fewer pups than the 
controls. Otherwise, progeny body weight, gestational parameters, foetal viability, 
survival, and malformation rate were similar to the control values (132).  
Pregnant New Zealand rabbits were exposed on gestation days 6-9, 10-14, and 
15-18 to 23 000 ppm isoflurane for 1 hour/day (n=15/group). All animals were 
sacrificed on gestation day 29. Maternal food consumption and weight gain were 
similar in all groups. No adverse reproductive effects were observed, and no 
evidence of teratogenic activity was obtained (132). 
Isoflurane: Juvenile studies 
Isoflurane was administered to young Sprague Dawley rats at 7 500, 10 000 or 
15 000 ppm for 6 hours at the age of 1, 3, 7, 10, or 14 days (n=4 - 10). Control 
offspring were exposed to air. Young rats went through perfusion fixation 18 
hours after anaesthesia and brain slices were stained with silver to assess apoptotic 
neurodegeneration. Isoflurane treated animals exhibited dose-dependent neuro-
degeneration in the laterodorsal and anteroventral thalamic nuclei at postnatal days 
1 and 3, significantly greater than in the corresponding controls at the highest ex-
posure level. The involvement of the intrinsic apoptotic pathway was investigated 
by measuring the cytosolic levels of anti-apoptotic protein (bcl-xL) and cytochrome 
c in brain extracts from the cortex and the anterior thalamus in 7- and 14-day old 
pups. In the same tissues, the involvement of the extrinsic apoptotic pathway was 
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investigated by measuring the expression of Fas (a member of the TNFα 
superfamily). Values in exposed pups did not differ from those of control pups 
(249). Another study used a similar exposure protocol, but limited the age at 
exposure to 7 days post partum. After anaesthesia, some of the young rats went 
through perfusion fixation and 50 µm brain sections were stained with silver or 
processed to reveal caspase-3. In control animals, both silver and caspase-3 
staining revealed a sparsely scattered pattern of baseline physiological cell death. 
Isoflurane treated animals exhibited dose-dependent neurodegeneration. The most 
vulnerable brain regions were the laterodorsal and anteroventral thalamic nuclei, 
where even the lowest concentration caused a significant increase in neuronal 
degeneration (16- and 9-fold, respectively). The parietal cortex was also affected 
in an apparently dose-dependent manner, although the damage was significantly 
greater than in controls only at the highest exposure level. Long-term electro-
physiological function was examined in hippocampal slices from pups exposed at 
postnatal day 7, prepared at postnatal days 29-33. Baseline excitatory postsynaptic 
potentials in isoflurane treated pups did not differ from controls. Long-term 
potentiation was less robust in treated animals, but this difference did not show 
significant when compared to controls (124). 
Infant mice were exposed to 7 500, 15 000, or 20 000 ppm isoflurane for 4, 2,  
or 1 hours, respectively. Group sizes ranged from 6 to 16 pups. At each condition, 
control and experimental pups were taken from the same litters, but probably only 
from one or two dams. The number of neuronal profiles undergoing apoptosis in 
the brains was evaluated quantitatively 5 hours after initiation of exposure by 
activated caspase-3 immunostaining. Blood glucose values were determined under 
the same conditions. Isoflurane was associated with significant increases of 178-
477% in neuroapoptosis in the caudate putamen, compared with the control 
condition. Blood glucose determinations indicated that hypoglycaemia was not a 
potential cause of the brain damage (125). 
These studies were partly replicated in vitro. Organotypic hippocampal slices 
were prepared from rat pups on postnatal days 4, 7, and 14 and cultured 7 days in 
vitro. The slices were exposed to 15 000 ppm isoflurane in fresh gas (21% oxygen, 
5% carbon dioxide, 69% nitrogen) or fresh gas only for 1, 3, or 5 hours. Hippo-
campal CA1, CA3, and dentate gyrus neuronal survival were assessed 3 days later 
(n ≥ 12 slices/condition and brain structure). Isoflurane significantly increased cell 
death in slices exposed to isoflurane for 5 hours. No significant effect was evident 
after 1 or 3 hours of exposure (244). 
Newborn Sprague Dawley rats were removed from their mother 2-4 hours  
after birth. The pups were placed on a heated pad and were administered either 
normobaric oxygen/carbon dioxide for 10 minutes or 20 000 ppm isoflurane for  
3 minutes followed by 10 000 ppm isoflurane for 7 minutes, in normobaric 
oxygen/carbon dioxide (group size not indicated). Neonatal anaesthesia did not 
affect body temperature and all animals fed at least once within 4 hours of being 
returned to their mothers. There was no effect of isoflurane on body weights at  
any time point postexposure. When reflex development was investigated three 
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times a week from postnatal day 2 to 15, isoflurane exposed offspring performed 
significantly slower in surface righting, and were able to hang onto the wood bar 
with their forepaws for significantly shorter times than control offspring; per-
formance in negative geotaxis and cliff aversion was similar in the two groups.  
On postnatal day 25, isoflurane offspring displayed significantly more foot slips 
while traversing a balance beam during 5 out of 6 trials. Learning in both the 
Morris water maze (postnatal days 45-46) and the radial arm maze (postnatal days 
58-72) was impaired in isoflurane exposed compared to control offspring. When 
the study was terminated at postnatal day 80, hippocampal volume and neuron 
number were decreased by approximately 20% in exposed offspring compared to 
controls (208). It should be mentioned, that none of the juvenile studies describes 
the allocation of pups from different dams to the different exposure groups, why 
litter effects cannot be excluded. 
Isoflurane: Myometrial contraction 
The effects of 6 000, 12 000 and 18 000 ppm isoflurane on isolated human uterine 
muscle were evaluated. Specimens were obtained from 15 non-gravid and 4 gravid 
uteri removed at elective operations (n=6-7 strips per dose level). Each muscle 
strip was placed in a freshly prepared bath solution and was attached to an iso-
metric force transducer. After 40-60 minutes of spontaneous contractions, the 
anaesthetic was added to the muscle-bath system. Direct measurements of iso-
flurane content in the bath solution showed that equilibration of the water with 
isoflurane vapour was essentially complete within 3-4 minutes. After exposure  
for at least 30 minutes, the anaesthetic was discontinued and a control pattern 
comparable to the initial control pattern reappeared. Myometrial response was 
evaluated by measuring the mean resting tension, developed tension, and fre-
quency of contractions, with contractility defined as the area between the resting 
and developed tensions per unit time. Gravid and non-gravid muscle strips showed 
similar, and progressive depression of contractility with increasing dose level, 
significantly different from control values at the lowest and the highest dose level 
(post hoc analysis corrected for multiple comparisons). The mean frequency of 
contractions decreased with increasing dose, but was only significantly different 
from controls at the lowest dose level. Significant reductions in developed tension 
occurred at the highest dose level (175).  
The effect was also investigated in myometrial strips from 11 non-gravid 
women undergoing elective abdominal hysterectomy (age range 29-57, mean  
39 years). Following 45 to 60 minutes of equilibration and spontaneous uterine 
activity, 22 strips were exposed to 5 000 ppm isoflurane. Eight strips were un-
exposed and served as controls. Frequency of contractions and uterine activity 
decreased significantly and the mean interval between contractions increased (41). 
Uterine specimens were obtained at the time of operation during hysterectomy 
and caesarean section from premenopausal women aged 18-54 years. Non-gravid 
uterine strips began to contract spontaneously, whereas gravid strips were initially 
stimulated by adding oxytocin. After 30-60 minutes, isoflurane was administered 
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for 30 minutes and then discontinued for at least 30 minutes until a comparable 
control pattern reappeared. Then the uterine strips were exposed to the next higher 
concentration. Each strip were exposed at two to four dose levels of 5 000, 10 000, 
20 000 and 30 000 ppm (n=6). Contractility of both gravid and non-gravid uterine 
muscle was significantly depressed at all dose levels. At 20 000 ppm, the effect 
was stronger in gravid than non-gravid strips (231). 
Isoflurane: Other reproductive effects 
Four-day-old chick embryos were exposed to 25 000 or 50 000 ppm of isoflurane 
vapour (n=5). Dorsal aortic blood velocity was measured with a pulsed-Doppler 
velocity meter. Neither cardiac stroke volume nor embryonic heart rate were 
affected by isoflurane (245). 
The antiproliferative potential of isoflurane was determined in vitro, in a C6 
glioma cell line, following exposure for 48 hours over a concentration range  
of 0-2.0 mM, estimated 48 hours after exposure. The drug concentration that 
inhibited C6 glioma proliferative action by 50% was approximately 1.0 mM. 
Antiproliferative action was not associated with anaesthetic-induced cytotoxicity. 
Flow cytometric analysis of growth-arrested cell populations revealed no specific 
accumulation in any cell cycle phase, as observed for e.g. the teratogen valproate 
(186). 
In preterm pregnant sheep, maternal and foetal cardiovascular data, amniotic 
pressure, uterine blood flow, and foetal brain oxygenation were monitored before, 
during, and after isoflurane anaesthesia at mid-gestation, i.e. gestation day 90 
(n=11). Anaesthesia was induced with thiopental after sedation with midazolam, 
and thereafter maintained with 15 000 ppm isoflurane in oxygen for 4 hours. Iso-
flurane produced moderate foetal hypotension and bradycardia, but markers of 
systemic oxygenation did not change from baseline. An initial increase in foetal 
oxygen saturation was observed, followed by a gradual decline to baseline.  
Within the foetal brain, oxygenated haemoglobin changed by less than 10% (non-
significant) and deoxygenated haemoglobin and total haemoglobin varied by less 
than 5%, although foetal mean arterial pressure decreased (170). 
Sevoflurane 
Rabbits were exposed to 23 000 ppm sevoflurane 4 hours/day on 5 consecutive 
days (n=7-8). Semen was collected on day 12, 19, 26, 33, and 41 after the first day 
of exposure, i.e. analysis was performed throughout a seminiferous tubule cycle. 
Following the last semen collection, testicular biopsies were stained and examined 
by light microscopy. The spermatogenic epithelium was classified as: normal, 
hypospermatogenic, maturation arrest or total or partial atrophy. From the 12th 
day after initiation of exposure, sperm concentration was decreased by 50% 
compared to the pre-exposure value, significantly so from the 19th to the 41st  
day. Furthermore, exposed rabbits displayed complete absence of motile sperm  
on day 33, with significantly decreased values also on day 26. On day 41, motility 
had returned to pre-exposure values. Histologically, varying degrees of injury to 
spermatogenic cells were observed in exposed animals on day 41, whereas Sertoli 
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and Leydig cells appeared normal (45). However, these observations should  
be interpreted in the light of the variation observed in the control animals. In  
these animals, sperm concentration values decreased progressively throughout  
the assessment period, and had decreased by 32% on day 41 compared to pre-
exposure. On day 26, the value was significantly different from the pre-exposure 
value. It can therefore not be excluded that the pre-exposure value in the exposed 
animals was a one-time high. If this is the case, the lower values in exposed 
animals may not be related to exposure, but are rather chance findings. Regarding 
motility values, controls presented with 0% immotile sperm cells pre-exposure, 
increasing to 17% at termination of the study. In the sevoflurane group, the 
corresponding pre-exposure value was much higher, i.e. 52% immotile sperms. 
Furthermore, data were presented as means without specification of variation, and 
the results of the histological assessment were presented as selected microphoto-
graphs, and abnormal findings from animals exposed to sevoflurane as totals 
together with findings from animals exposed to isoflurane; study described above 
in this section (“Isoflurane: Fertility and preimplantation development”). Thus no 
formal summing up or statistical analysis of the differences between the control 
and exposed groups was performed.  
Anaesthesia was induced with propofol in 10 pregnant goats. Following the 
induction, the animals inhaled 27 000 and 41 000 ppm end-tidal concentration of 
sevoflurane each for 30 minutes, and then recovered. Compared to pre-anaesthetic 
values, sevoflurane caused minimal change in maternal haemodynamics. Foetal 
blood pressure decreased significantly during the last minutes of exposure to 
27 000 ppm and remained low during exposure to 41 000 ppm sevoflurane. The 
uterine contractions disappeared throughout sevoflurane inhalation, but recurred 
within 15 minutes after cessation of exposure (218). 
The antiproliferative potential of sevoflurane was determined in vitro in a C6 
glioma cell line, following a single exposure over a concentration range of 0-2.0 
mM for 48 hours. Within this exposure range, the concentration of sevoflurane 
that inhibited C6 glioma proliferative action by 50% could not be determined. 
Antiproliferative action was not associated with anaesthetic-induced cytotoxicity. 
Flow cytometric analysis of growth-arrested cell populations revealed no specific 
accumulation in any cell cycle phase, as observed for e.g. the teratogen valproate 
(186). 
During elective caesarean section, a small sample of myometrium was isolated 
from 12 healthy women, and the effects of 2 010, 5 025, 10 050, 15 075, 20 100, 
30 150, 50 250, and 70 350 ppm sevoflurane were investigated after spontaneous 
contractions had appeared after approximately 90 minutes (n=6/dose level). 
Following a 10-minute exposure period, the mean values for three consecutive 
contractions were measured and expressed as a percentage of the preceding 
control measurements. Exposure was then discontinued for 10 minutes washout, 
after which exposure at the next dose level was initiated. Sevoflurane dose-
dependently depressed uterine contractility (defined as the area under the force-
time curve); significantly different from the control condition at 5 025 ppm and 
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above. Developed tension was similarly depressed, and differed significantly 
between the groups at concentrations of 10 050 ppm and greater. At the two 
highest dose levels (50 250 and 70 350 ppm), the frequency of spontaneous 
contractions were significantly increased and uterine activity was virtually 
abolished (234). 
Desflurane 
No animal or in vitro studies evaluating reproductive effects of desflurane were 
found in the literature, apart from the two studies on effects on myometrial 
contractions described below.  
Comparative studies on myometrial contraction 
Uterine specimens were obtained from normal full-term pregnant women under-
going elective lower-segment caesarean delivery. Longitudinal muscle strips were 
mounted to isometric force transducers and a resting tension was placed (n=11-
15). The isometric tension was recorded during exposure to isoflurane (6 500-
39 000 ppm), sevoflurane (10 000-60 000 ppm), or desflurane (30 000-180 000 
ppm). The three anaesthetics produced a dose-dependent depression in contract-
ility, although the response in exposed strips did not differ significantly from 
control specimens at the lowest dose levels. Contractility was significantly 
decreased at 13 000 ppm isoflurane and above, and for sevoflurane and desflurane 
at and above 20 000 and 60 000 ppm, respectively (250).  
A small segment of myometrium was excised from the lower uterine segment  
of 20 non-labouring term parturients undergoing caesarean section. The study 
protocol consisted of a 60-minute period of spontaneous contractions, control 
recording with oxytocin for 10 minutes, washout for 10 minutes, administration  
of sevoflurane (11 500, 23 000, and 46 000 ppm; n=10) or desflurane (28 500, 
57 000, and 114 000 ppm; n=10) (3 times per 15-minute period), response to 
oxytocin (10-minute period), a further washout interval (10-minute period) and 
subsequent control recording with oxytocin without anaesthetics. The frequency 
and amplitude of contractions induced with oxytocin decreased significantly at all 
dose levels. The duration increased at the two lowest dose levels, but decreased at 
the highest dose level. At the middle dose level, i.e. 1 MAC, desflurane inhibited 
the amplitude less than sevoflurane. The duration of contractions at the highest 
dose level decreased in both groups (248). A similar protocol was used in longi-
tudinal myometrial strips from non-pregnant and pregnant (gestation days 19-20) 
Wistar rats (n=10 per compound). Both agents inhibited the duration, amplitude, 
and frequency of induced contractions in a dose-dependent manner, and the 
responses differed significantly from the control condition at all dose levels (57). 
When the response of pregnant rat myometrium was compared with that of non-
pregnant rats in a similar experimental protocol (n=10 condition/ compound), both 
agents inhibited the duration, amplitude, and frequency of induced contractions in 
a dose-dependent manner, except at the lowest dose level in the non-pregnant 
group. Isolated strips of pregnant rat myometrium were more sensitive to the 
inhibitory effects of both agents than strips from non-pregnant rats (89).  
52 
Longitudinal smooth muscle layers were obtained from 24 pregnant Sprague 
Dawley rats, and cut into small strips. Muscle tissue was contracted with oxytocin, 
and isoflurane or sevoflurane (10 000, 20 000, or 30 000 ppm) were introduced 
into the tissue bath (n=6). Both volatile anaesthetics inhibited muscle contraction 
dose-dependently concomitant with a decrease in intracellular free Ca2+; signifi-
cantly so from the lowest dose level. When the anaesthetic concentrations were 
expressed as multiples of their MACs, the inhibitory potencies of the two agents 
were similar (247). 
Conclusions  
Isoflurane is the flurane best studied for reproductive effects. Regarding fertility, 
isoflurane was not associated with effects on male fertility in two studies in mice 
at exposure levels ranging from 1 000 to 10 000 ppm (154, 166). One study in 
rabbits demonstrated decreased sperm counts starting 26 days after initiation of 
exposure to 13 000 ppm isoflurane. In the latter study, control animals presented 
with significant variation in spermatogenic parameters, therefore the reported 
findings may not pertain to isoflurane exposure (45). None of the studies covered 
the full spermatogenic cycle. 
Two studies showed decreased development of 2-cell mouse embryos into  
the blastocyst stage after exposure to supraanaesthetic doses of isoflurane in vitro 
(47, 235), whereas one study at anaesthetic dose level did not (155). In an in vivo 
mouse study, female fertility was unaffected after exposure to up to 4 000 ppm 
isoflurane, 4 hours/day for 2 weeks before and during mating (166).  
The effects of isoflurane exposure on foetal development were investigated  
in several studies, in mice, rats, and rabbits. Isoflurane reduced offspring body 
weights at exposure levels at and above 6 000 ppm. One study showed signifi-
cantly increased incidences of minor anomalies (minor hydronephrosis, increased 
renal pelvic cavitation) and cleft palate in mice exposed prenatally to 6 000 ppm 
isoflurane, 4 hours/day during organogenesis. These offspring also displayed 
decreased foetal weight and delayed ossification (167). At 4 000 ppm and below, 
the studies consistently showed no effect of isoflurane (78, 166, 167). 
Exposure to isoflurane during neonatal life has been associated with increased 
apoptosis in neural tissue in rodents (125, 208, 244). The developmental stage of 
the nervous system in juvenile rodents corresponds roughly to that of the nervous 
system in the human foetus during the third term. These results indicate that, 
potentially, the foetal nervous system in humans may be sensitive to isoflurane 
exposure. It should be mentioned, that other recent results demonstrate that brief 
exposure to other anaesthetics, e.g. ketamine and midazolam also triggers neuro-
apoptosis in the developing mouse brain (125). In contrast, one study demonstrated 
decreased spontaneous apoptosis in term rat offspring exposed in utero to 13 000 
ppm isoflurane for 6 hours. Exposed offspring demonstrated indications of in-
creased cognitive performance later in life (157). 
For sevoflurane, the only study on fertility in male rabbits, showed decreased 
quality of semen after exposure to near MAC-values of sevoflurane (45). 
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However, in this study, control animals presented with significant variation in 
spermatogenic parameters, why the reported findings may not pertain to sevo-
flurane exposure. 
Finally, as investigated in vitro on myometrial strips, all 3 fluranes significantly 
inhibit muscle contraction, also at subanaesthetic dose levels around 0.5 MAC. 
The NOAEL for this effect has not been determined (41, 175, 231, 248, 250). 
11. Observations in man  
Isoflurane, sevoflurane and desflurane are used as anaesthetics. In comparison to 
most other compounds in the work environment, there is therefore relatively much 
knowledge as to the effects of single exposure to high dose levels in humans, i.e. 
side-effects. However, for most of these side-effects, the NOAELs are not known. 
The most common side-effects are listed in Appendix 2, where also the incidence 
of each effect is stated. In addition to the central nervous system, fluranes at 
anaesthetic levels have been shown to affect most organ systems. Most concern 
has concentrated around the potential for hepatotoxicity and nephrotoxicity. 
Hepatitis may occur in less than 1/1 000 after isoflurane anaesthesia, and in 
between 1/1 000 and 1/10 000 after sevoflurane and desflurane anaesthesia. 
Nephrotoxicity is only a concern for sevoflurane, with an incidence less than 
1/10 000 patients. Other side-effects include leukocytosis in patients undergoing 
anaesthesia with desflurane (≥ 1/10) and malign hyperthermia, which appears in 
between 1/1 00 and 1/1 000 patients after desflurane anaesthesia.  
The effects of isoflurane, sevoflurane and desflurane have been investigated in  
a number of experimental studies with a single acute exposure at subanaesthetic 
concentrations. These are described below together with a few cross-sectional 
studies that investigated the effects of occupational exposure to mainly isoflurane. 
The studies that are of relevance for dose-effect and dose-response relationships 
are summarised in Tables 16-19 in Chapter 12.  
11.1 Irritation and sensitisation  
11.1.1 Irritation 
Isoflurane 
None of 8 anaesthetists (gender not specified) experienced discomfort, and all 
subjects found inhaling isoflurane acceptable or pleasant and suffered no nausea 
after exposure to 1 150, 2 300, and 4 600 ppm of isoflurane in 100% oxygen for  
at least 20 minutes at least one week apart (178). In contrast, 6 of 12 volunteers 
(mixed gender) breathing 4 000 ppm isoflurane found the odour unpleasant, 2 
found it neutral, and 4 found it pleasant. Two rated the exposure unacceptable, 
whereas the remainder found it acceptable (172).  
Elicitation of airway reflexes by nasal exposure to isoflurane was investigated 
in 13 female patients anaesthetised with flunitrazepam, pentazocine, and nitrous 
oxide. The patients were intubated by a saline-filled double-cuffed endotracheal 
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tube, and spontaneous respiration resumed while the patients breathed 50% 
nitrous oxide in oxygen. Changes in breathing pattern were measured with a 
pneumotachograph while changes in laryngeal and tracheal wall tension were 
assessed by measuring changes in the proximal cuff pressure and the distal cuff 
pressure, respectively. In 8 of 13 patients, the dose-response relationship was 
determined by administering 10 000, 30 000, or 50 000 ppm isoflurane to the 
nostril. Nasal insufflation with 10 000 and 30 000 ppm isoflurane did not elicit 
responses. In all 13 patients, nasal insufflation at a concentration of 50 000 ppm 
prolonged mean (±SD) expiratory time (from 2.2 ± 0.5 to 3.9 ± 1.7 seconds). In 6 
patients, expiratory time increased by more than 5 seconds, during which there 
was a small but consistent increase in laryngeal wall tension. The prolongation in 
expiratory time possibly occurs due to activation of reflexogenic receptors in the 
nose, indicating airway irritation at high exposure levels (181).  
Sevoflurane 
No studies regarding irritation were found for sevoflurane besides the comparative 
studies described below. 
Desflurane  
Six unpremedicated young, adult males going through day-case arthroscopy of  
the knee were administered desflurane (and 60% nitrous oxide in oxygen) at an 
inspired concentration of 30 000 ppm, increased by 3% every 3-6 breaths as 
tolerated, up to a maximum of 120 000 ppm. Of the 6 patients, 5 developed 
laryngospasm, breath-holding, coughing, and increased secretions. Hiccups and 
bronchospasm occurred in 1 patient (34).  
MAC for desflurane in oxygen was determined to 72 500 ppm in 18-30-year old 
unpremedicated male patients, and to 60 000 ppm in the 31-65-year age group. 
Signs of minor airway irritation were apparent, i.e. more than half coughed during 
induction, and the odour was most commonly described as “burning” or “soap in 
the nose” (197). 
Comparative studies 
The effect of breathing 1 200 ppm isoflurane or 6 000 ppm desflurane for 3 
minutes on the incidence of adverse airway events was investigated. Twenty-five 
volunteers known to develop adverse airway events in response to surgical levels 
of desflurane or isoflurane took part in the study. Smokers were excluded. 
Adverse airway events were identified both clinically (cough) and by recording 
diagrams of inspiration and expiration, allowing identification of e.g. breath 
holding. None of the volunteers displayed adverse airway events during the 3 
minutes of breathing 1 200 ppm isoflurane or 6 000 ppm desflurane in 100% 
oxygen (86).  
Airway irritation was studied in 11 male volunteers after inhalation of 11 500 
and 23 000 ppm isoflurane and 17 100 and 34 200 ppm sevoflurane for 15 
seconds. The order of presentation of the four exposures was random and the 
interval between inhalations was at least three minutes. Inhalation of both agents 
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decreased tidal volume, increased respiratory frequency, and decreased functional 
residual capacity as measured by plethysmography. Activation of the cough reflex 
was also registered. Sevoflurane did not elicit cough, and overall the effects and 
subjective rating of airway irritation were relatively stronger for isoflurane (58).  
The pungency and tolerability of isoflurane, sevoflurane, and desflurane were 
compared in a randomised, double-blind study. Eighty-one unpremedicated male 
patients inhaled 23 000 ppm isoflurane, 40 000 ppm sevoflurane or 120 000 ppm 
desflurane for 60 seconds from an anaesthetic breathing circuit via a mask (n=27). 
One sevoflurane patient coughed, but completed the study, whereas 11 isoflurane 
patients and 20 desflurane patients coughed, objected verbally, or removed the 
mask forcefully before the end of the study. The irritability grading at 2 MAC 
was: desflurane > isoflurane > sevoflurane (230). 
Conclusion 
At anaesthetic dose levels, especially desflurane but also isoflurane irritates the 
airways. When the irritative effect of isoflurane and desflurane were evaluated  
at subanaesthetic dose levels (1 200 ppm isoflurane, 6 000 ppm desflurane), no 
adverse airway events were observed during the 3 minutes of exposure. Since 
sevoflurane displays lesser irritative effects than isoflurane and desflurane, the 
above studies indicate that irritative effects of the fluranes would not be expected 
to occur at the much lower exposure levels present in the workplace.  
11.1.2 Sensitisation 
There are a few case reports of allergic reactions to isoflurane and sevoflurane. No 
studies concerning allergic reactions to desflurane have been identified. Contact 
dermatitis has been reported in anaesthetists exposed to isoflurane (42, 74).  
Three cases of occupational asthma and allergy to sevoflurane and isoflurane 
have been described in anaesthetic staff after more than 3 years of occupational 
exposure. Evidence for asthmatic reactions to isoflurane and sevoflurane was 
evaluated giving sequentially increasing exposures to isoflurane or sevoflurane on 
separate days. Sequential exposures of 3 (2 500 ppm), 5 (2 500 ppm), and 7-10 
breaths (3 700-5 000 ppm) were given at 10-minute intervals, provided that the 
forced expiratory volume in one second (FEV1) was within 15% of baseline. In 
one case, sevoflurane exposure increased peak flow variability, decreased FEV1 
(by 32%), and increased the sensitivity to metacholine. The patient subsequently 
had an anaphylactic reaction to sevoflurane during general anaesthesia. Challenge 
testing of the second case was negative for both isoflurane and sevoflurane,  
but the latter resulted in a late asthmatic reaction with increased metacholine 
sensitivity. The third case developed a skin rash after exposure to isoflurane 
together with an increase in metacholine sensitivity, but no effect was observed 
for FEV1 (238).  
Anaphylactic reactions have been described in a patient exposed to isoflurane 
(220) and in an anaesthetic nurse during general sevoflurane anaesthesia after 4 
years of occupational exposure to isoflurane and sevoflurane (238).  
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11.2 Effects of single and short-term exposure  
11.2.1 Central nervous system 
Isoflurane, sevoflurane, and desflurane are all used as anaesthetic agents, i.e. they 
induce hypnosis and amnesia by acting on the central nervous system (193). Thus, 
all three agents cause sedation and analgesia at anaesthetic dose levels, with 
MAC-values of 12 000, 21 000 ppm, and 60 000 respectively (Table 4). Recovery 
from surgical anaesthesia generally occurs within 15-30 minutes, assessed as time 
from cessation of anaesthesia to response to command and to correct statement of 
place and date (67). Recovery is fastest after desflurane anaesthesia, followed by 
sevoflurane and then isoflurane, although the differences in terms of minutes are 
small (92).  
Isoflurane 
Peak velocity of saccadic eye movements was studied in 6 volunteers (gender not 
specified) exposed to 600 and 1 200 ppm of isoflurane for 25 minutes. Saccades 
were generated by having the subjects follow the movements of an illuminated 
target, which was presented on a linear array of light-emitting diodes. Mean 
saccadic peak velocity decreased significantly after exposure to 600 ppm iso-
flurane for 15 minutes, and decreased further when the concentration was doubled, 
as compared with exposure to air (79). 
Fourteen healthy volunteers (7 women, 7 men) inhaled vehicle (100% oxygen) 
and 1 000 and 2 000 ppm isoflurane for 40 minutes each, across separate sessions. 
Four psychomotor tests were applied (i.e. tests of digit-symbol substitution, 
logical reasoning, coordination, and auditory reaction time) together with ratings 
of drug effects. Feeling of sleepiness, tingling, and feeling ”high” increased dose-
dependently, as did mean inhalant drug effects score, but ratings differed signifi-
cantly from the control condition at the highest exposure level only. This also 
characterised the outcome of the psychomotor tests. For the digit-symbol sub-
stitution test, performance decreased significantly already at the lowest exposure 
level (24).  
Levels of consciousness and auditory evoked responses were evaluated in 8 
healthy male volunteers (anaesthetists) exposed to 0, 1 150, 2 300, and 4 600 ppm 
of isoflurane in 100% oxygen, at random sessions (total duration of gas exposure 
per session was 21 minutes) separated by at least one week. Experiments were 
constructed to allow blinding of both subjects and testers. The volunteers’ ability 
to react on verbal commands and remember lists of words were tested after 10 
minutes of exposure. Auditory evoked responses were recorded from electrodes  
at the subjects’ vertex and occipital bone. At the two lowest exposure levels, the 
eyelash reflex was present in all volunteers. Response to commands was impaired 
at 1 150 ppm in 3 subjects and at 2 300 ppm in all subjects. None of the subjects 
responded at the 4 600 ppm level, at which also 5 displayed absence of the eyelash 
reflex. The amplitudes of the auditory evoked responses decreased and latencies 
increased progressively with increasing anaesthetic concentration. Differences in 
auditory evoked responses were small, but inspection of the individual waveforms 
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showed clear differences as the concentration varied between 0 and 4 600 ppm. 
One hour after the experiment the subjects were interviewed about their memory 
of the experiment. At the lowest exposure level, some of the subjects showed 
impairment of recall of command, even if they apparently reacted normally during 
the session. Both recall and recognition of neutral words was lost at 2 300 ppm 
and higher, but 4 of the subjects remembered having heard a “shock” word at 
2 300 ppm. No clinically significantly changes (> 10%) occurred in either heart 
rate or arterial pressure at any exposure level (178, 179). 
Ten healthy male volunteers received isoflurane in increasing concentrations for 
15 minutes at each exposure level (end-tidal concentrations of 1 900, 3 500 and 
5 100 ppm in oxygen). Learning during anaesthesia was tested 1 hour after the end 
of anaesthesia by means of a category-example task by eliciting whether intra-
anaesthetic suggestions influenced subsequent verbal behaviour. Thus, examples 
from specific categories (e.g. colours, fruits, musical instruments) were presented 
to the anaesthetised volunteers, who were tested for their memory of these ex-
amples after recovering from anaesthesia. Already at the lowest exposure level did 
isoflurane decrease the percentage of explicitly remembered words, i.e. words the 
volunteers were aware of hearing during anaesthesia, and a further decrease was 
observed as exposure levels increased (48).  
Effects of subanaesthetic isoflurane concentrations on suppression of memory 
and responsiveness were evaluated in 17 healthy male volunteers. Each volunteer 
was studied at four end-tidal concentrations of isoflurane, consecutively 1 920, 
3 840, 5 760, and again 1 920 ppm. After 15 minutes of equilibration at each end-
tidal concentration, volunteers were tested for voluntary response to command and 
were presented with verbal information to be recalled after the study. Memory was 
evaluated the day after exposure in the 12 volunteers completing the study. Both 
voluntary response and memory decreased in a dose-related manner. At the lowest 
exposure level, all volunteers responded purposefully, and some responded even  
at the highest concentration. Memory decreased more steeply than voluntary 
response by increasing concentrations of isoflurane, and was prevented by 5 760 
ppm (60). 
A blind, randomised, cross-over trial was conducted to determine the degree of 
psychomotor/cognitive impairment and the recovery profile produced by exposure 
to 100% oxygen placebo, 2 000 or 4 000 ppm isoflurane in 4 female and 6 male 
healthy volunteers. Performance was assessed by the logical reasoning test that 
measures higher mental processes, recall of lists of words, auditory reaction time, 
and the digit-symbol substitution test, where the subject with a pencil replaces  
a number with a corresponding symbol. Fifteen minutes into exposure, both 
concentrations of isoflurane significantly decreased performance in the logical 
reasoning test and the digit-symbol substitution test. Only the highest exposure 
level was associated with significantly decreased performance in the free recall 
memory test and increased auditory reaction time during exposure. The subjects 
returned to control-level functioning 5 minutes after cessations of drug inhalation. 
However, isoflurane induced delayed amnesia, as the mean number of words 
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correctly recalled 60 minutes after cessation of exposure was decreased in both 
exposure groups compared to controls (252). 
Thirteen voluntary subjects (5 women, 8 men) performed an incidental 
encoding task for words presented auditorily during the inhalation of 2 600 ppm 
isoflurane. After termination of isoflurane administration, a 1-minute distractor 
task and self-assessment of wakefulness were performed. Then free recall of 
words was assessed together with recording of the event-related potential, by 
electroencephalography (EEG), during a syllable completion task and during a 
passive listening task. Eleven non-medicated control subjects (9 women, 2 men) 
were tested in a similar manner. When memory was assessed, wakefulness of the 
two groups did not differ significantly. Controls remembered significantly more 
words in the recall test and showed robust early and late event-related potential 
repetition effect. The isoflurane group displayed no free recall and showed no 
event-related potential repetition effect (243). 
The subjective, psychomotor, and memory effects of isoflurane were evaluated 
in a double-blind trial of 9 volunteers (mixed gender) exposed to 0, 3 000 and 
6 000 ppm isoflurane. Isoflurane odour was detected by more than half of the 
volunteers. Isoflurane significantly increased ratings of e.g. confusion and sedation 
and decreased ratings of body and mind control and impaired immediate and 
delayed free recall. Isoflurane lengthened auditory reaction time and lowered 
performance in the eye-hand coordination test. Five minutes after the inhalation 
period ceased, psychomotor performance returned to baseline levels (251). The 
statistical analysis does not indicate whether these changes in response differed 
significantly from the lower to the higher exposure level, but data indicate that 
isoflurane effects were concentration-related.  
Twelve volunteers (mixed gender) breathed 4 000 ppm isoflurane for 20 
minutes. Physical and mental tests were performed 35 minutes after initiation of 
drug administration. Choice reaction time, ability to tap two areas on a board,  
and ability to perform mathematical problems were significantly impaired by 
isoflurane inhalation as compared to oxygen inhalation. Performance returned 
promptly to the baseline after the discontinuation of exposure (172). 
In summary, the effects of subanaesthetic doses of isoflurane, ranging from 600 
to 6 000 ppm on the central nervous system have been investigated. The lowest 
test concentration of 600 ppm resulted in conspicuous but reversible neuro-
behavioral effects. 
Sevoflurane 
Volunteers (mixed gender) were presented with a series of 36 emotional and 
neutral slides while under 0, 1 000, 2 000, or 2 500 ppm sevoflurane in 100% 
oxygen for at least 20 minutes (n=5-9). Pictures were presented in random order 
for 6 seconds each and subjects registered their emotional arousal reaction ratings 
to each slide. Subjects exposed to sevoflurane rated significantly more slides as 
neutral (rather than emotional) at all exposure levels when compared to placebo. 
When tested one week later, sevoflurane dose-dependently reduced free recall, 
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significantly so at the two highest exposure levels. Recall was reduced by 49% 
when the slides were presented at 2 000 ppm. As measured with a recognition test, 
a memory boost was evident for emotionally arousing items in the placebo and the 
1 000 ppm groups, but was not observed for the 2 000 and 2 500 ppm groups. 
Although no additional effect on recall was observed when the exposure level was 
increased from 2 000 to 2 500 ppm, memory performance rates were lowered. In a 
second experiment, brain activity changes of 11 additional volunteers exposed to 
2 500 ppm sevoflurane were assessed with positron emission tomography (PET). 
Structural equation modeling of PET data revealed that sevoflurane suppressed the 
effective connectivity between amygdala and hippocampus (8). 
Fourteen healthy volunteers (mixed gender) inhaled vehicle (100% oxygen) and 
2 000 and 4 000 ppm sevoflurane, for 40 minutes each, across separate sessions. 
Four psychomotor tests were applied (tests of digit-symbol substitution, logical 
reasoning, coordination, and auditory reaction time) together with ratings of drug 
effects. In the digit-symbol substitution test, performance decreased significantly 
already at the lowest exposure level. Feeling of sleepiness, tingling, and feeling 
”high” as well as mean inhalant drug effects score increased dose-dependently, but 
only at the highest exposure level did ratings differ significantly from the control 
condition. This also characterised the outcome of the psychomotor tests (24).  
The effects 0, 2 000, 4 000, and 8 000 ppm sevoflurane in oxygen were studied 
in 16 light and 16 moderate drinkers (volunteers of mixed gender; average number 
of weekly drinks 0.7 and 13.9, respectively). During each of four sessions, subjects 
inhaled a concentration of sevoflurane or 100% oxygen (placebo) for 10 minutes 
each. Subjective and psychomotor testing commenced 5 minutes into each 
sampling trial. Psychomotor performance (the digit-symbol substitution test) 
decreased significantly in moderate drinkers at all three sevoflurane concentration, 
in light drinkers only at the two highest exposure levels. A number of subjective 
effects reported during inhalation of sevoflurane were significantly lower in the 
moderate than in the light drinking group at 4 000 and 8 000 ppm. Generally,  
only light drinkers reported increased subjective effects at these exposure levels 
compared to the placebo condition. However, on a drug-effect scale, ratings of the 
extent the participants currently felt a drug effect were similar in the two groups 
and differed from the placebo situation at all three exposure levels (253). 
Global and regional cerebral blood flows following exposure to escalating 
concentrations of sevoflurane were estimated by PET in 9 healthy human 
volunteers (mixed gender). PET scans were performed during baseline and after 
inhalation of 4 000, 7 000 and 20 000 ppm sevoflurane for at least 10 minutes. 
Exposure continued for at least 3 min during the PET scanning procedure. Cardio-
vascular and respiratory parameters were monitored and EEG and bispectral index 
were registered. Cardiorespiratory parameters and global cerebral blood flow were 
unaffected by exposures. Sevoflurane decreased the bispectral index values dose-
dependently and changed EEG signals, significantly so at all exposure levels. 
Regional blood flow increased in some and decreased in other brain areas, already 
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from the lowest exposure level. Some of the most profound changes in regional 
cerebral blood flow were observed in structures related to pain processing (216).  
Regional cerebral blood flow was measured by functional magnetic resonance 
imaging in 16 healthy volunteers (mixed gender). Subjects inhaled 5 000 ppm 
sevoflurane in two cycles of 25 minutes, separated by a control interval of 25 
minutes. The cerebral blood flow was measured before, during inhalation of 
sevoflurane and after termination of anaesthesia. During each assessment, the 
volunteers were presented with activation tasks: a flickering checkerboard pattern 
on a screen (visual task), a tone relayed over headphones (auditory task) and 
instruction to press a button in response to a visual cue (visually cued motor task). 
All subjects were awake during exposure, although some reported an inability to 
perform the motor tasks despite understanding the visual cue. Allover, sevoflurane 
decreased cerebral blood flow by 6.5% (not stated whether the decrease was 
significant) but in none of 11 regions of interest related to visual, auditory, and 
motor activation tasks did blood flow decrease significantly from pre-exposure 
values. However, the regional blood flow during activation tasks increased 
significantly less during exposure to sevoflurane as compared to the control 
condition, in the primary and secondary visual cortices, thalamus, hippocampus, 
and supplementary motor area (196). 
Sevoflurane anaesthesia may be associated with epileptiform activity. Thus, 
sevoflurane may produce epileptiform discharges as observed with EEG as well  
as clinical seizures. Apparently this effect is dose-dependent and appears only at 
surgical levels of anaesthesia (55, 122). 
Desflurane 
No studies evaluating the neurotoxic effect, apart from anaesthesia, were 
identified. 
11.2.2 Cardiovascular system  
The studies described below are central for several reviews of the cardiovascular 
effects of isoflurane, sevoflurane and desflurane (50, 55, 63). The fluranes affect  
a number of cardiovascular parameters at anaesthetic dose levels. As the depth of 
anaesthesia increases after induction, haemodynamic variables generally decrease. 
All three compounds exert hypotensive effects, starting at the lowest tested 
concentration, i.e. 7 000 ppm for isoflurane, 10 000 ppm for sevoflurane and 
30 000 ppm for desflurane (for details see below).  
Isoflurane 
Isoflurane was administered to 7 healthy, young (20-31 years) randomly selected 
male volunteers. Haemodynamic and neural measurements were carried out at 
conscious baseline. After induction of anaesthesia, measurements were repeated 
15 minutes after end-tidal isoflurane concentrations of 7 000, 14 000, and 21 000 
ppm. With increasing anaesthetic concentration, heart rate increased, and mean 
arterial and forearm venous pressures decreased progressively from the lowest 
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exposure level. Efferent muscle sympathetic nerve activity recorded by micro-
neurography was decreased at the lowest exposure level (62). 
Sevoflurane 
Sevoflurane was administered to 12 healthy, young (19-32 years) randomly 
selected male volunteers. Haemodynamic and neural measurements and blood 
sampling were carried out at conscious baseline. After induction of anaesthesia, 
measurements were repeated 10 minutes after end-tidal sevoflurane concentrations 
of 10 000, 20 000, and 30 000 ppm. With increasing anaesthetic concentration, 
mean arterial pressure decreased progressively from the lowest exposure level.  
No changes were observed in heart rate, central venous pressure, plasma nor-
epinephrine or in efferent muscle sympathetic nerve activity recorded by micro-
neurography (64). 
Desflurane 
Desflurane was administered to 9 healthy, young (19-32 years) randomly selected 
male volunteers. Haemodynamic and neural measurements and blood sampling 
were carried out at conscious baseline. After induction of anaesthesia, measure-
ments were repeated 10 minutes after end-tidal desflurane concentrations of 
30 000, 60 000, and 90 000 ppm. With increasing anaesthetic concentration, mean 
arterial and central venous pressures decreased progressively from the lowest 
exposure level. Heart rate was unchanged by exposure. Efferent muscle sym-
pathetic nerve activity recorded by microneurography was increased at the two 
highest levels and plasma norepinephrine at the highest concentration (64). In a 
study of almost similar design (exposure levels 36 000, 72 500, and 109 000 ppm; 
n=7), mean arterial and forearm vascular resistance also decreased progressively 
already from the lowest exposure level, and heart rate was increased at the highest 
level (62). 
11.2.3 Liver  
As described in Chapter 9, halogenated anaesthetics have been associated with 
two different forms of hepatotoxicity, metabolic and immune-mediated hepato-
toxicity, respectively. The latter occurs in a small number of patients. The 
incidence for halothane is 1:35 000, and occupational exposure to halothane has 
also been shown to induce hepatotoxicity. The incidences of hepatotoxicity after 
anaesthesia with isoflurane and desflurane are presumably much lower, due to the 
very limited metabolism of these substances. In a few case reports, hepatitis after 
isoflurane and desflurane anaesthesia have been described (26, 32, 44, 162, 214, 
219). Also, anti-trifluoroacetyl antibodies were detected in the sera of 3 patients 
diagnosed with isoflurane hepatitis (184). However, in 1987 a panel of experts 
reviewed 45 cases of liver injury following isoflurane anaesthesia. They concluded 
that current evidence did not indicate a reasonable likelihood of an association 
between the use of isoflurane and the occurrence of postoperative hepatic dys-
function (225).  
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As investigated at anaesthetic dose levels in a large number of patients, no 
findings indicate that sevoflurane impairs liver function (55, 131, 200). Abott 
Laboratories evaluated liver function tests from a total of 3 684 patients from 22 
controlled, comparative clinical studies with 2 069 patients receiving sevoflurane, 
and 1 615 patients receiving either isoflurane, enflurane, halothane or propofol. 
No clinically significant adverse effects on liver function were observed with 
sevoflurane or other anaesthetics (described by Delgado-Herrera et al (55)). The 
lack of liver effects of sevoflurane is probably due to its distinctly different 
metabolic pathway compared to the other halogenated anaesthetics (200). 
Isoflurane 
Hepatocellular integrity was monitored in 20 patients (mixed gender) who 
received long-term sedation (38 hours, ranging from 24-127 hours) with 1 000-
6 000 ppm isoflurane. Blood samples were collected before, 24 hours after the 
start of the sedation, and 0, 24, 72, 120, and 172 hours after termination of 
anaesthesia. The activities of alanine aminotransferase and aspartate amino-
transferase did not change appreciably, but glutathione transferase B1 concentration 
decreased significantly at all times studied. The enzyme activity/ concentration 
was similar in isoflurane patients and in 20 patients who received long-term 
sedation with low dose midazolam (114). 
Repeated anaesthetic exposure to isoflurane in 66% oxygen and nitrous oxide 
was investigated with respect to effects on liver function in 11 children (gender 
not specified) presenting daily for radiotherapy. The average number of exposures 
were 24 (range 10-39) and total anaesthetic time per exposure varied between 15 
and 30 minutes. Isoflurane concentrations ranged from 20 000 to 50 000 ppm. 
Liver function was assessed by determining serum total bilirubin, aspartate amino 
transferase, gamma glutamyl transferase, and alkaline phosphatase before the start 
of treatment and every 5 days thereafter. There was no measurable change in any 
of the monitored biomarkers (126). 
Isoflurane and sevoflurane 
Sixty patients had their liver function assessed after repeated exposure within 30 
to 180 days to isoflurane (30 patients) or sevoflurane (30 patients), in 67% nitrous 
oxide and oxygen. Approximately 4 MAC-hours were administered to each 
patient, roughly corresponding to 46 000 ppm-hours isoflurane and 68 000 ppm-
hours sevoflurane. Serum values were measured before and 1, 3, 7, and 14 days 
after surgery. Aspartate aminotransferase, alanine aminotransferase, and gamma-
glutamyl transpeptidase increased with peaks 7 days after surgery, and the number 
of patients with abnormal values was larger in the isoflurane than in the sevo-
flurane group. None of the variables showed differences between the first and 
second anaesthesia, indicating that repeated exposure impounded no additional 
risk (183). Another study of 10 patients undergoing sevoflurane anaesthesia twice 
within 30-90 days also demonstrated changes indicative of mild liver and kidney 
injury, but repeated exposure did not enhance these changes (182).  
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Desflurane 
No studies on liver effects were identified. 
11.2.4 Kidney 
Isoflurane and sevoflurane 
Sixty patients were studied for kidney function after repeated exposures within 30 
to 180 days to isoflurane or sevoflurane (30 patients per group, mixed gender) for 
approximately 4 MAC-hours in 67% nitrous oxide and oxygen. This corresponds 
roughly to 46 000 ppm-hours isoflurane and 68 000 ppm-hours sevoflurane. 
Urinary qualitative analyses were performed 1, 3, and 7 days after surgery. Blood 
urea nitrogen and creatinine were within the normal range after anaesthesia in 
either group. Renal excretion of protein and glucose was increased 1 and 3 days 
after anaesthesia with no difference between the anaesthetics. None of the 
variables differed between the first and the second anaesthesia (183)  
Sevoflurane 
Mazze et al (2000) retrospectively evaluated pooled renal laboratory data from  
22 different clinical trials that compared sevoflurane with three other widely used 
anaesthetics. The trials examined postoperative changes in serum creatinine and 
blood urea nitrogen levels from a total of 3 436 adult surgical patients administered 
either sevoflurane (n=1 941) or a control drug (isoflurane, enflurane, or propofol) 
as the maintenance anaesthetic (n=1 495). The incidences of increased serum 
creatinine and blood urea nitrogen concentrations were similar among patients 
administered sevoflurane and those administered control drugs. The data for 
changes in serum creatinine and blood urea nitrogen indicate that, for exposures  
of less than 80 000 ppm-hours, sevoflurane is not associated with an increased risk 
of renal toxicity compared with other commonly used anaesthetics (169).  
In an earlier review, results from five studies of more than 750 individuals ad-
ministered sevoflurane indicated that serum fluoride exceeded 50 µM in 7.7% of 
the cases. However, no evidence links sevoflurane with impaired renal function, 
as investigated at anaesthetic dose levels in this large number of patients. Further-
more, there is no evidence for exacerbation of pre-existing hepatic dysfunction in 
adults or children (55). 
Regarding smoking and exposure to sevoflurane, effects on kidney function  
and fluoride in serum were investigated in 25 non-smoking and 25 smoking (> 10 
cigarettes/day) women (19-68 years), undergoing gynaecological elective surgery 
under standardised anaesthesia with 27 000 ppm sevoflurane for 45 minutes. 
Glomerular and tubular function was assessed by measuring serum and urine 
tumour-associated trypsin inhibitor, β2-microglobulin, and serum creatinine for  
48 hours after sevoflurane inhalation. There were no differences between the two 
study groups with regard to serum fluoride or any other measures. Serum fluoride 
increased significantly in both groups: in non-smokers, from a baseline of 1.0-11 
µmol/l (median, 1.6 µmol/l) to a maximum of 8.2-40 µmol/l (26 µmol/l) and, in 
smokers, from a baseline of 0.5-5.2 µmol/l (1.7 µmol/l) to a maximum of 19-71 
µmol/l (25 µmol/l). Serum fluoride remained elevated for the entire sampling 
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period. In all 5 women (1 non-smoker and 4 smokers) with a maximum serum 
fluoride of 40 µmol/l or higher and an area under the serum fluoride concen-
tration-time curve of 500 µmol/h/l or higher, serum tumour-associated trypsin 
inhibitor increased above the pathological concentration of 3.0 nmol/l, whereas 
only 6 of the 45 patients with serum fluoride below 40 µmol/l had serum tumour-
associated trypsin inhibitor above 3.0 nmol/l. β2-Microglobulin increased signifi-
cantly (> 1 mg/l) in 2 of the 5 patients with high serum fluoride relative to 2 of the 
45 patients with serum fluoride below 40 µmol/l. None of the patients developed 
clinically detectable renal dysfunction (153). 
Desflurane 
No studies on kidney effects were identified. 
11.2.5 Other effects of single and short-term exposure 
In vivo nasal mucociliary clearance was evaluated before and after exposure to 
isoflurane, sevoflurane and desflurane in a prospective, randomised, double blind 
study. Patients scheduled for ear and neck surgery under general anaesthesia were 
randomised into three groups (n=20). Each group received 11 500 ppm isoflurane, 
20 000 ppm sevoflurane or 60 000 ppm desflurane during maintenance of 
anaesthesia, induced intravenously with propofol and remifentanil. A saccharin 
granule was placed on the inferior nasal concha (or turbinate), 1 cm behind the 
anterior end. Mucociliary clearance time was assessed by the time it took the 
patient to recognise sweet taste, taken to represent transport of saccharin to the 
oropharynx. The time was recorded before and after anaesthesia. The mean 
clearance values were similar for the three anaesthetics as were values pre and 
post anaesthesia for each gas (133).  
Systemic redox balance was investigated in patients undergoing laparohyste-
rectomy (n=20) under anaesthesia maintained with 20 000 ppm sevoflurane or 
60 000 ppm desflurane (induced with 3 mg/kg sodium thiopental). Anaesthesia 
was maintained for at least 60 minutes. Systemic redox balance was evaluated  
by measuring blood concentration of glutathione, plasma antioxidant capacity 
(Trolox equivalent antioxidant capacity), and lipid peroxidation products (malon-
dialdehyde and 4-hydroxynonenal protein adducts). Blood were sampled prior  
to anaesthesia, after 60 minutes, and 24 hours postoperatively. At 60 minutes, 
anaesthesia with sevoflurane was associated with significantly decreased plasma 
glutathione and general antioxidant capacity. A similar pattern was observed for 
desflurane, although values did not differ significantly from preanaesthesia values. 
Both anaesthetics seemed to shift the redox balance slightly towards oxidation 
(49). 
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11.3 Effects of long-term exposure 
Isoflurane 
Two groups of health professionals were studied (gender not specified). Eighty 
subjects were judged to be occupationally at potential hepatotoxic risk due to 
exposure to isoflurane (mean 0.16 ppm, SD 0.12) and nitrous oxide (30 ppm, SD 
29) for up to 6 hours daily, 30-36 hours a week, for a period varying from 2 to  
27 years. Ninety-two subjects with similar job titles but who were at no known 
hepatotoxic risk comprised the comparison group. Medical history with attention 
to liver and blood pathology and alcohol intake was collected. The environmental 
concentrations of nitrous oxide and isoflurane were measured in the breathing 
zone during a 2-hour period by personal samplers, and nitrous oxide and iso-
flurane were measured in urine collected at the end of the work shift. Blood 
samples were drawn on the same day. Serum alanine aminotransferase and 
aspartate aminotransferase and erythrocyte mean corpuscular volume did not 
differ significantly between exposed and control subjects. Alcohol consumption, 
but not anaesthetic exposure, was significantly correlated to an increase in 
aspartate aminotransferase (77). 
Neurofunction was investigated in 112 operating theatre workers exposed to 
anaesthetic gases (nitrous oxide and isoflurane) and 135 non-exposed hospital 
workers from 10 Italian hospitals (mixed gender, mostly women). The exposed 
and control subjects were comparable for both basic intellectual abilities and 
subjective stress levels. Before and after the shift on the first and the last day of a 
4-day working week, three different tests were administered: a complex reaction 
time test, a questionnaire for neuropsychological symptoms, and a test of visuo-
spatial conceptualisation ability. Urine samples were collected for each subject 
after the end of the shift, and time integrated exposure levels during the shift were 
monitored by means of stationary sampling. In the exposed population, the end of 
shift urinary isoflurane level was 0.7 µg/l (95th percentile 2.6, range 0-4.7) on the 
first day, and 0.8 µg/l (95th percentile 2.0, range 0-5.6) on the last. Atmospheric 
concentrations in operating theatres ranged from 0.1 to 6.2 ppm isoflurane, with 
an average value of approximately 0.35 ppm. No statistical differences were 
observed between exposed and control subjects for neuropsychological tests and 
symptoms. No dose-effect relationships were indicated by the exposure indicators 
combined with the test results (159).  
Sevoflurane 
A single study evaluated the renal effects by occupational exposure to sevoflurane 
(232). Exposure of 61 operating room staff members to nitrous oxide and sevo-
flurane was monitored by personal samplers and analysis of urine. In urine, also 
total urinary proteins, N-acetyl-β-D-glucosaminidase, and glutamine synthetase 
were measured. The latter was also measured in 43 control hospital staff, not 
occupationally exposed to anaesthetics. The mean (range) environmental sevo-
flurane level was 0.28 (0-1.88) ppm, hereof 0.41 (0.02-1.88) ppm in operating 
areas using open anaesthetic circuits, and 0.18 (0-1.4) ppm in areas with semi-
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closed anaesthetic circuits. Subjects working in areas with open circuits excreted 
significantly more sevoflurane in urine than subjects working in areas with semi-
closed circuits. Total urinary protein was slightly, but significantly, increased in 
exposed subjects compared to controls although all values were within the normal 
range. Total urinary protein did not correlate with indices of anaesthetic dose. For 
persons working with open, but not semi-closed anaesthetic circuits, positive 
correlations were observed for exposure to both nitrous oxide and sevoflurane 
with N-acetyl-β-D-glucosaminidase and glutamine synthetase. No significant 
correlation between length of exposure and urinary indices were observed. The 
authors concluded that no relevant effect on the kidney was present at the levels of 
exposure studied (232). Judging from the depiction of correlations of anaesthetic 
dose with urine biological measures, the reported positive correlations may well 
depend heavily on one single high value. 
Isoflurane, sevoflurane and desflurane 
The effect of chronic exposure (more than 5 years) to anaesthetic gases on balance 
control was tested in 53 operating room personnel (nurses and auxiliary nurses) 
and compared to 53 non-exposed individuals of the same occupational groups and 
of similar age, employment duration and postural demand (gender not specified). 
The subjects were not exposed to anaesthetic gases or alcohol during 48 hours 
before the test session. Exposed workers showed a poorer quality of balance 
control, especially when tested with their eyes closed. The exposure was not 
described in detail, but was reportedly mainly nitrous oxide (59 ppm, range 10-
100 ppm). The total concentration of isoflurane, sevoflurane and desflurane 
altogether was about ten times lower, i.e. approximately 6 ppm (246).  
11.4 Genotoxic effects  
The studies described below are summarised in Table 12. 
Isoflurane 
The frequency of SCEs in peripheral lymphocytes from 27 non-smoking operating 
room personnel exposed to isoflurane and nitrous oxide was compared to 27 non-
smoking controls (mixed gender). Occupational exposure was recorded in the 
breathing zone of the anaesthetists using a direct reading instrument. The 8-hour 
TWA of nitrous oxide was 11.8 ppm and that of isoflurane was 0.5 ppm. The 
mean frequency (±SD) of SCEs was increased significantly in exposed personnel 
(9.0 ± 1.3 ) as compared to control personnel (8.0 ± 1.4). Because the personnel 
were exposed to both isoflurane and nitrous oxide, it is unclear, which anaesthetic 
caused the increase in SCEs (111).  
Genetic damage was measured as SCEs and micronuclei in lymphocytes of 
peripheral blood of operating room personnel (mixed gender) exposed to 12.8 
ppm nitrous oxide and 5.3 ppm isoflurane (8-hour TWA). The mean frequency of 
SCEs was significantly higher (10.2 ± 1.9) in exposed personnel (n=10) than in 
controls (7.4 ± 2.4) (n=10). The proportion of micronuclei in exposed personnel 
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was also higher than in controls, but not significantly so. Because the personnel 
were exposed to both isoflurane and nitrous oxide, it is unclear, which anaesthetic 
caused the increase in SCEs (107). 
The mutagenicity of isoflurane and nitrous oxide was investigated by the SCE 
test using peripheral blood lymphocytes from 30 patients (mixed gender) before 
and after anaesthesia. There was no increase in SCEs in the patients immediately 
after completion of anaesthesia or on the following day when compared to the 
SCEs before anaesthesia. However, an increase in SCEs compared with pre-
anaesthetic values was observed in a subgroup of 11 cigarette smokers (115). 
The mutagenicity of isoflurane and nitrous oxide was investigated by the SCE 
test using peripheral blood lymphocytes from 63 cigarette smoking patients 
(mixed gender) before and after anaesthesia. There was no increase in SCEs in the 
patients immediately after completion of anaesthesia or on the following day when 
compared to the frequency of SCEs before anaesthesia (116).  
DNA single strand breaks were investigated in peripheral lymphocytes of 
patients (mixed gender) before and after 180 minutes exposure to a mixture of 
isoflurane, nitrous oxide, and oxygen. The frequency of DNA single breaks was 
increased immediately after anaesthesia. No increase in strand breaks could be 
detected the following day (201).  
DNA single strand breaks using the alkaline single cell gel electrophoresis 
technique (SCGE-comet assay) were investigated in peripheral lymphocytes of  
12 patients (mixed gender), before and after anaesthesia and in a control group. 
Twelve patients, aged 22-66 years old, were anaesthetised for elective abdominal 
surgery with isoflurane in oxygen for 120-162 minutes (mean 133.2 minutes). 
Venous blood samples were obtained from the patients before the induction of 
anaesthesia, at 60 and 120 minutes of anaesthesia, and on the 1st, 3rd, and 5th  
day after anaesthesia. The number of undamaged nuclei was almost the same in 
controls and in patients before anaesthesia. However, significant differences  
were observed in the proportion of undamaged, intermediate, and tailed nuclei  
of patients at 60 and 120 minutes of anaesthesia and on the day following 
anaesthesia. DNA damage started to normalise on the 3rd day after anaesthesia, 
and was almost identical with that of controls after 5 days (212). 
The genotoxic activity of isoflurane was evaluated by the comet assay by 
examining peripheral blood lymphocytes of patients (mixed gender) before, during 
and after anaesthesia as compared to an unexposed control group. Significant 
differences were observed in the proportions of undamaged, intermediate, and 
tailed nuclei of patients after 60 and 120 minutes of anaesthesia to 10 000-15 000 
ppm isoflurane (n=12) and on the following day, although DNA damage began to 
return to normal levels on the 3rd day following anaesthesia and was almost 
identical with those of controls on the 5th day (127). 
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Sevoflurane 
The genotoxicity of sevoflurane was studied by evaluating the DNA damage, 
apoptosis, DNA repair enzyme activity, and glutathione content in peripheral 
lymphocytes from 20 patients (mixed gender) before, 15 minutes after anaesthesia, 
and 24 hours after surgery. Lymphocytes isolated 15 minutes after anaesthesia 
showed an increase in oxidised purine and pyrimidine bases without DNA strand 
break formation. DNA strand breaks occurred on the 1st post-operative day, 
associated with an enhancement of DNA repair activity and a decrease in 
glutathione. Formation of strand breaks could be the consequence of DNA repair 
activity. Twenty-four hours after surgery, most of the oxidised DNA bases were 
repaired (9). 
The incidence of SCEs in peripheral lymphocytes of anaesthetists (n=25, mixed 
gender) exposed to anaesthetics was investigated before and after a 2-month leave. 
There was a significant difference in SCE values of the anaesthetists compared 
with the non-exposed physicians (11.9 ± 4.4 versus 4.2 ± 1.1). After a 2-month 
leave from the operating room, the SCE values of the anaesthetists were signifi-
cantly lower compared with those taken before the leave (4.8 ± 1.8 and 11.9 ± 4.4, 
respectively). The concentrations of sevoflurane and nitrous oxide in the operating 
rooms were 8.9 ± 5.6 ppm and 119 ± 39 ppm, respectively, as determined by infra-
red spectrophotometry measured close to the working anaesthetists. Because the 
anaesthetists were exposed to a mixture of anaesthetics it is not possible to decide 
which anaesthetics caused the effects (72).  
The formation of SCEs was investigated in lymphocytes of 40 children (mixed 
gender) before and after anaesthesia induced by inhalation of up to 80 000 ppm 
sevoflurane and maintained at 25 000-30 000 ppm in oxygen/nitrous oxide 
(65%/35%). The combined sevoflurane and nitrous oxide anaesthesia did not 
induce SCE in T-lymphocytes of children (142). 
Significant differences were observed in the proportions of undamaged, inter-
mediate, and tailed nuclei of patients (mixed gender) after 60 and 120 minutes  
of anaesthesia to 10 000-15 000 ppm sevoflurane (n=12) and on the following  
day. DNA damage began to return to normal levels after the 3rd day following 
anaesthesia and was almost identical with those of controls on the 5th day (127). 
Desflurane 
Only one study of the genotoxic effects of desflurane in humans has been 
identified. The frequency of SCEs was evaluated in peripheral blood lymphocytes 
of 15 female patients anaesthetised with 50 000-60 000 ppm desflurane in an 
oxygen/air mixture. Blood samples were taken before anaesthesia and 60 and 120 
minutes after the initiation of anaesthesia. In addition, postoperative blood samples 
were taken on the 1st, 3rd, 7th, and 12th day. The number of SCEs per cell was 
increased 60 and 120 minutes, and 1, 3, and 7 days after initiation of anaesthesia. 
On day 12, the number of SCEs per cell had returned to the level preceding 
anaesthesia (5). 
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Table 12. Genotoxic effects in peripheral lymphocytes from humans exposed to the 
fluranes.  
Anaesthetic/ 
co-exposure 
Exposure condition Effect Reference 
Isoflurane    
N2O Occupational Increased SCEs.  (107) 
N2O Occupational Increased SCEs. (111) 
N2O Patients No effect on SCEs. (115) 
N2O Patients No effect on SCEs. (116) 
N2O Patients Increased DNA strand breaks. (201) 
 Patients Increased DNA strand breaks. (212) 
 Patients Increased DNA strand breaks. (127) 
Sevoflurane    
N2O Occupational Increased SCEs. (72) 
N2O Patients (children) No effect on SCEs. (142) 
 Patients Increased DNA strand breaks. (127) 
 Patients Increase in oxidised DNA bases without 
DNA strand breaks (15 min after 
anaesthesia). 
Increase in DNA strand breaks, repair 
activity, number of apoptotic cells and 
decrease in GSH level (24 h after 
anaesthesia). 
(9) 
Desflurane    
 Patients Increased SCEs. (5) 
GSH: glutathione, N2O: nitrous oxide, SCE: sister chromatid exchange. 
Summary and conclusion 
For isoflurane, four SCE studies evaluating the genotoxic effects in humans  
were identified. The two studies performed in patients were negative (115, 116), 
whereas the two studies in occupationally exposed showed increased frequencies 
of SCEs (107, 111). Studies evaluating genotoxicity by the comet assay in 
lymphocytes from patients anaesthetised with isoflurane all showed increased 
DNA damage immediately after anaesthesia (127, 201, 212). In all the studies, the 
DNA damage was repaired within 1-5 days after the end of anaesthesia. As DNA 
repair is regulated genetically (85), isoflurane induced DNA damage could be 
hypothesised to persist longer in persons with DNA repair defects.  
One study of personnel occupationally exposed to both sevoflurane and nitrous 
oxide showed an increased number of SCEs (72), while a study of patients ex-
posed to sevoflurane and nitrous oxide showed no effect (142). Two studies of 
patients exposed only to sevoflurane showed increased levels of DNA strand 
breaks (9, 127). 
Only one study of genotoxicity of desflurane in humans has been identified. The 
study showed increased number of SCEs in patients exposed to desflurane (5).  
All three studies on occupational exposure to isoflurane and sevoflurane 
demonstrated increased frequencies of SCEs. However, it should be noted that in 
these as well as in several of the studies in patients, co-exposure to nitrous oxide 
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occurred. It is therefore not clear which agent caused the genotoxic effects. 
However, SCEs have not been clearly associated with exposure to nitrous oxide 
(174). The isolated effect of the three fluranes has only been studied in patients. 
All these studies showed genotoxicity (increases in DNA strand breaks or SCEs) 
after surgery and at anaesthetic dose levels. We note that the observed increases  
in SCEs or DNA strand breaks could be due to premedication. Together, these 
studies give rise to some concern regarding the genotoxic potential of the fluranes.  
Genotoxicity studies on human lymphocytes exposed in vitro to the fluranes 
have been described in Section 10.4. All three studies on isoflurane and the one on 
desflurane were positive (increases in SCEs and DNA strand breaks) whereas the 
only one on sevoflurane was negative (no increases in DNA strand breaks). 
11.5 Carcinogenic effects  
No studies evaluating the carcinogenic effects of the specific fluranes have  
been identified. One explanation to the lack of studies is that isoflurane and in 
particular sevoflurane and desflurane are new anaesthetics (introduced in the 
middle of the 1980s and 1990s), and cancer generally takes a long time to develop. 
Thus, it is not yet possible to evaluate carcinogenic effects in epidemiological 
studies. Furthermore, since health care personnel are exposed to a mixture of 
anaesthetics and other potential genotoxic agents such as X-rays, the effect of 
exposure to a single anaesthetic may be difficult to deduce from epidemiological 
studies.  
11.6 Reproductive and developmental effects  
Following uptake, the fluranes are rapidly distributed in the body. It has been 
shown that isoflurane and sevoflurane pass almost unimpeded from maternal to 
foetal blood (Section 7.2). This has not been investigated for desflurane, but, due 
to the structural similarities of the three compounds, desflurane probably also 
passes from maternal to foetal blood.  
Isoflurane 
The effect of anaesthesia on pregnancy outcome after gamete intrafallopian 
transfer during assisted reproduction was investigated in a multi-centre survey.  
US fertility programs were invited to contribute information for women who 
underwent this procedure in 1993-1994 concerning age, the use of propofol, 
nitrous oxide, midazolam, or a potent inhaled anaesthetic agent, pregnancy, and 
delivery rate. Seven medical centres participated and contributed data from 455 
women. No significant differences were found for the clinical pregnancy or 
delivery rates between those women who received propofol, nitrous oxide, 
midazolam, or isoflurane during the procedure and those who did not (25).  
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Sevoflurane and desflurane  
Fifty healthy women undergoing caesarean section and requesting general 
anaesthesia were randomly assigned to receive either 10 000 ppm sevoflurane  
or 30 000 ppm desflurane in combination with 50% nitrous oxide in oxygen. 
Twenty-five healthy women requesting regional anaesthesia received epidural 
anaesthesia with ropivacaine. The three groups of women displayed similar 
characteristics with respect to age, weight, height, parity, and gestational age. No 
significant differences were detected on neonatal outcomes assessed as Apgar 
scores 1 and 5 minutes after delivery, and by neurological adaptive capacity score 
(20 criteria in 5 areas: active tone, adaptive capacity, general assessment, passive 
tone and primary reflexes) 2 and 24 hours after delivery (128).  
Anaesthetic gases in general 
Several epidemiological studies have investigated the association between 
occupational exposure to anaesthetic gases in general and reproductive failure in 
women. These are described below. The results indicate that such exposure may 
increase the risk for spontaneous abortions and the incidence of malformations  
in the children. However, in these studies, hospital staff and other occupational 
groups were exposed to a mixture of anaesthetic gases, and no information on 
duration and actual levels of exposure were available. In addition, all studies were 
retrospective with the risk of recall bias, if couples with a reproductive failure will 
be motivated (by guilt or concern) to remember more adverse exposures (and 
outcomes) than couples with normal pregnancies (237).  
In a retrospective survey in the Netherlands (189, 207), referred in (99), time  
to pregnancy was investigated in 427 pregnant women employed in anaesthesia. 
These were compared to 1 010 pregnant women employed in departments of 
orthopaedics, gynaecology, or surgery. Time to pregnancy was not affected in 
operation chamber assistants. The concentrations of several anaesthetic gases were 
measured and the maximal concentration measured for isoflurane was 120 mg/m3 
(15.6 ppm). However, the composition of the anaesthetic gas mixtures and the 
level and duration of exposure were not reported. 
The outcome of a meta-analysis on studies on spontaneous abortion indicates an 
increased risk after occupational exposure to anaesthetic gases (28). The analysis 
was based on epidemiological studies published during the period 1984-1992, 
estimating the risk of spontaneous abortion. Only peer-reviewed studies were 
included. Several comparisons (n=24) between exposed and unexposed women 
were included, obtained from 17 retrospective follow-up studies and 2 case-
control studies. Occupational exposure to anaesthetic gases was mostly assessed 
through postal questionnaires to the mothers, or less often, by interviews. None  
of the studies included ambient gas sampling. Exposed women included nurses, 
physicians, technicians, dental assistants, veterinarians and veterinary assistants. 
Unexposed reference groups generally included women from the same 
occupational groups, but unexposed to anaesthetic gases. Spontaneous abortions 
were generally reported by respondents without further validation. Altogether,  
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the follow-up studies in the meta-analysis included 15 268 exposed pregnancies 
and 80 368 control (unexposed) pregnancies. The overall relative risk was 1.48 
(95% confidence interval (CI) 1.4-1.58). The relative risk varied according to 
occupation, ranging from 1.18 among physicians to 2.45 in veterinarians and 
veterinary assistants. To test whether the quality of the studies influenced this 
result, the validity of the reviewed papers was rated on the basis of three criteria: 
appropriateness of the unexposed comparison group, control for non-occupational 
confounding variables, and response rate. The estimate of risk increased to 1.9 
(95% CI, 1.72-2.09) when analysis was restricted to the six comparisons which 
were rated the most rigorous. Year of publication of the study did not influence 
the relative risk (28). This meta-analysis included studies published in 1984-1992. 
Isoflurane has been used from the early 1980s, whereas desflurane and sevoflurane 
are relatively newer (introduced in Denmark in 1994 and 1996, respectively). It 
must therefore be assumed that of the three fluranes described in this report, only 
isoflurane figures as an anaesthetic agent in this meta-analysis, together with other 
anaesthetic agents. 
Female anaesthetists (n=231) practicing primarily paediatric anaesthesia were 
hypothesised to experience increased exposure to trace anaesthetic agents due to 
increased waste spillage (because of the use of mask inductions and uncuffed 
tracheal tubes), and thereby a greater risk of obstetric complications, compared to 
female anaesthetists (n=1 275) performing primarily adult anaesthesia. Question-
naires were mailed to all female members of Society for Pediatric Anesthesia and 
to an equal number of randomly selected female members of American Society of 
Anesthesiologists. Subjects were explained the purpose of the study and asked to 
answer questions regarding their former pregnancy outcomes, work history and 
personal habits. Paediatric anaesthetists were defined as those having > 75% 
paediatric practice. Significantly more paediatric anaesthetists experienced more 
than 40 hours/week of operating room exposure during their pregnancies than did 
non-paediatric anaesthetists (79.2% versus 70.6%). Analysis was performed on a 
total of 1 506 pregnancies. No differences were observed with respect to preterm 
labour or delivery, birth weight, or birth defects. However, the prevalence of 
spontaneous abortion was significantly higher among paediatric than among non-
paediatric anaesthetists (80). The actual study period is not stated for this study, 
and no information is given as to exposure to specific anaesthetic gases. 
A retrospective study of 6 330 personnel exposed to anaesthetic gases in 
operating and recovery rooms in Ontario hospitals, and 2 200 non-exposed 
hospital staff were conducted by questionnaire during the period 1981-1985.  
A total of 10 232 pregnancies were reported by the exposed women or spouses  
of exposed men. The number of unexposed pregnancies was 3 656. Logistic 
regression analysis, with age and smoking standardised, showed that children of 
women in the exposed group had significantly more congenital abnormalities 
(odds ratio (OR) 2.24, 95% CI 1.69-2.97). This was also true for wives of male 
hospital staff (OR 1.46, 95% CI 1.04-2.05) (88). The concentration of the 
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anaesthetic gases is unknown in this study, and the study period at the most 
includes only a few years of exposure to isoflurane (used from 1984 in Denmark). 
The probably most recent study with respect to time-period of exposure, 
concerns women working in specified hospital departments for at least 2 months 
in the period 1990-1997. Questionnaires were mailed to 5 546 women. A total  
of 427 women were defined as exposed, as they were working during the first 
months of their last pregnancy. This group was composed of anaesthetists and 
assistants and operating room nurses. As referents, 1 010 nurses not exposed  
to anaesthetics or cytostatics were included. ORs corrected for differences in 
occupational factors indicated that exposure to anaesthetic gases increase the risk 
for giving birth to a child with malformation (OR 1.8, 95% CI 1.0-4.1). Exposure 
to anaesthetic gases is presumably highest during the induction phase and during 
tonsillectomy. Specific risks for these tasks were calculated, resulting in ORs of 
1.6 (95% CI 0.9-2.5) and 1.9 (95% CI 1.1-3-6), respectively. The risk of prolonged 
time to pregnancy, spontaneous abortion, and premature birth were similar in the 
two groups (207). No information regarding exposure to specific anaesthetic gases 
was provided.  
12. Dose-effect and dose-response relationships  
Effects of inhalation exposures to isoflurane, sevoflurane and desflurane in 
animals are listed in Tables 13-15 and in humans in Tables 16-19. Acute, high 
exposures are included in the tables if levels were below 0.8 of the human MAC-
value, i.e. 9 600 ppm for isoflurane, 16 800 ppm for sevoflurane, and 48 000 ppm 
for desflurane, as these concentrations are associated with pronounced acute 
effects in humans (178, 179). Genotoxicity studies in animals and humans are 
listed in Tables 11-12 (Sections 10.4 and 11.4).  
12.1 Animal and in vitro studies 
Isoflurane  
Single exposures to 530 or 1 160 ppm isoflurane for 45 minutes were without 
effects on cognitive function and pain sensitivity in rats (6). However, anti-
analgesic effects of isoflurane were observed in rats exposed to 1 145 ppm for  
30-40 minutes, based on a group size of 3 animals serving as their own controls 
(255). Thus, the acute NOAEL and LOAEL in rats are 530 and 1 145 ppm, 
respectively. Several studies in rats or rabbits have showed decreased cognitive 
function and analgesic effects at exposure levels of 2 000 ppm and above (Table 
13).  
Several studies have addressed the effects of repeated exposures to isoflurane 
on body weight, reproduction and development, and liver function and histology  
at exposure levels ranging from 150 ppm and up. The effects of 35 days of con-
tinuous exposure to 150, 500, and 1 500 ppm isoflurane were investigated in mice, 
guinea pigs, and rats. Mice exhibited reduced body weight gain to a similar extent 
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in all three exposed groups, at the two highest exposure levels already from day 7. 
Guinea pigs gained less weight at the highest exposure level, whereas rat weights 
were unaffected by exposure. At the highest exposure level, a tendency towards an 
increase in the number of animals with degenerative liver lesions (not significant) 
was observed in all species (224). The study seems well designed and performed 
although some miscalculations of body weight gains are apparent from the tables, 
and only body weight gains, not absolute body weights were stated. In another 
short-term animal study (4 hours/day for 5 days/week, 9 weeks), body weight was 
unaffected until 5 000 ppm in mice (202). 
Male fertility in mice seemed unaffected at exposure levels ranging from 1 000 
to 10 000 ppm (154, 166). One study in rabbits reported decreased sperm counts 
after exposure to 13 000 ppm isoflurane, but interpretation is hampered by control 
group fluctuations (45). None of the fertility studies investigated the full spermato-
genic cycle. At 4 000 ppm and below, developmental toxicity studies consistently 
showed no effect of isoflurane (78, 166, 167). Exposure to 6 000 ppm, 4 hours/day 
during organogenesis, reduced foetal weight and maternal weight gain, decreased 
ossification, and was associated with increased incidence of minor malformations 
often observed during retarded development and increased maternal stress (167). 
In rabbits, no maternal or foetal effects were observed after exposure to 23 000 
ppm isoflurane, 1 hour/day, during early gestation (132). 
A long-term study in mice did not report detectable toxicity to the liver or the 
kidneys after continuous exposure to 20 ppm isoflurane for 30 weeks (191). 
Exposure to 1 000 or 4 000 ppm isoflurane, 4 hours/day, 5 days/week for 78 weeks 
was not associated with carcinogenicity. However, body weights were decreased 
at both exposure levels, by 1-5% and 5-8%, respectively (no statistical analysis 
was provided for these data) (23).  
Studies evaluating genotoxic effects of isoflurane in human lymphocytes 
exposed in vitro (110, 123, 227) and in rats exposed in vivo (137, 206) were 
positive, whereas tests in bacteria, Drosophila melanogaster and Chinese hamster 
cells were negative (20, 22, 144, 233, 236, 241). 
Altogether, 150 ppm can be regarded as an overall LOAEL for isoflurane.  
Sevoflurane 
Analgesia was evident in rats after 45 minutes of exposure to 1 050 ppm (acute 
LOAEL) and above, and exposure to 1 100 ppm sevoflurane for 45 minutes 
caused enhanced aversive memory formation. Cognitive function was not affected 
in rats exposed at 1 050 and 2 160 ppm, whereas memory impairment was 
observed at 3 080 ppm and above (6, 7). Activity level and cognition were 
affected in rats exposed for 30 days, 4 hours/day to 3 000 ppm sevoflurane, the 
lowest exposure level tested (188). At anaesthetic dose levels (21 600-40 100 ppm, 
8 weeks), an exposure dependent reversible increase in the levels of liver enzymes 
in plasma was observed in cynomolgus monkeys. Apart from reduced blood cell 
counts and relative thymic weight in exposed animals, no exposure-related gross 
75 
pathological, histopathological or ultrastructural differences were found. Three 
monkeys in the high exposure group died (221) (Table 14). 
No studies on long-term exposure were identified. 
Considering genotoxicity studies, no increased frequency of DNA strand breaks 
was observed in human lymphocytes exposed in vitro (227) and no effect on gene 
mutation was observed in bacteria (21) whereas rats exposed in vivo (orally) had 
an increased frequency of micronucleated cells in the kidney (206).  
Desflurane  
Only three studies at subanaesthetic dose levels of desflurane were identified,  
all in rats (Table 15). Impaired cognitive function was observed after 45 minutes 
of exposure to 4 400 ppm desflurane (acute LOAEL). Effects increased further  
at higher exposure levels, i.e. 10 130 and 20 200 ppm (6). Activity level and 
cognition were altered in rats exposed to 6 000 ppm desflurane for 30 days, 4 
hours/day (measured after 1 day of no exposure) (188).  
No studies on long-term exposure were identified. 
In the only study evaluating genotoxic effects, a dose-dependent increase in 
DNA strand breaks was observed in human lymphocytes exposed in vitro (129). 
12.2 Human studies 
Tables 16-19 summarise dose-effect relationships in humans after inhalation 
exposure to isoflurane, sevoflurane and desflurane.  
Isoflurane  
In a range of studies, neurofunction in humans under experimental conditions has 
been investigated. At the lowest tested level, exposure to 600 ppm isoflurane for 
25 minutes was associated with decreased saccadic peak velocity (acute LOAEL) 
(79). Exposure to 1 000 ppm isoflurane for 40 minutes was associated with 
decreased performance in the digit-symbol substitution test (24). Most other 
studies investigating neurobehaviour above this exposure level also demonstrated 
effects of isoflurane (Table 16). 
Chronic occupational exposure to low levels of isoflurane did not affect liver 
function (0.16 ppm, sampled in breathing zone) (77) or neurofunction investigated 
by several tests (0.35 ppm, stationary sampler) (159). Two studies demonstrated 
increased frequencies of SCEs in peripheral lymphocytes from health care 
personnel exposed to 0.5 and 5.3 ppm isoflurane (8-hour TWAs, personal and 
stationary sampling, respectively) (107, 111). However, the personnel in both 
studies were concomitantly exposed to 12-13 ppm nitrous oxide (Table 19). It is 
therefore difficult to ascribe the effect to isoflurane, although SCEs have not  
been clearly associated with exposure to nitrous oxide either (174). In patients, 
combined isoflurane and nitrous oxide anaesthesia did not affect the frequency  
of SCEs (115, 116). However, increased frequencies of DNA strand breaks were 
seen, also without co-exposure to nitrous oxide (127, 201, 212).  
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Sevoflurane 
Effects on emotional memory and psychomotor performance after acute exposure 
to sevoflurane were demonstrated in three studies (8, 24, 253). At 1 000 ppm  
(the lowest exposure level studied) for 20 minutes, sevoflurane suppressed the 
emotional response (exposed volunteers rated significantly more pictures as 
neutral than emotional) (acute LOAEL). Additional effects were observed at  
2 000 ppm and above, e.g. impaired memory function (8). Psychomotor effects 
were shown at 2 000 ppm and these effects increased further at higher exposure 
levels (24, 253). Schlünzen et al reported increased regional cerebral blood flow 
in patients exposed to as low as 0.2 MAC sevoflurane (approximately 4 000 
ppm=light sedation). Some of the most profound changes were seen in regions 
related to pain processing (216) (Table 17). 
SCEs were increased in anaesthetists exposed to sevoflurane (8.9 ± 5.6 ppm, 
mean of stationary sampling close to subjects in 10 rooms) and nitrous oxide  
(119 ± 39 ppm) compared to non-exposed personnel. The SCE frequencies were 
significantly lower after 2 months of leave from the operating room than before 
the leave (72) (Table 19). As co-exposure to nitrous oxide occurred, it is difficult 
to ascribe the effect to sevoflurane, although SCEs have not been clearly 
associated with exposure to nitrous oxide either (174). In patients, anaesthetic 
doses of sevoflurane were not associated with increased frequencies of SCE in 
presence of nitrous oxide (142), but increased frequencies in DNA strand breaks 
have been observed in absence of nitrous oxide (9, 127). 
Desflurane 
Only three human studies with isolated exposure to desflurane were identified 
(Table 18). At the lowest exposure level tested, exposure to 6 000 ppm desflurane 
for 3 minutes was not associated with adverse airway events (86). Exposure to 
30 000 and 36 000 ppm desflurane for 10 minutes decreased vascular pressure and 
resistance, respectively (62, 64).  
In the only genotoxicity study available, patients anaesthetised with desflurane 
displayed an increased frequency of SCEs (5). 
Isoflurane, sevoflurane and desflurane 
Impaired balance control was demonstrated 48 hours after occupational exposure 
to 59 ppm nitrous oxide and “10 times lower concentration” of isoflurane, 
sevoflurane, and desflurane (246) (Table 19). Because of the poorly described 
exposure situation, it is not clear which anaesthetic caused the effect. 
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Table 13. Dose-effect relationships for experimental animals after inhalation exposure to isoflurane (for single exposures, only levels below 0.8 MAC 
(human) are included). 
Isoflurane 
level (ppm) 
Species No. of 
animals/group 
Exposure  
duration 
Effects References 
Single exposure     
530 Rat 10-12 45 min (minimum) No effect on learning, memory and pain sensitivity. (6) 
1 145 Rat 3 30-40 min  Antianalgesic effect. (255) 
1 160 Rat 10-15 45 min (minimum) No effect on learning, memory and pain sensitivity. (6) 
1 200 Rat 22 45 min (minimum) No effect on aversive memory. (7) 
2 000 Rabbit 7 20 min Slower acquisition of conditioned response. (70) 
2 010 Rat 9-11 45 min (minimum) Analgesic response and decreased memory. Trials to learning non-significantly 
increased. 
(6) 
2 500 Dog 14 40 min No effects on a range of cardiovascular and ventilatory parameters. (195) 
2 920 Rat 3 Delivered in stepwise 
manner at 1 145, 2 920 
and 5 840 ppm, each 
step held for 30-40 min. 
Analgesic effect (seen also at 5 840 ppm). (255) 
2 960 Mouse 15-20 2 h  Improved performance when memory of avoidance training was assessed. (139, 140) 
3 020 Rat 9-11 45 min (minimum) Analgesic response. Memory decreased even further compared to at 2 010 
ppm. Trials to learning non-significantly increased. 
(6) 
3 500 Rat 30-40 24 h on gestation day 8 Developmental endpoints unaffected. Dams slightly sedated with lower body 
weights on gestation day 12-16. 
(78) 
3 700 Rat 8-16 30 min Amnesia (seen also at 5 700 and 7 500 in a dose-dependent manner). (59) 
4 000 Rabbit 13 20 min Suppressed acquisition of conditioned response. (70) 
5 000 Dog 14 40 min Decrease in cardiac output and in vascular resistance. Other cardiovascular 
and ventilatory parameters unaffected. 
(195) 
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Table 13. Dose-effect relationships for experimental animals after inhalation exposure to isoflurane (for single exposures, only levels below 0.8 MAC 
(human) are included). 
Isoflurane 
level (ppm) 
Species No. of 
animals/group 
Exposure  
duration 
Effects References 
6 020 Mouse 15-20 2 h Performance similar to controls’ when memory of avoidance training was 
assessed. 
(139) 
7 500 Infant 
rat 
4-10 6 h Neurodegeneration similar in control and exposed pups.  (249) 
7 500 Infant 
rat 
4-10 6 h Increase in neuronal degeneration in the laterodorsal and anteroventral 
thalamic nuclei. 
(124) 
7 500 Infant 
mouse 
16 4 h Neuroapoptosis increased by 325% in the caudate putamen. (125) 
8 000 Rabbit 13 20 min Abolished acquisition of conditioned response. (70) 
9 000 Rabbit 10 30 min Increased heart rate. No effect on systolic, diastolic, and mean arterial pressure. (161) 
12 000 Human   MAC. (69) 
14 000- 
14 200 
Rat   MAC. (31, 66) 
13 100- 
17 700 
Mouse   MAC. (222) 
Short-term exposure     
60 Mouse 26 4 h/day on gestation 
days 6-15 
Body weights unaffected in dams and offspring, no teratogenic effects. (167) 
150 Mouse 31 35 days, continuous 
exposure 
Decreased body weight gain, liver histology unaffected. (224) 
150 Rat 16 35 days, continuous 
exposure 
No significant effect on body weight gain, liver histology unaffected. (224) 
150 Guinea 
pig 
14 35 days, continuous 
exposure 
No significant effect on body weight gain, liver histology unaffected. (224) 
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Table 13. Dose-effect relationships for experimental animals after inhalation exposure to isoflurane (for single exposures, only levels below 0.8 MAC 
(human) are included). 
Isoflurane 
level (ppm) 
Species No. of 
animals/group 
Exposure  
duration 
Effects References 
200 Mouse 26 4 h/day, 5 days/week,  
9 weeks 
No effect at necropsy, including several measures on liver function. (202) 
375 Mouse 50 and 120  
at 9 and 15 
months 
2 h/day on gestation 
days 11, 13, 15, and 17, 
and from 5 days after 
birth, every 2nd day for 
a total of 24 exposures 
No carcinogenic effect in offspring at 9 and 15 months of age. (65) 
500 Mouse 31 35 days, continuous 
exposure 
Decreased body weight, liver histology unaffected. (224) 
500 Rat 16 35 days, continuous 
exposure 
No significant effect on body weight gain, liver histology, or blood cell counts. (224) 
500 Guinea 
pig 
11 35 days, continuous 
exposure 
No significant effect on body weight gain or liver histology. (224) 
600 Mouse 27 4 h/day on gestation 
days 6-15 
Body weights unaffected in dams and offspring, no teratogenic effects. (167) 
1 000 Mouse 26 4 h/day, 5 days/week,  
9 weeks 
No effect at necropsy, including several measures on liver function.  (202) 
1 000 Mouse 15 4 h/day for 6 weeks 
before mating 
Male fertility and body weight unaffected. (166) 
1 000 Mouse 15 (male) 
32 (female) 
4 h/day for 2 weeks 
before mating and 
during mating and 
pregnancy 
No effects on copulatory or pregnancy rate, implantations, resorptions, or 
viability of foetuses; postnatal survival and weight gain of offspring 
unaffected.  
(166) 
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Table 13. Dose-effect relationships for experimental animals after inhalation exposure to isoflurane (for single exposures, only levels below 0.8 MAC 
(human) are included). 
Isoflurane 
level (ppm) 
Species No. of 
animals/group 
Exposure  
duration 
Effects References 
1 000 Mouse 5 4 h/day, 5 days No effect on epididymal spermatozoa.  (154) 
1 500 Mouse 78 and 107 at 9 
and 15 months 
2 h/day on gestation 
days 11, 13, 15, and 17, 
and from 5 days after 
birth, every 2nd day for 
a total of 24 exposures 
No carcinogenic effect in offspring at 9 and 15 months of age. (65) 
1 500 Mouse 29 35 days, continuous 
exposure 
Decreased body weight gain. Non-significant increase in liver lesions, 
otherwise, no abnormalities found at necropsy. 
(224) 
1 500 Rat 16 35 days, continuous 
exposure 
No significant effect on body weight gain. Non-significant increase in liver 
lesions, otherwise, no abnormalities found at necropsy. 
(224) 
1 500 Guinea 
pig 
16 35 days, continuous 
exposure 
Decreased body weight gain. Non-significant increase in liver lesions, 
otherwise, no abnormalities found at necropsy. 
(224) 
4 000 Mouse 15 4 h/day for 6 weeks 
before mating 
Male fertility and body weight unaffected. (166) 
4 000 Mouse 15 (male) 
32 (female) 
4 h/day for 2 weeks 
before mating and 
during mating and 
pregnancy 
Dams appeared lightly anaesthetised. No effects on copulatory or pregnancy 
rate, implantations, resorptions, or viability of foetuses; postnatal survival and 
weight gain of offspring unaffected. 
(166) 
5 000 Mouse 26 4 h/day, 5 days/week, 9 
weeks 
Body weight non-significantly reduced during week 2 in males, and week 1-3 
in females. No effect at necropsy, including several measures on liver function. 
(202) 
6 000 Mouse 117 and 205 at 
9 and 15 
months 
2 h/day on gestation 
days 11, 13, 15, and 17, 
and from 5 days after 
birth, every 2nd day for 
a total of 24 exposures 
No carcinogenic effect in offspring at 9 and 15 months of age. (65) 
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Table 13. Dose-effect relationships for experimental animals after inhalation exposure to isoflurane (for single exposures, only levels below 0.8 MAC 
(human) are included). 
Isoflurane 
level (ppm) 
Species No. of 
animals/group 
Exposure  
duration 
Effects References 
6 000 Mouse 23 4 h/day on gestation 
days 6-15 
Reduced foetal weight and reduced maternal weight gain, decreased 
ossification, increased minor malformations.  
(167) 
10 000 Mouse 5 4 h/day, 5 days No effect on epididymal spermatozoa. (154) 
10 500 Rat 21-25 6 h/day on gestation 
days 8-10, 11-13, or 
14-16 
Reduced foetal weights, development otherwise unaffected. Dams lightly 
anaesthetised with reduced weight gains. 
(168) 
13 000 Rabbit 7-8 4 h/day, 5 days Reduced sperm concentration, some histological findings related to 
spermatogenic cells (results difficult to interpret, see p 43). 
(45) 
13 440 Rat 16 2 h every 2nd day for  
2 weeks 
No effects at autopsy. (66) 
17 000 Rat 11-19 1 h/day on gestation 
days 1-5, 6-10, 11-15, 
or 15-20 
Depressed offspring weights in early groups, reduced litter size in late group. 
Maternal weight gain reduced in late exposure group. 
(132) 
23 000 Rabbit 15 1 h/day on gestation 
days 6-9, 10-14, or  
15-18 
No developmental or maternal endpoints affected. (132) 
Long-term exposure     
20 Rat 12 30 weeks, continuous 
exposure 
No hepatic or renal toxicity. (191) 
1 000  Mouse 167 4 h/day, 5 days/week, 
78 weeks 
No carcinogenicity. Organ weights unaffected, body weights reduced by 1-5% 
(body weights were not analysed statistically).  
(23) 
4 000 Mouse 165 4 h/day, 5 days/week, 
78 weeks 
No carcinogenicity. Organ weights unaffected, body weights reduced by 5-8% 
(body weights were not analysed statistically). 
(23) 
CO2: carbon dioxide, MAC: minimum alveolar concentration of anaesthetic that produces immobility in 50% of humans exposed to a supramaximal painful/noxious 
stimulus. 
82 
 
Table 14. Dose-effect relationships for experimental animals after inhalation exposure to sevoflurane (for single exposures, only levels below 0.8 
MAC (human) are included. 
Sevoflurane 
level (ppm) 
Species No. of 
animals/group 
Exposure duration Effects Reference 
Single exposure     
1 050 Rat 11-21 45 min (minimum) Analgesia, no effect on cognition. (6)  
1 100 Rat 22 45 min (minimum) Increased memory of aversive event. (7) 
2 160 Rat 7-12 45 min (minimum) Analgesia, no effect on cognition. (6)  
3 080 Rat 7-10 45 min (minimum) Analgesia, learning impaired, memory retention latency decreased. (6) 
4 000 Pig 7-8 6 h No effect on pulmonary haemodynamics or in lung tissue samples, evaluated 
by light and electron microscopy. In bronchoalveolar lavage, leukotriene C4, 
thromboxane B2, and nitrate levels were increased. Decreased total blood 
leukocyte count. 
(228, 229) 
4 110 Rat 8-10 45 min (minimum) Analgesia, decreased memory retention latency. (6)  
21 000 Human   MAC. (69) 
25 000 Rat   MAC. (66) 
25 000 Mouse   MAC. (194) 
Short-term exposure     
3 000 Rat 10 4 h/day, 30 days The day after termination of exposure: Decreased activity and time on open 
arms in elevated plus maze, impaired learning and memory. 
(188) 
21 600 Cynomolgus 
monkey 
8 3 h/day, 3 days/week, 
8 weeks 
1st week: Increased serum aspartate and alanine aminotransferase, creatinine 
kinase and lactate dehydrogenase; values normalised at autopsy.  
At autopsy, reduced erythrocyte counts and relative weight of thymus. Autopsy 
otherwise normal. 
(221) 
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Table 14. Dose-effect relationships for experimental animals after inhalation exposure to sevoflurane (for single exposures, only levels below 0.8 
MAC (human) are included. 
Sevoflurane 
level (ppm) 
Species No. of 
animals/group 
Exposure duration Effects Reference 
23 000 Rabbit 7-8 4 h/day, 5 days Reduced sperm concentration, some histological findings related to 
spermatogenic cells (results difficult to interpret, see pp 49-50). 
(45) 
32 000 Cynomolgus 
monkey 
8 3 h/day, 3 days/week, 
8 weeks 
Week 1-2: Increased serum aspartate and alanine aminotransferase, creatinine 
kinase and lactate dehydrogenase; values normalised at autopsy.  
At autopsy, reduced erythrocyte and white blood cell counts, and reduced 
relative weight of thymus. Autopsy otherwise normal. 
(221) 
40 100 Cynomolgus 
monkey 
8 3 h/day, 3 days/week, 
8 weeks 
First half of study: Increased serum aspartate and alanine aminotransferase, 
creatinine kinase and lactate dehydrogenase; values normalised at autopsy. 
End-tidal CO2 was increased at exposure.  
At autopsy, reduced white blood cell counts and relative weight of thymus. 
Autopsy otherwise normal. 3 animals died. 
(221) 
MAC: minimum alveolar concentration of anaesthetic that produces immobility in 50% of humans exposed to a supramaximal painful/noxious stimulus. 
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Table 15. Dose-effect relationships for experimental animals after inhalation exposure to desflurane (for single exposures, only levels below 0.8 MAC 
(human) are included).  
Desflurane 
level (ppm) 
Species No. of 
animals/group 
Exposure  
duration 
Effects References 
Single exposure     
4 400 Rat 10-13 45 min (minimum) Impaired memory. No effect on learning and pain sensitivity. (6) 
7 700 Rat 22 45 min (minimum) No effect on aversive memory. (7) 
10 130 Rat 12-15 45 min (minimum) Decreased learning, memory impaired further. Pain sensitivity unaffected. (6) 
20 200 Rat 10-12 45 min (minimum) Further impairment of memory and learning. Decreased pain sensitivity. (6)  
60 000 Human   MAC. (69) 
72 100 Rat   MAC. (31) 
65 500- 
91 200 
Mouse   MAC. (222) 
Short-term exposure     
6 000 Rat 10 4 h/day, 30 days The day after termination of exposure: decreased activity and time on 
open arms in elevated plus maze, impaired learning and memory.  
(188) 
MAC: minimum alveolar concentration of anaesthetic that produces immobility in 50% of humans exposed to a supramaximal painful/noxious stimulus. 
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Table 16. Dose-effect relationships in humans after inhalation exposure to isoflurane (for single exposure studies, levels below 0.8 MAC are included. 
Isoflurane  
level (ppm) 
Exposure 
duration 
No. of exposed Effect Reference 
Single exposure     
600 25 min 6 Decreased saccadic peak velocity after 15 min. (79) 
1 000 40 min 14 Decreased performance in the digit-symbol substitution test.  (24) 
1 150 10 min 8 Response to commands impaired in 3/8. Heart rate or arterial pressure unchanged. (178, 179) 
1 200   3 min 25 No adverse airway events. (86) 
1 200 25 min 6 Decreased saccadic peak velocity after 5 min. (79) 
1 900 15 min 10 Impaired learning (slight). (48) 
1 920 15 min 17 No effect on voluntary response.  (60) 
2 000 15 min 10 Decreased performance in the logical reasoning test and digit-symbol substitution test.  (252) 
2 000 40 min 14 Decreased performance in a number of psychomotor tests.  (24) 
2 300 10 min 8 Response to commands impaired in all. Recall and recognition of neutral words was lost, 
but half remembered having heard a ”shock” word. Heart rate and arterial pressure 
unchanged. 
(178, 179) 
2 600   5 min 13 Impaired free recall and no event-related potential repetition effect. (243) 
3 500 15 min 10 Further impairment of learning (explicit learning decreased). (48) 
3 840 15 min 17 Suppressed memory. It was estimated that memory was suppressed by 50% at 2 560 ppm 
and that voluntary response was prevented in 50% at 4 860 ppm. 
(60) 
4 000 15 min 10 Increased auditory reaction time and decreased performance in logical reasoning test,  
digit-symbol substitution test and free recall memory test.  
(252) 
4 000 20 min 12 Increased choice reaction time, decreased ability to tap two areas on a board, and 
decreased ability to solve mathematical problems.  
(172) 
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Table 16. Dose-effect relationships in humans after inhalation exposure to isoflurane (for single exposure studies, levels below 0.8 MAC are included. 
Isoflurane  
level (ppm) 
Exposure 
duration 
No. of exposed Effect Reference 
4 600 10 min 8 No response to verbal commands. 5/8 persons displayed absent eyelash reflex. Heart rate 
or arterial pressure unchanged. 
(178, 179) 
5 100 15 min 10 Learning abolished (explicit learning suppressed entirely). (48) 
5 760 15 min 17 Some subjects responded to verbal commands, memory completely abolished. (60) 
6 000 15 min 9 Increased auditory reaction time and decreased performance in the digit-symbol 
substitution test, eye-hand coordination test and impaired free recall.  
(251) 
7 000 15 min 7 Increased heart rate, decreased mean arterial and forearm venous pressures, decreased 
efferent muscle sympathetic nerve activity.  
(62) 
12 000   MAC. (69) 
Short-term exposure    
1 000-6 000 38 h continuous 
exposure (range 
24-127) 
40 patients 
(various 
surgery) 
Biomarkers of liver function (glutathione transferase, alanine and aspartate 
aminotransferase) similar to patients anaesthetised with midazolam. 
(114) 
20 000-50 000 15-30 min daily 
for 24 days 
(range 10-39) 
11 children 
(undergoing 
radiotherapy) 
Biomarkers of liver function (total bilirubin, aspartate aminotransferase, γ-glutamyl 
transferase and alkaline phosphatase) not impaired compared to pre-exposure.  
(126) 
MAC: minimum alveolar concentration of anaesthetic that produces immobility in 50% of subjects exposed to a supramaximal painful/noxious stimulus. 
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Table 17. Dose-effect relationships in humans after single inhalation exposures to sevoflurane (only levels below 0.8 MAC are included). 
Sevoflurane 
level (ppm) 
Exposure duration No. of 
exposed 
Effect Reference 
1 000 20 min (minimum) 5-9 Suppressed emotional response (exposed volunteers rated significantly more pictures as 
neutral than emotional).  
(8) 
2 000 20 min (minimum) 5-9 Increased rating of pictures as neutral rather than emotional, free recall decreased, memory 
boost abolished for emotionally arousing items. 
(8) 
2 000 40 min 14 Decreased performance in the digit-symbol substitution test. No effect on other psychomotor 
functions. 
(24) 
2 000   5 min 16 Decreased performance in the digit-symbol substitution test (moderate drinkers only). 
Participants reported drug effect. 
(253) 
2 500 20 min (minimum) 5-9 Increased rating of pictures as neutral rather than emotional, free recall decreased, memory 
boost abolished for emotionally arousing items.  
(8) 
4 000   5 min 16 Further decreased performance in the digit-symbol substitution test (light and moderate 
drinkers). Drug effect increased further. 
(253) 
4 000 40 min 14 Impaired performance in different psychomotor tests. (24) 
4 000 10 min (minimum) 9 Regional cerebral blood flow increased in some and decreased in other brain areas. Some of 
the most profound changes were in regions related to pain processing. Bispectral index values 
decreased dose-dependently and EEG signals changed significantly. 
(216) 
5 000 25 min 16 Regional blood flow in some brain areas increased less during exposure than in the control 
condition during activation tasks. 
(196) 
7 000 10 min (minimum) 9 Increased regional blood flow in some and decreased in other brain areas. Some of the most 
profound changes were in regions related to pain processing. Bispectral index values 
decreased dose-dependently and EEG signals changed significantly. 
(216) 
8 000   5 min 16 Further decreased performance in the digit-symbol substitution test. Drug effect increased 
further. 
(253) 
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Table 17. Dose-effect relationships in humans after single inhalation exposures to sevoflurane (only levels below 0.8 MAC are included). 
Sevoflurane 
level (ppm) 
Exposure duration No. of 
exposed 
Effect Reference 
10 000 10 min 12 Decreased mean arterial pressure. No change in heart rate, central venous pressure, plasma 
norepinephrine or in efferent muscle sympathetic nerve activity recorded by microneuro-
graphy. 
(64) 
21 000   MAC. (69) 
EEG: electroencephalography, MAC: minimum alveolar concentration of anaesthetic that produces immobility in 50% of subjects exposed to a supramaximal 
painful/noxious stimulus, N2O: nitrous oxide, PET: positron emission tomography, SCE: sister chromatid exchange. 
 
 
 
 
 
Table 18. Dose-effect relationships in humans after single inhalation exposure to desflurane (only levels below 0.8 MAC are included).  
Desflurane  
level (ppm) 
Exposure duration No. of  
exposed 
Effect Reference 
6 000   3 min 25 No adverse airway events. (86) 
30 000 10 min 9 Decreased mean arterial and central venous pressures. Unchanged heart rate, efferent muscle 
sympathetic nerve activity, and plasma norepinephrine. 
(64) 
36 000 10 min 7 Decreased mean arterial and forearm vascular resistance, no change in heart rate.  (62) 
60 000   MAC. (69) 
MAC: minimum alveolar concentration of anaesthetic that produces immobility in 50% of subjects exposed to a supramaximal painful/noxious stimulus. 
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Table 19. Dose-effect relationships in humans after occupational exposure via inhalation to isoflurane, sevoflurane and desflurane. 
Mean level of 
flurane (ppm) 
Mean level of 
N2O (ppm) 
Sampling No. of 
exposed 
Effect Reference 
Isoflurane      
0.16 ± 0.12 a 30 ± 29 Personal, breathing zone 80 No hepatic changes as evaluated by serum alanine aminotransferase 
and aspartate aminotransferase. 
(77) 
0.35 (0.1-6.2) 23.2 (3-183) Stationary 112 No effect on neurofunction. (159) 
0.5 (8-h TWA) 11.8 Personal, breathing zone 27 Increased frequency of SCEs in peripheral lymphocytes. (111) 
5.3 ± 12.8 a  
(8-h TWA) 
12.8 Stationary 10 Increased frequency of SCEs in peripheral lymphocytes. (107) 
Sevoflurane      
0.28 (0-1.88) 31.3 (0.9-112) Personal, breathing zone 61 Slight increase in total urinary protein, without dose-response (all 
values within normal range). Other indices of kidney function 
unaffected. 
(232) 
8.9 ± 5.6 a  119 ± 39 Stationary, close to 
working anaesthetists 
25 Increased levels of SCEs in exposed anaesthetists. After 2 months 
leave from the operating room, the levels of SCEs were significantly 
lower compared to those taken before the leave. 
(72) 
Isoflurane, sevoflurane and desflurane    
 ~6 (total of all 
the fluranes) 
59 (10-100) Not specified 53 Impaired balance control. (246) 
a
 Standard deviation. 
N2O: nitrous oxide, SCE: sister chromatid exchange, TWA: time-weighted average.  
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13. Previous evaluations by national and international bodies 
In 1987, the International Agency for Research on Cancer (IARC) concluded that 
volatile anaesthetics (unspecified) are not classifiable as to their carcinogenicity to 
humans (118). 
In 1993, the German Commission for the Investigation of Health Hazards of 
Chemical Compounds in the Work Area evaluated isoflurane, based on an extensive 
review on the literature published at the time, i.e. human experience at anaesthetic 
doses and findings in animal studies (acute, subchronic, chronic, and reproductive 
toxicity, and genotoxicity and carcinogenicity). Although the acute anaesthetic 
effects of isoflurane are well established, the committee found the knowledge of 
the effects of isoflurane insufficient for the establishment of a MAK (Maximale 
Arbeitsplatzkonzentration) value, especially concerning chronic exposure to 
subanaesthetic dose levels (56). 
The Swedish Criteria Group for Occupational Standards evaluated sevoflurane 
and desflurane in 1998. They concluded that there was no scientific information 
on either compound that could be used as a basis for identifying a critical effect 
relevant to occupational exposures (160).  
In 1998, the Dutch Expert Committee on Occupational Standards (DECOS) 
evaluated isoflurane. At that time, data on reproductive effects were lacking. 
However, as the toxicity profile for isoflurane resembled that of enflurane,  
the committee concluded that the mode of action is similar for isoflurane  
and enflurane. Given the similarity in chemical structure between these two 
compounds, the committee recommended the same value for a health based 
occupational exposure limit for isoflurane as for enflurane, i.e. 20 ppm (98). 
DECOS also evaluated the effects of isoflurane on reproduction, in 2002. They 
concluded that lack of appropriate human and animal data precluded the assess-
ment of the effect of isoflurane on fertility and lactation. Lack of appropriate 
human data precluded the assessment of the effect of isoflurane on foetal de-
velopment, but sufficient animal data showed that no classification for effects  
on development was indicated (99).  
In 2000, the Norwegian Labour Inspection Authority concluded that the 
documentation on the health risks concerning exposure to isoflurane, sevoflurane, 
and desflurane was too sparse to identify a critical effect (12-14). It was concluded 
that isoflurane is teratogenic at high doses based on the animal studies by Mazze 
et al 1985 (167) and Warren et al 1992 (235). 
The National Institute of Occupational Safety and Health (NIOSH) in the 
Unites States presently announces intentions to review and evaluate toxicity data 
for isoflurane, sevoflurane and desflurane (180).  
A list of occupational exposure limits is presented in Appendix 1. 
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14. Evaluation of human health risks  
14.1 Assessment of health risks 
Isoflurane, sevoflurane, and desflurane are all used as inhalation anaesthetics. 
Thus, all three agents cause sedation and analgesia at anaesthetic dose levels,  
with MAC-values in humans of 12 000, 21 000, and 60 000 ppm, respectively. 
The fluranes are used separately or in combination with other anaesthetics, mostly 
nitrous oxide. Human data for dermal uptake are lacking, but the potential for 
systemic uptake of fluranes via the skin seems low. 
Due to the anaesthetic nature of the three fluranes, neurological effects would 
be expected to occur also at subanaesthetic exposures of short duration. This is 
confirmed by experimental studies of neurofunction in human volunteers. There  
is also relatively much knowledge as to other effects of single exposure to high 
dose levels in humans. However, for most such effects NOAELs are unknown. 
Apart from the central nervous system effects, concern has mostly concentrated 
around the potential for hepatotoxic, nephrotoxic, and reproductive and develop-
mental effects. Hepatitis may occur in less than 1/1 000 patients after isoflurane 
anaesthesia, and in 1/1 000-1/10 000 patients for sevoflurane and desflurane. 
Nephrotoxicity is only a concern for sevoflurane, with an incidence less than 
1/10 000 patients.  
Several studies indicate that occupational exposure to anaesthetic gases in 
general (including agents such as nitrous oxide, halothane, diethylether and also 
isoflurane) may increase the risk for spontaneous abortion and the incidence of 
malformations. However, the studies are weak and due to mixed exposure to 
anaesthetic gases the causative agent and exposure levels are not known. For 
isoflurane, animal studies at 4 000 ppm and below consistently showed no such 
effects. At subanaesthetic dose levels around 0.5 MAC, all three fluranes 
significantly inhibited myometrial muscle contraction (in vitro). Results from 
studies on rodents exposed neonatally at anaesthetic levels indicate that the foetal 
nervous system in humans may be sensitive to isoflurane. No NOAELs can be 
identified for these outcomes.  
A few long-term exposure studies have demonstrated genotoxic (increased 
frequency of SCEs) effects in subjects occupationally exposed to fluranes. The 
genotoxicity of the three fluranes has also been studied in patients at anaesthetic 
concentrations, with some positive findings. Together, these studies give rise to 
some concern regarding the genotoxic potential of the fluranes. However, in these 
studies, co-exposure to other anaesthetics, especially nitrous oxide or patient 
premedication, hampers the interpretation.  
The few animal studies on carcinogenicity do not indicate that isoflurane is 
carcinogenic.  
Irritative effects are not to be expected at present exposure levels at the work-
place, although especially desflurane, but also isoflurane, irritates the airways at 
anaesthetic exposure levels. Sevoflurane seems to irritate the airways to a lesser 
extent.  
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A few cases of contact dermatitis, occupational asthma and allergy to isoflurane 
and sevoflurane have been described.  
Isoflurane, sevoflurane, and desflurane 
A study in nurses and auxiliary nurses exposed mainly to nitrous oxide (59 ppm) 
but also the three fluranes (approximately 6 ppm) demonstrated impaired balance 
control following more than 5 years of occupational exposure. As the subjects  
had not been exposed to anaesthetics or ethanol during 48 hours before the test, 
the impairment does not reflect an acute effect. Because of the poorly described 
exposure situation, it is not clear which anaesthetic caused the effect.  
Isoflurane 
In human volunteers, exposure to 600 ppm isoflurane (LOAEL, lowest dose 
tested) for 25 minutes decreased saccadic eye movements and exposure to 1 000 
ppm for 40 minutes resulted in decreased performance in the digit-symbol sub-
stitution test. In rats, neither analgesia nor effects on cognitive function were 
observed after a single exposure to 530 ppm (NOAEL), however, antianalgesia 
was observed at 1 145 ppm. 
Long-term occupational exposure to 0.16 and 0.35 ppm isoflurane were not 
associated with effects on liver function or neurofunction, respectively. Also, no 
effects on liver function were observed in a short-term study in children, exposed 
at anaesthetic dose levels for short periods for several days. In rats, no detectable 
effects on the liver or kidneys were observed after continuous exposure to 20  
ppm isoflurane for 30 weeks. In rats, mice and guinea pigs, 35 days of continuous 
exposure to 150 and 500 ppm did not affect the liver, but at 1 500 ppm, liver 
lesions were non-significantly increased in all three species. Body weight gains 
were reduced to a similar extent at and above 150 ppm (overall LOAEL) in mice, 
and in guinea pigs only at 1 500 ppm.  
At anaesthetic concentrations, isoflurane affected male fertility in rabbits in  
one study, whereas studies in mice showed no such effect. The rabbit study is 
hampered e.g. by a depressive trend with respect to sperm concentration also in 
the controls. Thus, the adverse effects cannot be entirely attributed to the isoflurane 
exposure. The design of the mice studies did not allow detection of effects on the 
earlier stages of spermatogenesis.  
Isoflurane anaesthesia during gestation does not seem to interfere with foetal 
development in animals. However, exposures at or above 6 000 ppm during 
organogenesis are associated with developmental effects in rats and mice.  
Exposure during neonatal life at anaesthetic dose levels has been associated 
with increased apoptosis in rodent neural tissue. The developmental stage of the 
nervous system in juvenile mice and rats is comparable to that of the nervous 
system in the human foetus during the 3rd term. These results indicate that also 
the nervous system of the human foetus may be sensitive to isoflurane.  
Increased SCEs were observed in humans after chronic exposure to 0.5 and 5.3 
ppm isoflurane. In both studies, nitrous oxide was the dominating anaesthetic 
agent, thus it is not possible to assess the potential impact of isoflurane although 
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SCEs have not been clearly associated with exposure to nitrous oxide either. 
Isoflurane did not induce SCEs in patients at anaesthetic concentrations. The 
isolated effect of isoflurane has been studied in patients after anaesthesia and in 
human lymphocytes exposed in vitro to isoflurane. These studies have all shown 
genotoxicity (increases in DNA single strand breaks or SCEs). However, there are 
also negative in vitro/in vivo studies (bacterial tests, Drosophila tests as well as 
Chinese hamster cell line tests were negative). 
Sevoflurane 
At the lowest dose studied, 1 000 ppm for 20 minutes, sevoflurane suppressed the 
emotional response (exposed human volunteers rated significantly more pictures 
as neutral than emotional) (LOAEL). In rats, analgesia and enhanced aversive 
memory formation were observed after exposure to 45 minutes at 1 050 and 1 100 
ppm, respectively (lowest levels tested).  
Increased SCEs in anaesthetists exposed to 8.9 ppm sevoflurane was reported in 
one study, while a study of patients exposed to sevoflurane showed no effect on 
this endpoint. In both these human studies, the subjects had also been exposed to 
nitrous oxide. Thus the responsible agent cannot be identified. The isolated effect 
of sevoflurane has been studied in patients after anaesthesia and in vitro. The 
studies of patients showed genotoxicity, whereas sevoflurane did not induce 
genotoxicity in human lymphocytes in vitro.  
One study in rabbits indicated that sevoflurane may have the potential to affect 
male fertility at near MAC dose levels. The interpretation of the study is hampered 
by a depressive trend with respect to sperm concentration also in the controls. 
Thus, the observed decrease may have been caused by other factors than sevo-
flurane. 
Desflurane 
Neurofunction was not tested at subanaesthetic desflurane concentrations in 
humans. No sign of airway irritation was observed at the lowest exposure level 
tested (6 000 ppm for 3 minutes). At much higher, but still subanaesthetic 
concentrations (30 000 ppm), vascular resistance decreased. In rats, cognitive 
function was impaired at 4 400 ppm, the lowest dose tested. Effects of chronic 
exposure have not been studied for desflurane in animals. Desflurane induced 
SCEs in patients at anaesthetic concentrations and a dose-dependent increase in 
DNA strand breaks was observed in human lymphocytes exposed in vitro to 
desflurane. 
14.2 Groups at extra risk  
No groups at extra risk have been identified. In epidemiological studies, 
occupational exposure to anaesthetic gases in general has been associated with 
increased risk of spontaneous abortions and increased incidence of malformations, 
but the studies are weak and the causative agent is not identified. 
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14.3 Scientific basis for an occupational exposure limit  
The critical effect for acute exposure to isoflurane, sevoflurane and desflurane is 
neurotoxicity. A few long-term exposure studies have demonstrated neurotoxic 
(impaired balance control) and genotoxic (increased frequency of SCEs) effects in 
subjects occupationally exposed to fluranes. The genotoxicity of the three fluranes 
has also been studied in patients at anaesthetic concentrations, with some positive 
findings. Together, these studies give rise to some concern regarding the geno-
toxic potential of the fluranes. However, in these studies, co-exposure to other 
anaesthetics, especially nitrous oxide or patient premedication, hampers the inter-
pretation. Thus, the data are not sufficient to identify a critical effect for long-term 
exposure to any of the three fluranes.  
Isoflurane 
Considering acute effects in humans, decreased eye movements were reported  
at 600 ppm (LOAEL). In addition, a decreased performance in the digit-symbol 
substitution test was observed after exposure to 1 000 ppm. No acute NOAEL has 
been identified in humans. 
Regarding animal studies, continuous exposure to 150 ppm for 35 days was 
associated with depressed body weight gain in mice (overall LOAEL).  
Developmental toxicity was observed in mice exposed to 6 000 ppm during 
gestation. At 4 000 ppm and below, no developmental toxicity of isoflurane was 
observed. Results from studies on rodents exposed neonatally at anaesthetic levels 
indicate that the foetal nervous system in humans may be sensitive to isoflurane. 
The few animal studies on carcinogenicity do not indicate that isoflurane is 
carcinogenic.  
Sevoflurane 
An acute effect on neuropsychological function in humans was observed at  
1 000 ppm. Sevoflurane caused analgesia at 1 050 ppm in rats. No NOAELs  
can be identified.  
Desflurane 
Data for desflurane are very scarce. In rats, impaired cognitive function was 
observed at acute exposure to 4 400 ppm. No NOAELs can be identified.   
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15. Research needs 
Because data on the newer agents, sevoflurane and desflurane are limited, research 
in the health effects of these agents are needed to gain more knowledge about 
adverse health effects.  
- For desflurane, data for most organ systems/toxicological effects are lacking. 
This is to some extent also true for sevoflurane. 
- Due to the anaesthetic nature of the three fluranes, neurological effects would 
be a concern. However, there is a lack of long-term studies on neurological 
effects, in animals as well as humans.  
- Male fertility. One study indicates that isoflurane and sevoflurane may affect 
male semen production and motility, but interpretation is difficult due to great 
variation in values from the concurrent control group (45). In addition, no 
study has yet investigated the full spermatogenic cycle.  
- The carcinogenic effect of isoflurane has only been investigated in one species. 
Additional studies on the carcinogenicity of isoflurane in another species 
would gain further insight into the carcinogenic effects of isoflurane. Studies 
of the long-term effects of desflurane and sevoflurane should be established  
to obtain knowledge about carcinogenicity. The genotoxic potential of the 
fluranes should be established.  
- Developmental neurotoxicity, after exposure throughout gestation. Also, 
NOAELs for apoptosis in nerve cells after juvenile exposure should be 
established. 
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16. Summary  
Saber AT and Hougaard KS. The Nordic Expert Group for Criteria Documentation 
of Health Risks from Chemicals. 141. Isoflurane, sevoflurane and desflurane. 
Arbete och Hälsa 2009;43(9):1-117.  
 
Isoflurane, sevoflurane and desflurane (fluranes) are halogenated ethers. They  
are stable, clear, and colourless volatile liquids at room temperature. None of the 
fluranes occur naturally. The sole use of fluranes is as anaesthetic agents after 
vapourisation. Isoflurane is the most potent, and 50% of human subjects inhaling 
12 000 ppm remain immobile when exposed to a painful stimulus (MAC). MAC-
values for sevoflurane and desflurane are 21 000 and 60 000 ppm, respectively. 
Occupational exposure occurs mainly by inhalation and remains generally below  
2 ppm in the most recent assessments. Effects have primarily been studied at 
anaesthetic dose levels at a single occasion rather than in personnel exposed to 
low concentrations for long periods. Isoflurane is the most studied of the three 
compounds, whereas the toxicological database on sevoflurane is limited and the 
one on desflurane is very poor. 
Due to the properties of the three fluranes, i.e. low irritancy and low frequency 
of side-effects even at the anaesthetic level, neurological effects are considered to 
be the critical effect for acute exposures.  
For isoflurane, the acute human lowest observed adverse effect level (LOAEL) 
is 600 ppm (eye movement). An overall LOAEL can be set at 150 ppm, at which 
continuous exposure for 35 days was associated with reduced body weight gain in 
mice.  
For sevoflurane, an acute effect on neuropsychological function in humans was 
observed at 1 000 ppm. Sevoflurane also caused analgesia at 1 050 ppm in rats. 
Data for desflurane are very scarce. In rats, impaired cognitive function was 
observed at acute exposure to 4 400 ppm.  
For the three fluranes, studies on effects of long-term exposure are scarce  
or non-existing. A few studies of subjects exposed occupationally or during 
anaesthesia have shown genotoxicity. In some of the studies, co-exposure to 
nitrous oxide or premedication hampers interpretation. The few animal studies  
on carcinogenicity do not indicate that isoflurane is carcinogenic. 
Irritative effects would not be expected to occur at exposure levels present in 
the workplace, whereas at anaesthetic dose levels, especially desflurane but also 
isoflurane irritates the airways. Sevoflurane seems to irritate the airways to a lesser 
extent.  
Only a few cases of contact dermatitis, occupational asthma and allergy to 
isoflurane and sevoflurane have been described.  
 
Keywords: anaesthetic, desflurane, isoflurane, neurotoxicity, occupational 
exposure limit, review, risk assessment, sevoflurane, toxicity 
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17. Summary in Danish  
Saber AT and Hougaard KS. The Nordic Expert Group for Criteria Documentation 
of Health Risks from Chemicals. 141. Isoflurane, sevoflurane and desflurane. 
Arbete och Hälsa 2009;43(9):1-117. 
 
Isofluran, sevofluran og desfluran (fluraner) er halogenerede ætere. De er stabile, 
klare og farveløse fordampelige væsker ved stuetemperatur. Ingen af fluranerne 
forekommer naturligt. Fluraner anvendes udelukkende som anæsteserende stoffer 
efter fordampning. Isofluran er det mest potente af fluranerne, og 50% af de 
mennesker, som indånder 12 000 ppm forbliver immobile ved udsættelse for 
smertefulde stimuli (MAC). MAC-værdierne for sevofluran og desfluran er 
henholdsvis 21 000 og 60 000 ppm. Erhvervsmæssig eksponering forekommer 
primært ved indånding og eksponeringsniveauerne ligger generelt under 2 ppm  
i nyere undersøgelser. Effekterne er fortrinsvis studeret efter enkeltudsættelser  
for anæstetiske doser frem for efter personales længerevarende eksponering ved 
lavere doser. Isofluran er den best undersøgte af de tre forbindelser. Den toksiko-
logiske viden om sevofluran og desfluran er henholdsvis begrænset og meget 
ringe. 
Eftersom de tre fluraner selv ved anæstetiske doser er associeret med ringe 
luftvejsirritation og en lav frekvens af bivirkninger, anses neurologiske effekter 
som den kritiske effekt ved akutte eksponeringer. 
For isofluran er der observeret en akut human LOAEL på 600 ppm (øjen-
bevægelse). En overordnet LOAEL bestemmes til 150 ppm, hvor kontinuert 
eksponering i 35 dage var forbundet med reduceret kropsvægtsøgning i mus. 
For sevofluran blev der ved 1 000 ppm observeret en akut påvirkning af neuro-
psykologiske funktioner i mennesker. Sevofluran forårsagede analgesi (nedsat 
smertefølsomhed) ved 1 050 ppm i rotter.  
Data for desfluran er meget begrænsede. Rotter udviste nedsat kognitiv funktion 
ved akut eksponering ved 4 400 ppm. 
For de tre fluraner er studier af effekter af langtidseksponering begrænset eller 
ikke-eksisterende. Enkelte studier af personer eksponeret erhvervsmæssigt eller 
ved anæstesi har vist genotoksicitet. I nogle af disse studier besværliggøres 
fortolkningen af resultaterne af samtidig eksponering for dinitrogenoxid eller 
premedicinering. De få dyrestudier af carcinogenicitet indikerer ikke at isofluran 
er carcinogent. 
Irritative effekter forventes ikke at forekomme ved de eksponeringsniveauer, 
som findes på arbejdspladser. Derimod irriterer især desfluran men også isofluran 
luftvejene ved anæstetiske dosisniveauer. Sevofluran irriterer tilsyneladende 
luftvejene i mindre grad. Der er blevet beskrevet ganske få tilfælde af kontakt-
dermatitis, erhvervsbetinget astma og allergi overfor isofluran og sevofluran. 
 
Nøgleord: anæstesimiddel, desfluran, erhvervsmæssig grænseværdi, isofluran, 
neurotoksicitet, review, risikovurdering, sevofluran, toksicitet 
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19. Data bases used in search of literature 
A number of reviews on isoflurane, sevoflurane and desflurane formed the basis 
for the search for literature on the health effects to the agents; Burm, 2003 (35), 
Byhahn et al, 2001 (40) and Delgado-Herrera, 2001 (55). Literature was retrieved 
from the online databases: 
Medline (April 2008)  
Toxline Special (April 2008) 
DART (January 2007) 
RTECS (July 2007)  
RISKLINE (April 2008)  
Application of specific search terms depended on database. CAS-numbers were 
applied in all searches in all databases, and the options for addition of relevant 
synonyms for the fluranes were chosen when possible. For example were 
synonyms added from ChemIDplus when using the TOXNET databases DART 
and TOXLINE. Studies were included in the document only when written in 
English, German, Swedish, Norwegian, and Danish. 
 
Terms used in the literature search. 
Agent Effects Occupational 
Anaesthetics Allergy Health care 
Isoflurane Asthma Anaesthetists 
Sevoflurane Cancer  
Desflurane Carcinogenicity  
26675-46-7 Genotoxicity  
28523-86-6 Mutagenicity  
57041-67-5 Reproductive effects  
 Teratogenicity  
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Appendix 1. Occupational exposure limit values 
Occupational exposure limit values for the fluranes in different countries as 8-hour 
TWAs (numbers in brackets are short-term exposure limits). 
Country Isoflurane Sevoflurane Desflurane Ref. 
 ppm mg/m3 ppm mg/m3 ppm mg/m3  
Denmark  - - - - - - (1) 
Finland  10 (20) 77 (150) 10 (20) 83 (170) 10 (20) 70 (140) (2) 
Germany (MAK) - - - - - - (3) 
The Netherlands - - - - - - (4) 
Norway  2 (4) 15 (30) 20 (30) 140 (210) 20 (30) 140 (210) (5) 
Sweden  10 (20) 80 (150) 10 (20) 80 (170) 10 (20) 70 (140) (6) 
United Kingdom  50 ( - ) 383 ( - ) - - - - (7) 
US (ACGIH)  - - - - - - (8) 
US (NIOSH)  2 C a - 2 C a - 2 C a - (9) 
European Union - - - - - - (10, 11) 
a
 Recommended exposure limit (REL) for exposure to waste anaesthetic gas. 
C: ceiling (60 min), TWA: time-weighted average. 
 
References 
1. Grænsværdier for stoffer og materialer. At-vejledning. Stoffer og materialer-C.0.1. Køpenhavn: 
Arbejdstilsynet, August 2007. 
2. HTP-värden 2007. Koncentrationer som befunnits skadliga. Helsingfors: Social- och 
hälsovårdsministeriets publikationer 2007:20. 
3. MAK- und BAT-werte-liste 2007. Senatskommission zur Prüfung gesundheitsschädlicher 
Arbeitsstoffe. Mitteilung 43. Bonn: Deutsche Forschungsgemeinschaft (DFG), 2007. 
4. Wijziging Arbeidsomstandighedenregeling. Staatscourant 28 december 2006, nr. 252 / pag. 23. 
Den Haag: Ministerie van Sociale Zaken en Werkgelegenheid, 2007.  
5. Administrative normer for forurensning i arbeidsatmosfære 2009. Veiledning til 
arbeidsmiljøloven. Oslo: Arbeidstilsynet, 2009. 
6. Hygieniska gränsvärden och åtgärder mot luftföroreningar. Arbetsmiljöverkets författnings- 
samling, AFS 2005:17. Solna: Arbetsmiljöverket, 2005. 
7. EH40/2005 Workplace exposure limits. Table 1: List of approved workplace exposure limits (as 
consolidated with amendments October 2007). London: Health and Safety Executive, 2007. 
8. 2007 TLVs and BEIs. Based on the documentation of the “Threshold limit values for chemical 
substances and physical agents and biological exposure indices”. Cincinnati, Ohio: The 
American Conference of Governmental Industrial Hygienists (ACGIH), 2007. 
9. NIOSH pocket guide to chemical hazards. Cincinnati, Ohio: National Institute for Occupational 
Safety and Health, 2005. 
10. Indicative occupational exposure limit values. Commission directives: 2000/39/EC of 8 June 
2000. Official Journal of the European Communities: L 142/47-50. Brussels: The commission 
of the European communities, 2000. 
11. Indicative occupational exposure limit values. Commission directives: 2006/15/EC of 7 
February 2006. Official Journal of the European Communities: 9.2.2006. Brussels: The 
commission of the European communities, 2006. 
113 
Appendix 2. Side-effects of the fluranes at anaesthetic dose levels 
Side-effects of isoflurane, sevoflurane and desflurane at anaesthetic dose levels (150-152). 
Organ system Incidence 
 Isoflurane  Sevoflurane  Desflurane  
Heart    
Arrhythmia >1/100 ≥1/1 000 to <1/100  
Tachycardia, bradycardia  ≥1/100 to <1/10 ≥1/10 
Bradycardia (older patients) ≥1/10  
Lung oedema  <1/10 000  
Blood- and lymph system    
Leukocytosis >1/100 ≥1/1 000 to <1/100 ≥1/10 
Leucopoenia  ≥1/1 000 to <1/100  
Haemorrhage   ≥1/1 000 to <1/100 
Nervous system    
Increased secretions   ≥1/100 to <1/10 
Headache  ≥1/100 to <1/10 ≥1/100 to <1/10 
Vertigo  ≥1/100 to <1/10 ≥1/100 to <1/10 
Fever  ≥1/100 to <1/10 ≥1/100 to <1/10 
Tremor  ≥1/100 to <1/10  
Somnolence  ≥1/100 to <1/10 ≥1/100 to <1/10 
Migraine   <1/10 000 
Convulsions  <1/10 000 <1/10 000 
Dystonic movements  ≥1/10 000 to <1/1 000  
Shivering >1/100 ≥1/100 to <1/10  
Eyes    
Conjunctival hyperaemia   ≥1/100 to <1/10 
Eye irritation   <1/10 000 
Airways, thorax and mediastium   
Coughing (children)  ≥1/10  
Coughing >1/100 ≥1/100 to <1/10 ≥1/10 
Depression of respiration  ≥1/100 to <1/10  
Laryngospams/laryngismus  <1/1 000 ≥1/100 to <1/10 ≥1/100 to <1/10 
Bronchospasms <1/1 000  ≥1/100 to <1/10 
Asthma, hypoxia  ≥1/1 000 to <1/100 ≥1/1 000 to <1/100 
Dyspnoea   ≥1/1 000 to <1/100 
Apnoea  ≥1/1 000 to <1/100 ≥1/100 to <1/10 
Pharyngitis   ≥1/100 to <1/10 
Acute respiratory deficiency syndrome,  
lung oedema, respiratory failure 
 <1/10 000 
Gastrointestinal tract    
Nausea, vomiting >1/1 000 to <1/100 ≥1/10 ≥1/10 
Ilius <1/1 000   
Diarrhoea   <1/10 000 
Increased saliva secretion  ≥1/100 to <1/10  
Skin and subcutaneous tissue   
Pruritis   ≥1/1 000 to <1/100 
Skin eruption, urticaria   <1/10 000 
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Side-effects of isoflurane, sevoflurane and desflurane at anaesthetic dose levels (150-152). 
Organ system Incidence 
 Isoflurane  Sevoflurane  Desflurane  
Bones, joints, muscles and connective tissue   
Myalgia   ≥1/1 000 to <1/100 
Kidneys and the urinary system   
Urine retention, glucosuria  ≥1/1 000 to <1/100  
Acute kidney insufficiency  <1/10 000  
Metabolism and nutrition    
Hyperglycaemia  ≥1/1 000 to <1/100  
Hyperpotassaemia   ≥1/1 000 to <1/100 
Increased serum glucose 
and serum creatinine. 
Decreased serum 
cholesterol and alkaline 
phosphatase 
>1/100   
Malign hyperthermia <1/1 000 ≥1/10 000 to <1/1 000 ≥1/1 000 to <1/100 
Hypothermia  ≥1/100 to <1/10  
Affection of the liver <1/1 000   
Infections and parasitic diseases   
Pneumonia   <1/10 000 
Vascular diseases    
Hypotension >1/100 ≥1/10  
Hypertension  ≥1/100 to <1/10 ≥1/100 to <1/10 
Liver and biliary passage    
Hepatitis <1/1 000 ≥1/10 000 to <1/1 000 ≥1/10 000 to <1/1 000 
Decreased liver function  ≥1/10 000 to <1/1 000  
Increased level of liver 
enzymes 
<1/1 000   
Liver necrosis <1/1 000  <1/10 000 
Icterus <1/1 000   
Psychological effects    
Agitation (children)  ≥1/10  
Agitation  ≥1/1 000 to <1/100 ≥1/1 000 to <1/100 
Confusion  ≥1/1 000 to <1/100  
Hostility   <1/10 000 
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Appendix 3. Previous NEG criteria documents 
NEG criteria documents published in the scientific serial Arbete and Hälsa (Work 
and Health): 
 
Substance/Agent Arbete och Hälsa issue 
Acetonitrile 1989:22, 1989:37* 
Acid aerosols, inorganic 1992:33, 1993:1* 
Acrylonitrile 1985:4 
Allyl alcohol 1986:8 
Aluminium 1992:45, 1993:1* 
Ammonia 1986:31, 2005:13* 
Antimony 1998:11* 
Arsenic, inorganic 1981:22, 1991:9, 1991:50* 
Arsine 1986:41 
Asbestos 1982:29 
Benomyl 1984:28 
Benzene 1981:11 
1,2,3-Benzotriazole 2000:24*D 
Boric acid, Borax 1980:13 
1,3-Butadiene 1994:36*, 1994:42 
1-Butanol 1980:20 
γ-Butyrolactone 2004:7*D 
Cadmium 1981:29, 1992:26, 1993:1* 
7/8 Carbon chain aliphatic monoketones 1990:2*D 
Carbon monoxide 1980:8 
Ceramic Fibres, Refractory 1996:30*, 1998:20 
Chlorine, Chlorine dioxide 1980:6 
Chloromequat chloride 1984:36 
4-Chloro-2-methylphenoxy acetic acid 1981:14 
Chlorophenols 1984:46 
Chlorotrimethylsilane 2002:2 
Chromium 1979:33 
Cobalt 1982:16, 1994:39*, 1994:42 
Copper 1980:21 
Creosote 1988:13, 1988:33* 
Cyanoacrylates 1995:25*, 1995:27 
Cyclic acid anhydrides 2004:15*D 
Cyclohexanone, Cyclopentanone 1985:42 
n-Decane 1987:25, 1987:40* 
Deodorized kerosene 1985:24 
Diacetone alcohol 1989:4, 1989:37* 
Dichlorobenzenes 1998:4*, 1998:20 
Diesel exhaust 1993:34, 1993:35* 
Diethylamine 1994:23*, 1994:42 
2-Diethylaminoethanol 1994:25*N 
Diethylenetriamine 1994:23*, 1994:42 
Diisocyanates 1979:34, 1985:19 
Dimethylamine 1994:23*, 1994:42 
Dimethyldithiocarbamates 1990:26, 1991:2* 
Dimethylethylamine 1991:26, 1991:50* 
Dimethylformamide 1983:28 
Dimethylsulfoxide 1991:37, 1991:50* 
Dioxane 1982:6 
Enzymes, industrial 1994:28*, 1994:42 
Epichlorohydrin 1981:10 
Ethyl acetate 1990:35* 
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Substance/Agent Arbete och Hälsa issue 
Ethylbenzene 1986:19 
Ethylenediamine 1994:23*, 1994:42 
Ethylenebisdithiocarbamates and Ethylenethiourea 1993:24, 1993:35* 
Ethylene glycol 1980:14 
Ethylene glycol monoalkyl ethers 1985:34 
Ethylene oxide 1982:7 
Ethyl ether 1992:30* N 
2-Ethylhexanoic acid 1994:31*, 1994:42 
Flour dust 1996:27*, 1998:20 
Formaldehyde 1978:21, 1982:27, 2003:11*D 
Fungal spores 2006:21* 
Furfuryl alcohol 1984:24 
Gasoline 1984:7 
Glutaraldehyde 1997:20*D, 1998:20 
Glyoxal 1995:2*, 1995:27 
Halothane 1984:17 
n-Hexane 1980:19, 1986:20 
Hydrazine, Hydrazine salts 1985:6 
Hydrogen fluoride 1983:7 
Hydrogen sulphide 1982:31, 2001:14*D 
Hydroquinone 1989:15, 1989:37* 
Industrial enzymes 1994:28* 
Isophorone 1991:14, 1991:50* 
Isopropanol 1980:18 
Lead, inorganic 1979:24, 1992:43, 1993:1* 
Limonene 1993:14, 1993:35* 
Lithium and lithium compounds 2002:16* 
Manganese 1982:10 
Mercury, inorganic 1985:20 
Methacrylates 1983:21 
Methanol 1984:41 
Methyl bromide 1987:18, 1987:40* 
Methyl chloride 1992:27*D 
Methyl chloroform 1981:12 
Methylcyclopentadienyl manganese tricarbonyl 1982:10 
Methylene chloride 1979:15, 1987:29, 1987:40* 
Methyl ethyl ketone 1983:25 
Methyl formate 1989:29, 1989:37* 
Methyl isobutyl ketone 1988:20, 1988:33* 
Methyl methacrylate 1991:36*D 
N-Methyl-2-pyrrolidone  1994:40*, 1994:42 
Methyl-tert-butyl ether 1994:22*D 
Microbial volatile organic compounds (MVOCs) 2006:13* 
Microorganisms 1991:44, 1991:50* 
Mineral fibers 1981:26 
Nickel 1981:28, 1995:26*, 1995:27 
Nitrilotriacetic acid 1989:16, 1989:37* 
Nitroalkanes 1988:29, 1988:33* 
Nitrogen oxides 1983:28 
N-Nitroso compounds 1990:33, 1991:2* 
Nitrous oxide 1982:20 
Oil mist 1985:13 
Organic acid anhydrides 1990:48, 1991:2* 
Ozone 1986:28 
Paper dust 1989:30, 1989:37* 
Penicillins 2004:6* 
Permethrin 1982:22 
Petrol 1984:7 
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Substance/Agent Arbete och Hälsa issue 
Phenol 1984:33 
Phthalate esters 1982:12 
Platinum 1997:14*D, 1998:20 
Polyethylene,  1998:12* 
Polypropylene, Thermal degradation products in the 
processing of plastics 
1998:12* 
Polystyrene, Thermal degradation products in the 
processing of plastics 
1998:12* 
Polyvinylchloride, Thermal degradation products in the 
processing of plastics 
1998:12* 
Polytetrafluoroethylene, Thermal degradation products 
in the processing of plastics 
1998:12* 
Propene 1995:7*, 1995:27 
Propylene glycol 1983:27 
Propylene glycol ethers and their acetates 1990:32*N  
Propylene oxide 1985:23 
Refined petroleum solvents 1982:21 
Refractory Ceramic Fibres 1996:30* 
Selenium 1992:35, 1993:1* 
Silica, crystalline 1993:2, 1993:35* 
Styrene 1979:14, 1990:49*, 1991:2 
Sulphur dioxide 1984:18 
Sulphuric, hydrochloric, nitric and phosphoric acids 2009;43(7)* 
Synthetic pyretroids 1982:22 
Tetrachloroethane 1996:28*D 
Tetrachloroethylene 1979:25, 2003:14*D 
Thermal degradation products of plastics 1998:12* 
Thiurams 1990:26, 1991:2* 
Tin and inorganic tin compounds 2002:10*D 
Toluene 1979:5, 1989:3, 1989:37*, 2000:19* 
1,1,1-Trichloroethane 1981:12 
Trichloroethylene 1979:13, 1991:43, 1991:50* 
Triglycidyl isocyanurate 2001:18* 
n-Undecane 1987:25, 1987:40* 
Vanadium 1982:18 
Vinyl acetate 1988:26, 1988:33* 
Vinyl chloride 1986:17 
Welding gases and fumes 1990:28, 1991:2* 
White spirit 1986:1 
Wood dust 1987:36 
Xylene 1979:35 
Zinc 1981:13 
* in English, remaining documents are in a Scandinavian language.  
D = collaboration with the Dutch Expert Committee on Occupational Standards (DECOS).  
N = collaboration with US National Institute for Occupational Safety and Health (NIOSH).  
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